The Regulation of the Alternative Splicing of Caspase 9 by Goehe, Rachel
Virginia Commonwealth University
VCU Scholars Compass
Theses and Dissertations Graduate School
2010
The Regulation of the Alternative Splicing of
Caspase 9
Rachel Goehe
Virginia Commonwealth University
Follow this and additional works at: http://scholarscompass.vcu.edu/etd
Part of the Biochemistry, Biophysics, and Structural Biology Commons
© The Author
This Dissertation is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in
Theses and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.
Downloaded from
http://scholarscompass.vcu.edu/etd/144
 Virginia Commonwealth University 
 
 
 
This is to certify that the dissertation prepared by Rachel Goehe entitled  
THE REGULATION OF THE ALTERNATIVE SPLICING OF CASPASE 9  
has been approved by his or her committee as satisfactory completion of the dissertation 
requirement for the degree of Ph.D. 
 
 
 
 
Dr. Charles Chalfant, Virginia Commonwealth University  
 
 
 
Dr. Tomasz Kordula, Virginia Commonwealth University 
 
 
 
Dr. Lynne Elmore, Virginia Commonwealth University 
 
 
 
Dr. Robert Tombes, Virginia Commonwealth University 
 
 
 
Dr. James Roesser, Virginia Commonwealth University 
 
 
 
Dean, Virginia Commonwealth University 
 
 
 
Dr. F. Douglas Boudinot, Dean of the School of Graduate Studies 
 
 
 
September 24
th
, 2010 
 
  
 
 
 
 
© Rachel Wilson Goehe 2010 
All Rights Reserved 
 
 THE REGULATION OF THE ALTERNATIVE SPLICING OF CASPASE 9  
 
A Dissertation submitted in partial fulfillment of the requirements for the degree of 
Doctor of Philosophy at Virginia Commonwealth University. 
 
by 
 
RACHEL WILSON GOEHE 
Bachelor of Science, University of Mary Washington, 2006 
 
 
 
Director: DR. CHARLES E. CHALFANT, PH.D. 
Associate Professor of Biochemistry & Molecular Biology 
 
 
 
 
 
Virginia Commonwealth University 
Richmond, Virginia 
September 2010 
ii 
Acknowledgement 
I owe my deepest gratitude to my husband Bradley Goehe, for your endless patience and 
support throughout the duration of this experience. 
 
I would like to thank my parents, Harold and Christine Wilson, who have loved and 
supported me throughout my life and were understanding yet critical during the hard 
times.  And to my brother, Aaron Wilson, who pushed me by his smart remarks about my 
mere “Ph.D.”  
 
To my mentor, Dr. Charles Chalfant, who has been the driving force for this project and 
myself though the difficult times.  For his constructive criticisms and enjoyment of 
science which is simply contagious. 
 
I would also like to thank the members of my committee: Drs. Lynne Elmore, Robert 
Tombes, Tomasz Kordula, and James Roesser. Their advice and guidance throughout the 
duration of this project was irreplaceable. 
 
Thanks to the Chalfant laboratory members for the great memories! 
 
And I must thank a special friend, Dr. Jacqueline Shultz, who spent countless hours 
listening to me vent over the past years.  Also, your support and our “dynamic duo-ness” 
was priceless. 
 
Lastly, this work was supported by funding from the National Institutes of Health and the 
Veterans Administration. 
 
 
iii 
Table of Contents 
Page 
Acknowledgements ............................................................................................................. ii 
List of Tables .............................................................................................................. vii-viii 
List of Figures .............................................................................................................. viii-ix 
Chapter 
1 Introduction and Review of the Literature .........................................................1 
1.1. Overview ................................................................................................1 
1.2. Pre-mRNA Splicing ...............................................................................5 
 1.2.1. Splicing and the Spliceosome Assembly .......................................5 
 1.2.2. Cis-regulatory elements and RNA trans-factors in splicing .........8 
      1.2.3. Enhancers ......................................................................................9 
      1.2.4. Repressors ...................................................................................11 
      1.2.5. Alternative Splicing .....................................................................15 
                       1.3. Apoptosis .............................................................................................18 
 1.3.1. Initiator and Effecter Caspases ....................................................19 
 1.3.2. Extrinsic Pathway (Death Receptor Pathway) ............................20 
      1.3.3. Intrinsic Pathway (Mitochondrial Pathway) ................................22 
      1.3.4. Caspase 9 .....................................................................................25 
2 The Alternative Splicing of Caspase 9 Plays a Major Role in the  
Tumorigenic Capacity in A549 Xenografts ................................................27 
iv 
2.1. Introduction ..........................................................................................27 
2.2. Materials and Methods .........................................................................31 
 2.2.1. Cell Culture .................................................................................31 
 2.2.2. Quantitative/Competitive RT-PCR .............................................32 
 2.2.3. Western Immunoblotting .............................................................32 
2.3. Results ..................................................................................................33 
2.3.1. The alternative splicing of caspase 9 is dysregulated in NSCLC 
tumors and cell lines ......................................................................33 
2.3.2. The alternative splicing of caspase 9 regulates the anchorage- 
independent growth and tumorigenic capacity of NSCLC cells ....39 
2.4. Discussion ............................................................................................45 
3 Identification of the RNA Trans-factor hnRNP L and its Association with an 
Exonic Splicing Silencer in Exon 3 of Caspase 9 .......................................46 
3.1 Introduction ...........................................................................................46 
3.2 Materials and Methods ..........................................................................49 
 3.2.1. Nuclear Extracts ..........................................................................49 
 3.2.2. Electromobility Shift Assays (EMSA) ........................................49 
 3.2.3. Mass Spectrometry Analysis .......................................................50 
 3.2.4. Streptavidin-Agarose Affinity Purification .................................50 
 3.2.5. Western Immunoblotting .............................................................51 
v 
 3.2.6. Imaging/Quantification ...............................................................51 
3.3 Results ...................................................................................................52 
 3.3.1. Identification of a purine-rich exonic splicing silencer in exon 3 
of caspase 9 pre-mRNA ........................................................................52 
 3.3.2. hnRNP L binds specifically to the exonic splicing silencer in 
exon 3 of caspase 9 pre-mRNA .............................................................56 
3.3. Discussion ............................................................................................61 
4 hnRNP L Regulates the Tumorigenic Capacity of Lung Cancer Xenografts in 
Mice via the Alternative Splicing of Caspase 9 ..........................................62 
4.1 Introduction ...........................................................................................62 
4.2 Materials and Methods ..........................................................................64 
 4.2.1. Cell Culture .................................................................................64 
 4.2.2. Quantitative/Competitive RT-PCR .............................................65 
 4.2.3. Silence Interfering RNA Transfection ........................................66 
 4.2.4. Plasmid Transfection ...................................................................66 
 4.2.5. Stable Transfection ......................................................................67 
 4.2.6. Immunoprecipitation ...................................................................67 
 4.2.7. Confocal Microscopy ..................................................................68 
 4.2.8. Statistical Analysis ......................................................................69 
 4.2.9. Imaging/Quantification ...............................................................69 
vi 
 4.2.10. Animals and Tumor Models ......................................................69 
4.3. Results ..................................................................................................70 
 4.3.1. hnRNP L regulates the alternative splicing of caspase 9 in non-
small cell lung cancer cells ....................................................................70 
 4.3.2.  hnRNP L regulates the anchorage-independent growth  of 
NSCLC cells via the alternative splicing of caspase 9 ..........................80 
 4.3.3. hnRNP L regulates the tumorigenic capacity of NSCLC cells via 
the alternative splicing of caspase 9 ......................................................84 
 4.3.4. hnRNP L is hyper-phosphorylated in a cancer specific manner .87 
 4.3.5. The phosphorylation of hnRNP L on serine
52
 regulates the 
alternative splicing of caspase 9 in NSCLC ..........................................89 
4.4. Discussion ............................................................................................95 
5 hnRNP U, a novel splicing enhancer, regulates the alternative splicing of 
caspase 9 ......................................................................................................96 
5.1. Introduction ..........................................................................................96 
5.2. Materials and Methods .........................................................................97 
 5.2.1 Mass Spectrometry Analysis ........................................................97 
 5.2.2. Streptavidin-agarose Affinity Purification. .................................97 
 5.2.3. Cell Culture. ................................................................................98 
 5.2.4. Small Interfering RNA Transfection. ..........................................99 
vii 
 5.2.5. Quantitative/Competitive RT-PCR. ..........................................100 
 5.2.6. Western Immunoblotting ...........................................................101 
 5.2.7. Imaging/Quantification .............................................................101 
5.3. Results ................................................................................................102 
 5.3.1. The RNA trans-factor hnRNP U interacts with exon 3 of caspase 
9 ...........................................................................................................102 
 5.3.2. hnRNP U regulates the alternative splicing of caspase 9 in non-
small cell lung cancer cells ..................................................................104 
 5.3.3. hnRNP U regulates the alternative splicing of caspase 9 in non-
transformed cells .................................................................................106 
5.4. Discussion ..........................................................................................108 
6 General Discussion ........................................................................................109 
References  .......................................................................................................................118 
 
List of Tables 
Page 
Table 2-1: Pathology-verified patient normal and tumor samples. ....................................34 
Table 2-2: Characterization of NSCLC cell lines ..............................................................37 
Table 2-3: A549 stable cell lines. ......................................................................................40 
Table 3-1: Designed RNA oligonucleotdies used in affinity-based assays. ......................57 
Table 3-2: Designed RNA oligonucleotides used in competitive affinity-based assays. ..59 
viii 
Table 4-1: Possible phospho-sites for hnRNP L predicted by various phosphosite 
determination databases……………………………………………...………...…..…..90 
Table 5-1: RNA trans-factors identified by nano-LC-MS/MS analysis. .........................103 
 
 
List of Figures 
Page 
Figure 1-1: Schematic Representaion of the Spliceosomal Assembly ................................7 
Figure 1-2: Domain structures of various hnRNP family members ..................................12 
Figure 1-3: Patterns of alternative splicing ........................................................................16 
Figure 1-4: Various Initiator and Executioner Caspases in Mammals ..............................20 
Figure 2-1: Intrinsic pathway of apoptosis ........................................................................28 
Figure 2-2: Caspae 9a/9b ratio is dysregulated in lung adenocarcinoma tumors ..............35 
Figure 2-3: Caspase 9a/9b ratio is dysregulated in transformed lung epithelial cells .......38 
Figure 2-4: Caspase 9 regulates the anchorage-independent growth in A549 cells ..........41 
Figure 2-5: Caspase 9 regulates the anchorage-independent growth in lung 
adenocarcinoma cell lines. .................................................................................................42 
Figure 2-6: Caspase 9 regulates the tumorigenic capacity in A549 cells. .........................44 
Figure 3-1: Caspase 9 minigene construct in pcDNA 3.1 (-). ............................................53 
Figure 3-2: Potential cis-regulatory elements in the exon 3,4,5,6 cassette in caspase 9. ..54 
ix 
Figure 3-3: Identification of an exonic splicing silencer in exon 3 of caspase 9  
pre-mRNA .........................................................................................................................55 
Figure 3-4: hnRNP L associates to the purine-rich sequences in exon 3 of caspase 9 ......58 
Figure 3-5: hnRNP L associates specifically with the C9-E3/ESS....................................60 
Figure 4-1: Downregulation of hnRNP L, but not hnRNP A2/B1 increases the ratio of 
caspase 9a/9b mRNA .........................................................................................................72 
Figure 4-2 ...........................................................................................................................73 
Figure 4-3: Both siRNA and shRNA against hnRNP L demonstrate an increase in the 
caspase 9 spicing ratio .......................................................................................................74 
Figure 4-4 ...........................................................................................................................77 
Figure 4-5 ...........................................................................................................................78 
Figure 4-6: Low ectopic expression of hnRNP L decreases the caspase 9a/9b splicing 
ratio ....................................................................................................................................79 
Figure 4-7: hnRNP L regulates the anchorage-independent growth  in A549 cells via the 
alternative splicing of caspase 9 .................................................................................. 81-83 
Figure 4-8: hnRNP L regulates the tumorigenic capacity in A549 cells via the alternative 
splicing of caspase 9 ..........................................................................................................85 
Figure 4-9: The role of hnRNP L in regulating the alternative splicing of caspase 9 in 
non-transformed human bronchial epithelial cells .............................................................87 
Figure 4-10 .........................................................................................................................88 
x 
Figure 4-11: hnRNP L is hyper-phosphorylated in NSCLC cells versus non-transformed 
cells ....................................................................................................................................89 
Figure 4-12: Serine
52
 of hnRNP L is hyper-phosphorylated in NSCLC cells and regulates 
the alternative splicing of caspase 9 ...................................................................................93 
Figure 4-13: Ser
52
 of hnRNP L regulates the anchorage-independent growth of NSCLC 
cells ....................................................................................................................................94 
Figure 5-1: hnRNP U associates to exon 3 of caspase 9..................................................104 
Figure 5-2:  Downregulation of hnRNP U, but not hnRNP R decreases the ratio of 
caspase 9a/9b mRNA .......................................................................................................105 
Figure 5-3 .........................................................................................................................106 
Figure 5-4 .........................................................................................................................107 
xi 
List of Abbreviations 
 
α    anti 
A   adenosine 
AIG   Anchorage Independent Growth 
Apaf-1  apoptotic protease activating factor 1  
ASF/SF2   alternative splicing factor/splicing factor 2 (SRp30a) 
C   Cytiditine 
CARD  caspase recruitment domain 
DTT   Dithiotreitol 
EDTA  Ethylenediaminetetraacetic acid 
ESE   Exonic Splicing Enhancer 
ESS   Exonic Splicing Silencer 
FBS   Fetal Bovine Serum 
G   Guanosine 
HBEC-3KT   human bronchial epithelial cells immortalized with hTERT and 
cdk4 
hnRNP  Heterogeneous Nuclear Ribonuclear Protein 
ISE    Intronic Splicing Enhancer 
ISS   Intronic Splicing Silencer 
kDA   kilo Dalton 
M   Molar 
mRNA  Messenger RNA 
NE   Nuclear Extract 
NSCLC   non-small cell lung cancer 
nt   Nucleotides 
PAGE  Polyacrlamide Gel Electrophoresis 
PCR   Polymerase Chain Reaction 
RNA   Ribonucleic Acid 
RO   RNA oligonucleotide 
RRM    RNA recognition motif 
RS   Arginine-Serine Rich Domain 
RT-PCR  Reverse Transcription Polymerase Chain Reaction 
SCLC  Small cell lung cancer 
SDS   Sodium Dodecyl Sulfate 
shRNA   short hairpin RNA  
siRNA   small interfering RNA  
snRNP   small nuclear ribonucleoprotein  
snRNA  small nuclear RNA 
xii 
TSG   Tumor suppressor genes 
WT   Wild-type 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
xiii 
 
 
 
Abstract 
 
 
 
THE REGULATION OF THE ALTERNATIVE SPLICING OF CASPASE 9  
By: Rachel Wilson Goehe, Ph.D. 
A Dissertation submitted in partial fulfillment of the requirements for the degree of Ph.D.  at 
Virginia Commonwealth University. 
 
Virginia Commonwealth University, 2010 
 
Major Director:  Charles E. Chalfant, Ph.D. 
Associate Professor of Biochemistry & Molecular Biology 
 
 
 
 
The pro-apoptotic, caspase 9a, and the anti-apoptotic, caspase 9b, are derived from the 
caspase 9 gene by alternative splicing. This study demonstrates that the alternative splicing of 
caspase 9 is dysregulated in a large percentage of non-small cell lung cancer (NSCLC) tumors of 
the adenocarcinoma type. Furthermore, modulation of the levels of splice variants of caspase 9 
had dramatic effects on the anchorage-independent growth and tumorigenic capacity of NSCLC 
cells. Due to these findings, the molecular mechanisms regulating the post-transcriptional 
processing of caspase 9 were therefore examined and an exonic splicing silencer (ESS) 
regulating the pre-mRNA processing of caspase 9 was identified. To study the possible RNA 
trans-factors interacting with this RNA sequence, we utilized an electromobility shift assay 
(EMSA) coupled with competitor studies and demonstrated three specific protein:RNA 
complexes for this ESS.  Affinity purification and mass spectrometry analysis identified hnRNP 
L as part of these protein:RNA complexes.  Downregulation of hnRNP L induced a significant 
increase in caspase 9a/caspase 9b mRNA ratio, which translated to the protein level. Expression 
of hnRNP L verified the siRNA specificity lowering the caspase 9a/9b ratio, but expression of 
hnRNP L produced the contrasting effect in non-transformed cells suggesting a post-translational 
modification specific for NSCLC cells. Indeed, the phospho-status of hnRNP L was significantly 
increased in NSCLC cells, and mutagenesis studies identified Ser
52
 as a critical residue 
regulating the ability of hnRNP L to repress the inclusion of the exon 3,4,5,6 cassette into the 
xiv 
mature caspase 9 mRNA. The biological relevance of this mechanism was demonstrated by 
stable downregulation of hnRNP L in NSCLC cells, which induced a complete loss of both 
anchorage-independent growth and tumorigenic capacity. This effect of hnRNP L 
downregulation was due to distal modulation of the alternative splicing of caspase 9 as the loss 
of both phenotypes was “rescued” by ectopic expression of caspase 9b. Therefore, this study 
identifies cancer-specific mechanism of hnRNP L phosphorylation and subsequent lowering of 
the caspase 9a/9b ratio, which is required for the tumorigenic capacity of NSCLC cells. 
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CHAPTER ONE 
 
Introduction and Review of the Literature 
 
 
 
1.1. Overview 
 
Cancer is a disease characterized by an abnormal growth of cells which tends to 
proliferate in an uncontrolled manner, and in some cases metastasize. This disease was first 
described around 3000-1500 BC in an ancient Egyptian textbook called Edwin Smith 
Papyrus.  The first descriptions of this disease were stated in this excerpt, “if thou puttst thy 
hand upon his breast upon these tumors, and thou findst them very cool, there being no 
fever at all when thy hand touches him, they have no granulation, they form no fluid, they 
do not generate secretions of fluid, and they are bulging to thy hand“and were suggested to 
be non-curable (Breasted, 1930).  Since then and after a quarter century of rapid advances, 
cancer research has generated a rich body of knowledge.  Research has recognized a 
number of molecular, biochemical and cellular traits known as “acquired capabilities” 
shared by all types of human cancers.  Several lines of evidence have indicated that cancer 
development is a multi-step process that reflects these acquired capabilities which drive the 
2 
progressive transformation of normal cells into cancerous cells. These essential attributes 
which alter normal cell physiology into malignancy are:  self-sufficiency in growth signals, 
insensitivity to growth-inhibitory (antigrowth) signals, evasion of programmed cell death 
(apoptosis), limitless replicative potential, sustained angiogenesis, and tissue invasion and 
metastasis (Hanahan and Weinberg, 2000) .  
Cancers can be divided into 3 main classes including sarcomas, 
leukemias/lymphomas, and carcinomas. Sarcomas are cancers that occur in connective 
tissues such as muscle, bone, and cartilage. There are close to 100 different varieties of 
sarcomas where osteosarcomas, also known as bone sarcomas, are the most prevalent.  
Leukemias and lymphomas are malignant cancers of the bone marrow or blood and are 
characterized by the uncontrolled proliferation of blood cells. Lastly, carcinomas in which 
abnormal cells start in the epithelial tissues are the most common of cancer cases.  The 
most seen carcinomas are located in the breast, prostate, colon and lung. 
Lung carcinoma is a type of carcinoma in which abnormal cells start in the 
epithelial tissues found in the lung.  According to the American Cancer Society (ACS) and 
Centers for Disease Control and Prevention (CDC), lung cancer is the leading cause of 
death amongst both men and women in the United States and worldwide.  It was reported 
that cancer alone caused 13% of all human deaths in the year 2007 (Garcia M, 2007). 
Specifically, 29% of these cancer deaths came from lung cancer, a percentage so fatal that 
it accounts for more than breast, colon, and prostate cancers combined (Garcia M, 2007).  
Moreover, non-small cell lung cancer (NSCLC) presents ~80% of lung cancer cases with a 
5-year survival rate at ~15% (Cortes-Funes, 2002; Ferreira et al., 2002).  Smoking is not 
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the only causative factor involved in NSCLC, but other risk factors such as exposure to 
second-hand smoke, asbestos, radon, arsenic, or living in areas with extreme air pollutants 
play a role.  Unlike small cell lung cancer (SCLC), NSCLCs have several histologies with 
each having their own way of growing and spreading.  Although there are a variety of 
NSCLC histologies, squamous cell carcinoma, large cell carcinoma and adenocarcinoma 
are most commonly seen in lung cancer patients.   
In 1990, the NIH and U.S. Department of Energy placed coordinated efforts on the 
human genome project.  Unexpectedly, the results from the project estimated for 
approximately 32,000 human genes (Lander et al., 2001) in comparison to the predicted 
50,000 – 140,000 human genes (Venter et al., 2001).  This apparent discrepancy between 
organism complexity and the resulting gene number raised eyebrows and questioned the 
source of organism‟s complexity.  It was proposed that eukaryotic diversity was generated 
by such mechanisms as: post-translational modifications, alternative transcription and 
translation start sites, alternative 3‟-end processing, RNA editing, and alternative pre-
mRNA splicing (Hui and Bindereif, 2005). Through computational analyses such as 
microarray profiling and EST-cDNA sequence data, it has been estimated that two-thirds 
of human genes contain one or more alternatively spliced exon (Pan et al., 2008).  
Recently, combining mRNA-Seq and EST-cDNA sequence data, Blencowe and co-
workers estimate that transcripts from ~95% of multiexon genes undergo alternative 
splicing (Pan et al., 2008). Literature has demonstrated that alternative pre-mRNA splicing 
appears to be a key factor underlying increased complexity and diversity in higher 
eukaryotes.  
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The caspase 9 gene, for example, is subject to alternative splicing regulation. 
Caspase 9 is an apoptotic gene in which its generated alternative splice form possesses an 
antagonistic role.  Two groups in 1999 identified the alternative splice variant of caspase 9, 
termed caspase 9b, which lacks the large subunit caspase domain (specifically exons 3,4,5, 
and 6) (Seol and Billiar, 1999; Srinivasula et al., 1999). Specifically, these studies found 
caspase 9b to interfere with the formation of the apoptosome complex via binding to the 
CARD domain of Apaf-1 (Seol and Billiar, 1999; Srinivasula et al., 1999).  Investigations 
in our laboratory with regards to the molecular mechanisms regulating the alternative 
splicing of caspase 9 have identified the splicing enhancer element, SRp30a, to regulate the 
alternative splicing of caspase 9 (Massiello and Chalfant, 2006).  Additionally, Akt was 
shown to modulate the exclusion of the exon 3,4,5,6 cassette of caspase 9 via the phospho-state 
of the RNA trans-factor, SRp30a.  In this document I demonstrate the role of caspase 9 in 
maintaining the transformed phenotype of NSCLC cells. Furthermore, I demonstrate the 
mechanistic regulation of caspase 9 involving a repressor, hnRNP L, which interacts with 
an exonic splicing silencer in exon 3 of caspase 9. In addition, I present hnRNP L and its 
role in cellular transformation and tumorigenesis.  And finally, I reveal a post translational 
modification of hnRNP L and its role in modulating the alternative splicing of caspase 9.  
The following sections highlight past discoveries and provide the necessary background 
information for a more complete understanding of the splicing event described in future 
chapters. 
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1.2. Pre-mRNA Splicing 
In eukaryotes, a process known as pre-mRNA splicing must take place after 
transcription.  Gene transcripts contain non-coding (introns) regions which must be 
removed from between coding (exons) regions to encode functional proteins.  The pre-
mRNA splicing event must take place with high fidelity so that the genetic information can 
be delivered properly. However, many cases of aberrant splicing have been found in 
disease states.  The following sections review the mechanisms and regulation of splicing 
and describe how improper splicing results in diseases. 
 
1.2.1. Splicing and the Spliceosome Assembly 
The protein-coding eukaryotic genes contain non-coding intervening sequences 
known as introns, which have to be removed from the mRNA precursor (pre-mRNA) in 
the nucleus before it is transported out into the cytoplasm. The spliceosome, a highly 
dynamic RNP machine, is a major player that exhibits compositional and structural 
dynamics that are exploited during this event.  A number of RNA sequence elements 
located at the exon/intron boundaries as well as within the intron are required for a splicing 
event to take place. The special sequences located at the exon/intron boundaries are 
formally called splice sites.  The 5‟ splice site (5‟SS) marks the exon/intron junction at the  
5‟end of the intron which includes a GU dinucleotide consensus sequence (Black, 2003).  
On the other end of the intron lies the 3‟ splice site (3‟SS) which marks the exon/intron 
6 
boundary containing three conserved sequence elements.  At the extreme end of the intron 
lies an AG dinucleotide conserved sequence. Another important sequence called the branch 
point is located upstream of the AG dinucleotide and contains an invariant adenosine 
(Black, 2003). Lastly, the region between the branch point and the 3‟SS is the 
polypyrimidine tract which is rich with pyrimidine nucleotides (especially uracil) and is 
generally 15-20 base pairs long (Black, 2003) .  
The U1, U2, U4/U6 and U5 small nuclear ribonucleoproteins (snRNPs) are the main 
building blocks of the spliceosome, which are responsible for the removal of pre-mRNA 
introns and ligation of exons (Black, 2003) .  Each snRNP contains a small nuclear RNA 
(snRNA) along with many specific-complex and auxiliary proteins.  Spliceosomal 
assembly begins with U1 snRNP binding to the 5‟SS of the intron via base-pairing (Das et 
al., 2000) (Figure 1-1). This step is an ATP-independent manner. The non-snRNP 
associated factors SFI and U2 auxilliary factor (U2AF) binds to the branch point (BPS) 
and polypyrimidine tract, respectively (Das et al., 2000) (Figure 1-1).  These initial 
arrangements play crucial roles in the initial recognition of the 5‟SS and 3‟SS of an intron 
forming the E (early) complex and committing the pre-mRNA to the splicing reaction 
(Black, 2003).  The E complex is joined by the RNA portion of U2 snRNP which tightly 
associates with the BPS completing the A complex (Figure 1-1). The bond between U2 
snRNP and the BPS creates a bulge allowing the BPS adenosine specifying it as a 
nucleophile for the first transesterification reaction (Query et al., 1994).  Once the pre-
spliceosomal A complex has formed, further recruitment of the U4/U6-U5 tri-snRNP leads 
to the formation of the B complex (Figure 1-1).  At this stage, all the spliceosomal subunits 
7 
are present to carry out pre-mRNA splicing (Black, 2003). Subsequently, many extensive 
conformational changes and remodeling take place, including the loss of U1 and U4 
snRNP, ultimately resulting in the formation of the C complex, which is the catalytically 
active splicosome (Figure 1-1).  It is the active spliceosome in the C complex that 
catalyzes the two transesterification steps of splicing (Black, 2003). The first 
transesterifcation step involves the spliceosome catalyzing the nucleophilic attack of the  
 
 
 
 
Figure 1-1. Schematic Representaion of the Spliceosomal 
Assembly. The conserved 5’ and 3’ splice site (ss) sequences are 
indicated along with the branch point (A) and the polypyrimidine tract 
(Py)n. The 5 snRNPs are bound appropriately with the indicated complex 
step (E,A,B, and C). 
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BPS on the 5‟SS, leading to the formation of the upstream exon and ligation of the intronic 
5‟ end to the branch point 2‟ OH forming the lariat-exon intermediate. The second 
transesterification involves the detached upstream exon attacking the phosphate at the 3‟ 
end of the intron.  At the end, the result of the transesterification steps releases the lariat 
structure and ligates the upstream and downstream exons (Black, 2003).  
While the core splicing signals: 5‟SS, 3‟SS, and BPS are highly important, these are 
not the only critical elements for splicing regulation and specificity.  A reason for this is 
simply because most human genes contain multiple and relatively short exons (typically, 
50-250bp) which are intervened by considerably larger introns that are generally thousands 
of basepairs long.  Berget et al. found that splice sites are predominantly recognized in 
pairs across the exon through “exon definition” (Berget, 1995).  Exon definition involves 
the recognition of 5‟SS and 3‟SS by splicing components and is deemed to be a crucial 
step for splicing regulation and specificity (Berget, 1995).  Splicing has been found to be 
processed with high fidelity, implying there are more variables which play roles in the 
equation than just the core splice signals in splice site selection.  The following sections 
further discuss these additional elements in the splicing mechanism with emphasis on 
repressor elements, specifically the hnRNP family of proteins. 
 
1.2.2. Cis-regulatory elements and RNA trans-factors in splicing  
Recent global analyses have indicated that cis-regulatory elements and trans-acting 
factors to further facilitate both constitutive and alternative splicing exons by silencing or 
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repressing actions.  Cis-regulatory elements are regions of DNA or RNA that regulate the 
expression of genes and are located in the 5‟ or 3‟ protein coding region or in introns.  
These elements are conventionally referred to as exonic splicing enhancers (ESEs) or 
silencers (ESSs) and intronic splicing enhancers (ISEs) or intronic splicing silencers 
(ISSs).   Additionally, these cis-regulatory elements function by recruiting trans-acting 
splicing factors which can activate or repress splice site recognition or spliceosome 
assembly by various mechanisms.   
Disruption of cis-regulatory elements for pre-mRNA processing and/or RNA trans-
factors necessary for splicing regulation have been demonstrated to have significant effects 
on splicing and the regulation of alternative splicing.  Errors in these components (e.g. 
mutations) are responsible for aberrant events such as altering the encoded protein, 
activating a cryptic splice site, causing the splicing machinery to skip an exon and alter 
pre-mRNA splicing patterns. Recently, there is growing evidence that disruption of these 
mechanisms which are involved in recognition and function of splicing events can be 
significant in the etiology of several genetic diseases such as cancer.  The following 
sections will review the additional splicing signals necessary for the high fidelity of 
splicing and cover mechanisms by which aberrant signals contribute to disease states.  
 
1.2.3. Enhancers 
Enhancers in splicing play a role to help facilitate splice site recognition and splicing 
event.  The ESEs are a well established group where many if not all exons contain internal 
ESE sequences (Cartegni et al., 2003; Fairbrother et al., 2002; Schaal and Maniatis, 1999).  
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Most ESEs function to recruit members of the SR protein family (Graveley, 2000); 
however, in certain circumstances SR proteins can also bind ISEs to promote recognition 
of nearby splice sites (Gallego et al., 1997).  SR proteins are the most extensively studied 
group of regulatory proteins (Caceres et al., 1997; Graveley, 2000; Manley and Tacke, 
1996).  These proteins are rich with arginine/serine dipeptides, termed the RS domain, 
which is a common structure amongst all members.  SR proteins exhibit another common 
domain structure known as the RNA recognition motif (RRM) for RNA binding (Long and 
Caceres, 2009).   Literature has found that these factors usually regulate splicing by 
binding ESEs and regulating alternative splicing events through their RRM domains.  For 
instance, the N-terminal RRM domains have been demonstrated to provide means of RNA-
binding specificity (Wu and Maniatis, 1993), where as the C-terminal RRM domains 
provide means of protein-protein interactions which facilitate recruitment of the 
spliceosome (Kohtz et al., 1994).  Another way in which these RNA trans-factor proteins 
influence alternative splice site selection is in a concentration dependent manner.  For 
example, the protein expression and concentration of various SR proteins change during T-
cell activation with concomitant changes in alternatively spliced isoforms of CD44 and 
CD45 (ten Dam et al., 2000).  
Initially, splicing regulatory sequences were identified with the use of minigenes.  The 
first ESEs were found using functional minigenes in vivo in alternative exons (Cooper and 
Ordahl, 1989; Hampson et al., 1989; Mardon et al., 1987).  Minigenes are designed to 
contain a genomic segment of a gene that includes the alternatively spliced region. This 
tool is commonly used as an in vivo assay and allows researchers to study intrinsic features 
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of a gene that control exon usage such as cis-regulatory elements and trans-factors 
(Cooper, 2005).  While this method is still used by the scientific community, additional 
methods have been introduced.  SELEX (systematic evolution of ligands by exponential 
enrichment) is commonly used for the identification of ESEs.  SELEX utilizes a random 
pool of sequences to identify sequences with enhancer activity (Coulter et al., 1997; Liu et 
al., 2000; Liu et al., 1998; Schaal and Maniatis, 1999). In addition, ESEfinder is a web-
based resource which scans nucleotide sequences and predicts putative ESEs for multiple 
SR proteins (Cartegni et al., 2003).  While there has been extensive analysis of enhancer 
elements, the splicing silencer elements remain poorly examined.  The next section will 
provide a detailed understanding of the splicing silencer elements.  
 
 
1.2.4.  Repressors 
In comparison to the enhancer splicing elements being bound mainly by SR proteins, 
the repressor splicing elements are often bound by hnRNPs (heterogeneous 
ribonucleoproteins).  hnRNPs are a diverse family of pre-mRNA binding proteins which 
functions in both constitutive and alternative splicing (Pozzoli and Sironi, 2005) (CMLS 
pozzoli, silencers regulate both…and add others here).  The family consists of about 20 
major proteins from A1 to U, which range in sizes from 30 – 120 kDa (Pinol-Roma et al., 
1988). These proteins demonstrate an array of cellular activities including: mRNA 
stability, transcription, RNA metabolism, and alternative splicing (Dreyfuss et al., 2002; 
Glisovic et al., 2008; Pullman and Martin, 1983).  In addition, hnRNPs are highly diverse 
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and consist of at least one binding motif such as an RNA recognition motif (RRM), hnRNP 
K homology domain (KH), or arginine/glycine rich (RGG) box. In addition to these 
binding motifs, many manifest auxiliary domains which mediate protein-protein 
interactions (Cartegni et al., 1996; Krecic and Swanson, 1999).  Figure 1-2 is a schematic 
representation of the domain structures in various hnRNP members.   
 
 
 
 
 
Figure 1-2.  Domain structures of various hnRNP family 
members.  The hnRNP family of proteins contains a diverse set of 
domains. hnRNP proteins contain RNA reconignition motif (RRM) and 
KH domains for RNA recognition along with RGG and B30.2/SPRY 
domains for protein-protein interactions.  In addition, some hnRNP 
proteins also present a nuclear localization signal (NLS). 
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hnRNP proteins are primarily localized in the nucleus.  However, various studies 
have demonstrated nucleocytoplasmic transport ability of hnRNP proteins.  
Nucleocytoplasmic shuttling requires import and export factors to target them to the 
nucleoporin, and is transportin dependent (Lichtenstein et al., 2001). Shuttling into the 
cytoplasm allows these proteins to control various activities of mRNA including mRNA 
transport, mRNA translation, and mRNA turnover which can be both beneficial and 
unfavorable.  The shuttling capability amongst various members of these proteins has been 
described in the literature.  For instance, hnRNP A1 contains an NLS which enables 
translocation to the cytoplasm to release its cargo and back into the nucleus by transportin-
1 (Siomi et al., 1997).  In addition, stress signals such as osmotic stress, UV, and the 
activation of the MKK3/6p38 pathway has demonstrated hnRNP A1 to shuttle between the 
nucleus and cytoplasm (Siomi et al., 1997).  Moreover, hnRNP U has demonstrated to 
translocated with betaTrCP induced by the tobacco-specific carcinogen NNK (Lin et al.).  
This induction causes DNMT1 nuclear accumulation and hypermethylation of the 
promoters of tumor suppressor genes (TSGs) (Lin et al.). 
Many studies have been reported supporting the role of hnRNPs in pre-mRNA 
splicing.  The most extensively studied hnRNP member in regards to splicing regulation is 
hnRNP A1.  Mayeda and Krainer were first to report that hnRNP A1 regulated pre-mRNA 
alternative splicing via antagonizing SF2 protein in in vitro assays (Mayeda and Krainer, 
1992).  In this study, the relative concentrations of hnRNP A1 and SF2 determine the 5‟ 
splice site selection.  For hnRNP A1 to function as a regulator of alternative pre-mRNA 
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splicing, the two RRM domains are essential (Mayeda et al., 1994).  These conserved 
domains were also found important in other hnRNP A/B proteins (Mayeda et al., 1994).   
In addition, hnRNP proteins are subject to post translational modifications such as 
methylation, acetylation and phosphorylation.  Several cellular kinases have been 
demonstrated to act on hnRNPs (Guil et al., 2006; Mayrand et al., 1993; Xie et al., 2003).  
One of the best characterized hnRNP proteins modified by phosphorylation is hnRNP A1.  
Caceres and co-workers demonstrated in response to activation of the stress kinase p38, 
hnRNP A1 is targeted for phosphorylation by the Mnk1/Mnk2 cellular kinases (Guil et al., 
2006).  This phosphorylation event inhibits the nucleocytoplasmic activity of hnRNP A1, 
resulting in its cytoplasmic accumulation (Guil et al., 2006). At the end, the cytoplasmic 
accumulation of hnRNP A1 has demonstrated an alterated splicing pattern of the 
adenoviral E1A splicing reporter (van der Houven van Oordt et al., 2000).  In addition to 
hnRNP A1, many other hnRNP family members have been subject to phosphorylation 
resulting with aberrant activities.  For instance, NNK treatment results in the activation of 
AKT which phosphorylates hnRNP U (Lin et al.).  Phosphorylated hnRNP U leads to a 
disturbance of the DNMT1/BetaTrCP interaction and leads to DNMT1 nuclear 
accumulation. DNMT1 nuclear accumulation results in subsequent hypermethylation of 
TSGs leading to tumorigenesis (Lin et al.).   Collectively, these studies demonstrate that 
post translational modification of RNA trans-factors can contribute to disease 
development.   
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1.2.5. Alternative Splicing 
The definition of alternative pre-mRNA splicing is the process that allows 
individual genes to express multiple mRNAs by the joining of different 5‟ and 3‟ splice 
sites.   Research has found that the human genome undergoes a high rate of alternative 
splicing, with 35-59% of human genes demonstrating at least one alternative splicing event 
(Kan et al., 2001; Lander et al., 2001; Mironov et al., 1999; Modrek et al., 2001).  
Moreover, alternative splicing is a major mechanism seen to be involved in protein 
diversity, gene expression, and an array of biological processes (Brett et al., 2002; Lareau 
et al., 2004; Modrek and Lee, 2002; Stetefeld and Ruegg, 2005).  And because this is a 
highly important event for organism‟s complexity, its misregulation underlies many human 
diseases. Research has estimated that approximately 15% of disease causing mutations in 
human genes involves mis-regulation of alternative splicing (Philips and Cooper, 2000). 
Mis-regulated alternative splicing events have been seen in a variety of diseases such as 
Parkinson‟s disease, retinitis pigmentosa, and cancer.  Therefore, understanding how 
alternative splicing is altered can offer promising perspectives into disease therapy.  The 
following sections in this chapter will focus on the molecular mechanism of alternative 
pre-mRNA splicing, with emphasis on the diverse roles RNA trans-factors demonstrate in 
regards to splicing regulation and their roles in human diseases.  I will begin by providing 
a comprehensive background of alternative splicing and then highlight important RNA 
trans-factors that regulate this event. 
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1.2.6.  Patterns of Alternative Splicing 
Alternative splicing has five basic patterns which include: the use of alternative 5‟ 
splice sites, alternative 3‟ splice sites, cassette exon skipping, mutually exclusive cassette 
exons, and intron retention (Black, 2003; Hui and Bindereif, 2005; Ward and Cooper)  
(Figure 1-3).  Two other mechanisms known as alternative promoters and alternative 
poly(A)sites can be classified separately and affect either the first or last exon of a 
transcript respectively (Black, 2003; Hui and Bindereif, 2005; Ward and Cooper).  
 
 
Figure 1-3: Patterns of alternative splicing.  There are 5 basic 
patterns of alternative splicing: cassette exon, mutually exclusive 
exon, alternative 5’ splice sites, alternative 3’ splice sites, and intron 
retention.  The red rectangles present alternative exons.  The black 
dotted lines in the pre-mRNA present portions that can be spliced 
out. 
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Many aspects of the protein function can be generated by alternative splicing 
patterns.  It has been estimated that 70-90% of alternative splices alter the protein coding 
sequence of the resulting protein (Kan et al., 2001; Modrek et al., 2001).  The protein 
products which arise by this event demonstrate an array of cellular processes such as: cell 
growth, cell death, differentiation, activity of transcription factors, mRNA stability, 
translation, and intracellular localization of proteins. Moreover, alternative splicing is an 
important mechanism in developmental states and can account for various tissue and cell 
type specific patterns of expression (Stamm et al., 2000).   This event has also been evident 
to change in response to external stimuli, for example, insulin administration influences the 
incorporation of the alternative exon 11 of the insulin receptor (Sell et al., 1994). In 
addition, insulin activates exon ßII inclusion in the PKC gene (Chalfant et al., 1995; 
Chalfant et al., 1998; Patel et al., 2001). Furthermore, neuronal activity changes the 
alternative splicing pattern of clathrin light chain B, the NMDAR1 receptor, and c-fos 
(Daoud et al., 1999).  Lastly, alternative splicing of several cell death regulatory proteins 
are involved in the regulation of apoptosis (Jiang and Wu, 1999). Alternative splicing of 
apoptotic genes are especially relevant to the studies described in future chapters and will 
be discussed in more detail later in this chapter; however, a general description in regards 
to apoptosis and the major players in this event will be reviewed. 
 
. 
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1.3 Apoptosis 
Apoptosis, or programmed cell death, is a highly dynamic and morphologically 
distinct process in which organisms can dispose of unwanted, infected or diseased cells.  
This phenomenon has demonstrated to be vital in events such as embryonic development 
and tissue homeostasis, and its aberrations have been linked to disease states such as 
Alzheimer‟s disease, Parkinson‟s disease, autoimmune diseases, and cancer.  
Back in 1972, Wyllie at al. studies demonstrated that apoptosis had distinct 
morphological features in comparison to other modes of cell death, such as necrosis. Cells 
which undergo apoptosis exhibit the following features: cell shrinkage, chromatin 
condensation, nucleosomal fragmentation, and blebbing of the plasma membrane (Kerr et 
al., 1994; Kerr et al., 1972; Wyllie et al., 1980).  In addition to features above, there are 
biochemical features which take place during apoptosis which include protein cleavage, the 
appearance of phosphatidylserine at the cell membrane surface and increased 
mitochondrial permeability (Kerr et al., 1994; Kerr et al., 1972; Wyllie et al., 1980).  The 
increased mitochondrial permeability results in the “leakage” of pro-apoptotic proteins and 
subsequent formation of apoptotic bodies.  Two classes of proteins, known as the pro-
apoptotic (stress or death signals) and anti-apoptotic (mitogenic or survival signals) 
proteins, creates an equilibrium balance amongst the two and decide whether a cell 
survives or dies by apoptosis. 
Dysregulation in apoptosis can have detrimental effects on the cell and result in 
organ dysfunction.  Apoptosis in normal cells is a finely balanced process involving more 
than 200 proteins.  Many of these proteins are dysregulated or defected in human diseases 
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including cancer.  A large number of apoptotic proteins are regulated via alternative 
splicing, which often pose antagonistic roles strongly implying a crucial importance in life 
and death decisions.  The following sections review basic knowledge of the intrinsic and 
extrinsic pathways of cell death with special emphasis on caspase 9. 
 
1.3.1 Initiator and Effector Caspases 
 Depending on the origin of the death stimuli, the apoptotic response can go through 
the mitochondrial (intrinsic) pathway or the death receptor (extrinsic) pathway.  These 
pathways are initiated and executed by caspases (Cysteinyl ASPartate proteinASES) and 
their activation if a hallmark of apoptosis.  Caspases are synthesized as inactive zymogens 
containing a prodomain followed by p20 (large) and p10 (small) subunits (Figure 1-4). 
Caspases are a conserved family of enzymes and 14 caspases have been identified in the 
literature to date. Although the first mammalian caspase, caspase-1 (ICE), demonstrated a 
role in inflammatory, 7/14 have important roles in apoptosis (Earnshaw et al., 1999; Shi, 
2002).  The caspases with important roles in apoptosis can be divided into two classes: 
initiator caspases, which include caspase-2,8,9, and 10; and executioner (effector) 
caspases, which include caspase-3,6, and 7 (Figure 1-4).  The apoptotic initiator caspases 
possess longer prodomains along with either a caspase activation recruitment domain 
(CARD) or death effector domain (DED) (Figure 1-4).  The CARD and DED domains of 
these inititator caspases mediate the interaction with upstream adaptor molecules.  In 
contrast, the apoptotic executioner caspases possess short prodomains which are typically 
activated by upstream caspases and perform many of the biochemical events of cell death. 
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Figure 1-4.  Various initiator and executioner caspases in 
mammals.  Only caspases with the potential role in apoptosis 
are shown.  The domain organization of caspases including 
the large subunit and small subunits are indicated along with 
the CARD and DED protein-protein interaction motifs.   
 
 
  
 
1.3.2 Extrinsic Pathway (Death Receptor Pathway) 
The extrinsic pathway, also known as the death receptor pathway, is initiated by the 
binding of an extracellular death ligand.  These ligands include Apo2L/TRAIL,CD95/FasL 
and TNFα which bind to their cognate receptors DR4/DR5,CD95/Fas,and TNFR1/TNFR2, 
respectively.  An example of this pathway involves FasL binding to its respective receptor 
Fas (Nagata, 1999), which allows for homotrimeric receptor clustering and recruitment of 
cytosolic factors adaptor protein Fas associated death domain (FADD) and the initiator 
procaspases 8 or 10 (Boldin et al., 1995; Chinnaiyan et al., 1995). The recruitment of these 
cytosolic factors forms an oligomeric death-inducing signaling complex (DISC) which 
leads to the activation of the procaspase 8 into caspase 8. Activated caspase 8 cleaves the 
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effector caspase, caspase 3 which then undergoes many biochemical changes within the 
cell ultimately leading you to cell death.  Literature has demonstrated that the extrinsic 
pathway can converge with the intrinsic pathway through the caspase 8 mediated cleavage 
of BID (Li et al., 1998; Luo et al., 1998) becomes truncated into tBID, resulting in its 
translocation to the mitochondria which trigger the release of mitochondrial factors to 
augment cell death (Li et al., 1998; Luo et al., 1998).   
 
Disruption of the extrinsic pathway in cancers 
Literature has shown that cancer cells have evolved numerous strategies to resist 
cell death induction via the extrinsic pathway.  It has been demonstrated that impaired 
surface expression of death receptors is one avenue in which cancer cells demonstrate 
resistance to apoptosis.  For example, deletions or mutations of TRAIL-R1 or R2 resulting 
in the loss of both copies have been demonstrated in a variety of cancers such as non-
Hodgkin‟s lymphoma, breast cancer, head and neck cancer, and lung carcinomas (Dechant 
et al., 2004; Pai et al., 1998).  In addition, decoy receptor 3 (DcR3) have been found to 
competitively bind with CD95L, which ultimately interferes with the CD95-triggered 
apoptosis.  Moreover, DcR3 has been found to be genetically amplified or overexpressed 
in colon and lung carcinomas (Pitti et al., 1998; Roth et al., 2001).  Signaling through the 
extrinsic pathway is also altered by being negatively regulated by proteins that associate 
with cytoplasmic domains.  An example of this dysregulation has been demonstrated by 
FLICE-like inhibitory protein (FLIP). Two splice variants of FLIP, a long form (FLIPL) 
and a short form (FLIPS) have been identified and demonstrated to have sequence 
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homology to caspase 8 and caspase 10, but lack the catalytic domain.  Due to the lack of 
the catalytic domain, recruitment of FLIP to the DISC instead of procaspases 8 or 10 can 
block caspase activation.   
 
 
1.3.3 Intrinsic Pathway (Mitochondrial Pathway) 
The intrinsic pathway is mediated by the mitochondria and takes place by apoptotic 
stimuli such as hypoxia, DNA damage, UV, and other types of cellular stress. Such stress 
stimuli triggers the mitochondrial outer membrane permeabilization (MOMP) leading to 
the release of many apoptotic factors from the intermembrane space of the mitochondria.  
Some of the well-characterized factors include: cytochrome c, second mitochondria-
derived activator of caspases/direct inhibitor of apoptosis (SMAC/DIABLO), apoptosis-
inducing factor (AIF), endonuclease G (EndoG) and high-temperature-requirement protein 
A2 (OMI/HTRA2) (Fulda and Debatin, 2006; Thornberry and Lazebnik, 1998; Wang, 
2001).  Although these proteins all have important roles, the most intriguing pro-apoptotic 
factor is cytochrome C.  Upon release of cytochrome C from the intermembrane space of 
the mitochondria, cytochrome C binds and activates to apoptotic-protease-activating 
factor-1 (APAF1) which induces conformational changes that allows the formation of the 
apoptosome and subsequent caspase cascade (Jiang and Wang, 2000).   
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Disruption of the intrinsic pathway in cancers 
 Aberrations in the mitochondrial pathway of apoptosis are very common in cancer 
cells.  Many anticancer therapies trigger apoptosis more so by activating the intrinsic 
pathway. One family of proteins that harbor many mutations or alterations in cancer cells 
is the Bcl-2 family.  Many groups have explored how perturbed regulation of Bcl-2 and its 
relatives contribute to cancer develop and impedes on cancer therapies.  In response to 
diverse stress stimuli, the decision of whether a cell should live or die is largely determined 
by the balance of anti- and pro-apoptotic Bcl-2 family members. It is now evident that the 
interplay amongst the pro- and anti-apoptotic Bcl-2 family members integrates intracellular 
cues to arbitrate whether the initiator caspases are unleashed. The Bcl-2 family consists of 
at least 20 proteins and is classified into three subfamilies: the Bcl-2 subfamily which 
promotes cell survival and usually has all four conserved BH domains, the Bax subfamily 
which is pro-apoptotic and usually has conserved BH 1-3 domains, and the BH3 only 
domain subfamily which is also pro-apoptotic. It has been demonstrated that mutations, 
overexpression, and modifications (e.g. phosphorylation) of Bcl-2 members contribute to 
disease development.  For example, the well characterized Bcl-2 protein is upregulated in 
various cancers.  Overexpression of Bcl-2 has been reported to bind with BAX and prevent 
its activation and translocation to the mitochondria which ultimately precents the release of 
cytochrome c from the mitochondria (Finucane et al., 1999; Park et al., 2001).  Moreover, 
BAD phosphorylation results in its loss of ability to heterodimerize with survival proteins 
Bcl-xL and Bcl-2 (Zha et al., 1996a).  Phosphorylated BAD binds to 14-3-3 and is 
sequestered in the cytoplasm ultimately preventing MOMP to occur (Zha et al., 1996b).  
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Collectively, these studies demonstrate the detrimental effects Bcl-2 family members can 
produce and their impact on the intrinsic pathway of apoptosis.    
 In addition, the IAP family of proteins presents ways to dysregulate the intrinsic 
pathway of apoptosis.  These are structurally- and functionally-related anti-apoptotic 
proteins which demonstrate roles in cell division, cell cycle progression, signal 
transduction pathways and cell death (Deveraux and Reed, 1999; Salvesen and Duckett, 
2002; Shi, 2002).  Various members of the IAP family demonstrate the ability to bind and 
inhibit the function of caspases 3, 7, and 9.  Specifically, the BIR3 domain of XIAP 
associates with the caspase 9/APAF-1 holoenzyme complex by binding to the linker 
peptide of caspase 9 (Shiozaki et al., 2003; Srinivasula et al., 2001).   On the other hand, 
the inhibitory ability of XIAP is different in regards to the effector caspases 3 and 7.  In 
comparison to caspase 9, the BIR1 and BIR2 domains of XIAP bind and inhibit caspases 3 
and 7.  These studies demonstrate that the balance between cell death, which induces 
caspase activity versus the status of IAPs, which inhibit apoptosis constitutes a 
fundamental decision point within the cell.  With the knowledge that evasion of apoptosis 
is a fundamental aspect of cancer, understanding the anti-apoptotic activities of IAPs is 
highly important with the great potential as being outstanding therapeutic targets.   
 
 
.   
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1.3.4 Caspase 9 
 Caspase 9 is a ubiquitous protease found to be constitutively expressed in a variety 
of tissues such as the breast, heart, brain, and lung.  Importantly, studies have demonstrated 
caspase 9 as a critical upstream activator of the caspase cascade via caspase 9 knockout 
mice.  Flavell and co-workers concluded that Casp9 -/- mice died perinatally and presented 
pronounced disturbance of telencephalic development from the reduced amount of 
apoptosis. As a consequence of the lack of apoptosis, various brain abnormalities with a 
markedly enlarged and malformed cerebrum were present (Kuida et al., 1998). 
Collectively, these studies indicate caspase 9 as a critical player in apoptosis and the 
physiological functions of caspase 9 are crucial in organism development. 
 Caspase 9 has also been demonstrated to play a distinct role in oncogenesis.  In this 
regard, Lowe and co-workers found caspase 9 and its cofactor APAF-1 to be required 
downstream components of p53 in Myc-induced apoptosis with the use of  caspase 9 -/- 
and APAF-1 -/- mouse embryonic fibroblasts (MEF) cells (Soengas et al., 1999).  
Moreover, caspase 9 -/- cells displayed reduced c-Myc induced cell death and enhanced the 
oncogenic transformation of cells by c-Myc and Ras identifying caspase 9 as a tumor 
suppressor (Soengas et al., 1999).   
 It has become apparent over the years that many apoptotic factors are regulated by 
alternative splicing. Caspase 9 is an apoptotic gene in which its generated alternative splice 
form possesses an antagonistic role.  Two groups in 1999 identified the alternative splice 
variant of caspase 9, termed caspase 9b, which lacks the large subunit caspase domain 
containing the entire catalytic domain (Seol and Billiar, 1999; Srinivasula et al., 1999). 
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This dominant-negative splice variant interferes with the formation of the apoptosome 
complex via binding to the CARD domain of Apaf-1which ultimately interferes with the 
recruitment of procaspase 9.  In addition, caspase 9b has been demonstrated to 
heterodimerize with caspase 9a, rendering the protein structurally incapable of auto-
proteolysis (Seol and Billiar, 1999; Srinivasula et al., 1999).  Therefore, regulation of the 
alternative splicing of caspase 9 is highly important in determining whether apoptosis in 
the cell will occur or not (Ebert et al., 2005; Hakem et al., 1998; Seol and Billiar, 1999; 
Srinivasula et al., 1999). 
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CHAPTER 2 
 
 
THE ALTERNATIVE SPLICING OF CASPASE 9 PLAYS A MAJOR ROLE IN 
THE TUMORIGENIC CAPACITY IN A549 XENOGRAFTS 
 
2.1 Introduction 
Apoptosis (programmed cell death) is a highly dynamic cell suicide mechanism 
which plays a significant role in events such as homeostasis, development, and defense.  
There are more than 200 proteins that participate in this mechanism.  Among these proteins 
are caspases, a family of cysteine proteases which are the main executioners of the 
apoptotic process. 
Specifically, caspase 9 is considered to be the apex in the intrinsic pathway of 
apoptosis.  This pathway is triggered by diverse apoptotic stimuli such as radiation, stress 
agents and various chemotherapies, which converge at the mitochondria.  Cytochrome c is 
released from the mitochondria, binds to APAF-1 and procaspase 9, and creates the 
apoptosome (Igney and Krammer, 2002; Jiang and Wang, 2000).  Once the apoptosome is 
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formed, caspase 9 is activated, leading to the processing of caspase 9 and other 
biochemical events of apoptosis (Igney and Krammer, 2002; Shi, 2002) (Figure 2-1).  
 
 
 
 
Figure 2.1: Intrinsic pathway of apoptosis. The intrinsic (mitochondrial) 
pathway of apoptosis is triggered by a death stimuli. Following the death 
stimuli, the mitochondria is activated and releases cytochrome c into the 
cytosol where it binds with the apoptotic protease activating factor 1 
(APAF-1) and pro-caspase 9 to form the apoptosome.  The apoptosome 
acts to activate caspase 9 followed by the caspase caspase ultimately 
undergoing to cell death. 
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Lowe and co-workers demonstrated that caspase 9 (also known as caspase 9a) plays 
a distinct role in oncogenesis. In this regard, these researchers demonstrated that caspase 9 
-/- cells were resistant to apoptosis induced by c-Myc and oncgenic ras (H-rasV12) 
expression (Soengas et al., 1999). This study also demonstrated that cells transfected with 
c-Myc and oncogenic ras demonstrated enhanced transformation ability in caspase 9 null 
cells in comparison to wild-type cells as assayed by colony formation in soft agar and 
tumorigenesis in nude mice (Soengas et al., 1999). Studies to orient the tumor suppressing 
pathway by the same laboratory group also demonstrated that caspase 9 was downstream 
of p53. Thus, caspase 9 acts as a tumor suppressor of c-Myc and H-rasV12 transformation 
by playing a major role in the p53-dependent pathway of apoptosis and senescence 
(Soengas et al., 1999). 
Dysregulation of the apoptotic pathways may lead to pathological disorders such as 
autoimmune diseases, neurodegeneration, or cancer.  One way in which apoptotic 
pathways are dysregulated is by the means of alternative splicing.  Literature has 
demonstrated that the alternative splicing of apoptotic genes can be detrimental to the cell.  
For instance, Bcl-x alternative splicing, particularly the anti-apoptotic splice variant Bcl-
xL, is frequently seen in higher proportion in both NSCLC and SCLC.  Moreover, the 
dysregulation of pro- to anti-apoptotic splice variants can potentially contribute to 
tumorigenesis (Groeger et al., 2004; Karczmarek-Borowska et al., 2006; Reeve et al., 
1996).  Caspase 9 has also been described to undergo alternative splicing.  Reports in the 
literature demonstrate one aspect regulating the expression of caspase 9, specifically, a 
complex post-transcriptional mechanism involving alternative splicing (Seol and Billiar, 
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1999; Srinivasula et al., 1999). In this regard, the caspase 9 gene produces two splice 
variants, caspase 9a and caspase 9b, via inclusion or exclusion of a four exon cassette, 
exons 3, 4, 5, and 6. Inclusion of this cassette into the mature transcript produces the pro-
apoptotic, tumor suppressor, caspase 9a, while the exclusion produces the anti-apoptotic, 
caspase 9b (Seol and Billiar, 1999; Srinivasula et al., 1999). The caspase 9b protein lacks 
the catalytic domain while retaining all other amino acid sequence such as the APAF-1 
association region (Seol and Billiar, 1999; Srinivasula et al., 1999). Caspase 9b inhibits 
activation of caspase 9a in two distinct ways. Primarily, caspase 9b competes with full-
length caspase 9a for binding to the apoptosome, a large multi-protein structure formed in 
the process of apoptosis and responsible for activating caspase 9a. Secondly, caspase 9b 
has been demonstrated to heterodimerize with caspase 9a, rendering the protein structurally 
incapable of auto-proteolysis (Seol and Billiar, 1999; Srinivasula et al., 1999). Hence, 
regulation of the inclusion of this four exon cassette is a critical factor in determining 
whether a cell is susceptible or resistant to apoptosis as well as possible modulation of the 
tumor suppressing ability of the enzyme. 
 In this chapter, I demonstrate that the alternative splicing of caspase 9 is 
dysregulated in a large percentage of NSCLC tumors.  In addition, I present how the 
alternative splicing of caspase 9 regulates the anchorage-independent growth and 
tumorigenic capacity of NSCLC cells. 
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2.2 Materials and Methods 
2.2.1. Cell Culture  
 
A549 cells were grown in 50% RPMI 1640 (Invitrogen Life Technologies, Carlsbad, CA) 
and 50% Dulbecco's modified Eagle's medium (Invitrogen Life Technologies, Carlsbad, 
CA) supplemented with L-glutamine, 10% (v/v) fetal bovine serum (Sigma), 100 units/ml 
penicillin G sodium (Invitrogen Life Technologies, Carlsbad, CA), and 100 μg/ml 
streptomycin sulfate (Invitrogen Life Technologies, Carlsbad, CA). H2030 and H838 cells 
were grown in RPMI 1640 supplemented with 10% (v/v) fetal bovine serum (Sigma), 100 
units/ml penicillin G sodium (Invitrogen Life Technologies, Carlsbad, CA), and 100 μg/ml 
streptomycin sulfate (Invitrogen Life Technologies, Carlsbad, CA). All adenocarcinoma 
cell lines were purchased from ATCC (Rockville, MD, USA). HBEC-3KT cells, a 
generous gift from J.D. Minna (Sato et al., 2006), were cultured with keratinocyte serum-
free medium containing 50μg/ml bovine pituitary extract and 5ng/ml recombinant 
epidermal growth factor (Life Technologies, Gaithersburg, MD). All cell lines were 
maintained at less than 80% confluency under standard incubator conditions (humidified 
atmosphere, 95% air, 5% CO2, 37 °C).  For all comparison studies between cell lines, 1.2 
x 10
5
 cells were plated in tissue culture plates (6-well dish). The following day, media was 
removed, cells were washed extensively with 1 x PBS and plated in keratinocyte serum-
free medium without supplements overnight. Total RNA and/or protein was then isolated 
for analysis. 
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2.2.2. Quantitative/Competitive RT-PCR 
Total RNA from cell lines were isolated using the RNeasy® Mini Kit (Qiagen Inc., 
Valencia, CA) according to the manufacturer„s protocol. Total RNA (1 μg) was reverse-
transcribed using Superscript III reverse transcriptase (SuperScript™ First-Strand 
Synthesis System for RT-PCR, Invitrogen™, Carlsbad, CA) and oligo (dT) as the priming 
agent. After 50 min of incubation at 42°C, the reactions were terminated by heating at 
70°C for 15 min. Template RNA was then removed using RNase H (Invitrogen, Carlsbad, 
CA). To quantitatively evaluate the expression of endogenous caspase 9 splice variants, an 
upstream 5„primer to caspase-9 (5„-GCT CTT CCT TTG TTC ATC TCC-3„) and a 3„ 
primer (5„-CAT CTG GCT CGG GGT TAC TGC-3„) (Integrated DNA Technologies, Inc., 
Coralville, IA) were used. Using these primers, 20% of the reverse transcriptase reaction 
was amplified for 25 cycles (94°C, 30 s melt; 57°C, 30 s anneal; 72°C, 1 min extension) 
using Platinum Taq DNA polymerase (Invitrogen Life Technologies, Carlsbad, CA). Gene 
products produced from endogenous caspase 9 PCR resulted in a 1248 base pair caspase 9a 
splice variant and 798 base pair caspase 9b splice variant. The final PCR products were 
resolved on a 5% TBE acrylamide gel electrophoresis, stained with SYBR® Gold 
(Invitrogen™, Carlsbad, CA) and visualized using a Molecular Imager® FX (Bio-Rad) 
with a 488 nm EX (530 nm BYPASS) laser. 
 
2.2.3. Western Immunoblotting 
Cells were lysed using CelLytic™ lysis Buffer (Sigma-Aldrich) supplemented with 
protease inhibitor cocktail (Sigma-Aldrich). Protein samples (5 μg) were subjected to 10% 
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SDS-PAGE, transferred to a polyvinylidene difluoride membrane (PDVF) (Bio-Rad) and 
blocked in 5% milk/1 X PBS – 0.1% Tween (M-PBS-T) for 2 h. Primary antibodies were 
anti-caspase 9 (1:1,000, Assay Designs) and anti-β-actin (1:5,000, Sigma-Aldrich). 
Secondary antibodies were HRP-conjugated goat anti-mouse (1:5,000, Sigma-Aldrich). 
Immunoblots were developed using Pierce enhanced chemiluminescence (ECL) reagents 
and Bio-Max film. 
 
2.3. Results 
2.3.1. The alternative splicing of caspase 9 is dysregulated in NSCLC tumors and cell 
lines.  In this study, we tested the hypothesis that the alternative splicing of caspase 9 was 
dysregulated in cancer phenotypes (in a pro-survival/lower caspase 9a/C9b mRNA ratio). 
Specifically, the ratio of caspase 9a/9b mRNA was compared between pathologist-verified 
human lung tumor samples and normal human lung tissue (Table 2-1). Depending on the 
level of dysregulation of each sample, tumor samples were sub-divided into 3 groups 
respectively: normal, a caspase 9a/9b mRNA ratio of ≥3.5; moderately dysregulated, 
ranging from a 2.3-3.4 ratio of caspase 9a/9b mRNA; and highly dysregulated, a caspase 
9a/9b mRNA ratio ≤2.2 (Figure 2-2, Panels A and B). The normal group corresponds to the 
normal ratio of caspase 9a/9b mRNA observed in non-transformed cells; the moderately 
dysregulated group corresponds to a ratio of caspase 9a/9b reported to have a significant, 
but minor to moderate effect on caspase 9 activity (Seol and Billiar, 1999; Srinivasula et 
al., 1999); and the highly dysregulated group corresponds to a ratio of caspase 9a/9b 
reported to significantly reduce caspase 9 activity and inhibit the association of caspase 9a  
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Figure 2-2: Caspase 9a/9b ratio is dysregulated in lung 
adenocarcinoma tumors.  A) Upper Panel: A sample population of 
cDNAs from pathologist-verified lung adenocarcinomas, which underwent 
quantitative/competitive PCR for caspase 9 splice variants.  Lower Panel:  
The figure depicts a sample of the matched pair analysis where N = normal 
tissue and T = tumor tissue.  B) The graph depicts the percentage of lung 
tumors grouped by caspase 9a/9b mRNA ratio. The data are N=81. C) The 
graph depicts human lung tumor samples (NSCLC) directly compared to 
normal lung tissues (normal); *P<0.05, student t-test.   
 
 
 
and APAF-1 (Seol and Billiar, 1999; Srinivasula et al., 1999).  Quantitative/competitive 
RT-PCR analysis (Siebert and Larrick, 1992) of caspase 9 splice variants (Chalfant et al., 
2002) showed that 40% of the NSCLC tumors examined (N=81) presented with a highly 
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dysregulated ratio of caspase 9a/9b mRNA compared to normal lung tissue. Only 15% of 
the lung tumor samples demonstrated a normal ratio of caspase 9a/9b mRNA, and 45% of 
the lung tumor samples demonstrated a moderately dysregulated ratio of caspase 9a/9b 
mRNA.  The entirety of the human lung tumors were also compared directly to normal 
lung tissue demonstrating a reduction of 36% in the caspase 9a/9b mRNA ratio in human 
lung tumors (Figure 2-2, Panel C).  Thus, the ratio of caspase 9a/9b mRNA is dramatically 
lower in a high percentage of clinically relevant NSCLC tumors correlating with loss of 
activity of the tumor suppressor, caspase 9a, and favoring a pro-survival/apoptotic 
resistance phenotype.  
 Although all of our samples are >50% NSCLC tumor, contamination of other cell 
types may affect results. Therefore, we examined a pure population of non-transformed 
lung epithelial cells, specifically HBEC-3KT cells, for their caspase 9a/9b ratio in 
comparison to the transformed lung adenocarcinoma cell lines, A549, H838, and H2030 
cells (see Table 2-2 for cell line phenotypes). HBEC-3KT cells demonstrated a “normal” 
ratio of caspase 9a/9b mRNA of 4.5 ± 0.08 (Figure 2-3, Panel A). In comparison to the 
non-transformed cell line, all three adenocarcinoma cells lines (A549, H838, H2030 cells) 
demonstrated a dysregulated ratio of caspase 9a/9b mRNA: A549: 2.2 ± 0.14; H838: 1.4 ± 
0.08; H2030: 2.6 ± 0.12 (Figure 2-3, Panel A). Importantly, the dysregulation in the ratio 
of caspase 9a/9b mRNA translated to the protein level (Figure 2-3, Panel B). These 
observations indicate that the alternative splicing of caspase 9 is dysregulated in lung 
adenocarcinoma cell lines as well as NSCLC tumors. 
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Figure 2-3: Caspase 9a/9b ratio is dysregulated in transformed lung 
epithelial cells. A and B) The figure depicts the caspase 9 splicing ratio 
observed in non-transformed HBEC-3KT cells versus NSCLC cell lines at 
the RNA (A) and protein level (B). Data are N=3 on two separate 
occasions. 
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2.3.2. The alternative splicing of caspase 9 regulates the anchorage-
independent growth and tumorigenic capacity of NSCLC cells.  Based on the above 
findings and the knowledge that caspase 9a is a possible tumor suppressor (Soengas et al., 
1999), although controversial (Scott et al., 2004), we hypothesized that the alternative 
splicing of caspase 9 has a major role in maintaining the transformed phenotype of NSCLC 
cells. To test this hypothesis, multiple clones and “batch cultures” of A549 cells stably 
expressing either caspase 9b cDNA and caspase 9b shRNA were produced (Figure 2-4, 
Panel A and Table 2-3). Stable expression of caspase 9b shRNA essentially abolished the 
ability of A549 cells to grow in soft agar and reduced the mean diameter of cellular 
colonies (Figure 2-4, Panels B-D). In contrast, low ectopic expression of caspase 9b 
significantly increased the ability of A549 cells to grow in soft agar (Figure 2-4, Panels B 
and C). These effects did not require stable expression and were not due to integration 
artifacts as short term expression of caspase 9b shRNA and caspase 9b cDNA or use of 
stable “batch” cell lines produced comparable results (data not shown).  
These observations translated to the NSCLC cell lines, H838 and H2030 cells, in 
several ways. First, stable expression of caspase 9b shRNA was obtained in both H2030 
and H838 cells with both demonstrating a dramatic loss in the ability of these cells to grow 
in soft agar analogous to the findings in A549 cells (Figure 2-5). In addition, H838 and 
H2030 cells stably expression low ectopic expression of caspase 9b demonstrated a 
marked increase in colony formation in constrast to control cell lines (Figure 2-5).  Thus, 
the biological effects of modulating caspase 9b translate to other NSCLC cell lines.  
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            Figure 2-4: Caspase 9 regulates the anchorage-independent growth in 
A549 cells.  A) Total RNA was isolated from the listed clonal cell lines and 
analyzed by competitive/quantitative RT-PCR for caspase 9 splice variants.  
B) Cells (2 x 103) were plated into 6-well dishes in soft agar and cultured 
for 14 days before the colony count.  C) Quantization (mean) of the number 
of colonies for the indicated clonal cell lines.  N=6; error bars represent SE; 
*P < 0.005 between A549 + shRNA control versus A549 + C9b shRNA; **P 
< 0.001 between A549 + vector control versus A549 + C9b ectopic, student 
t-test. D)  Colony formation assays in soft agar for the A549 vector control, 
A549 + C9b shRNA, and A549 + C9b ectopic cell lines. Quantization 
(mean) of colony diameters (cm) for the indicated clonal cell lines.  N=6; 
error bars represent SE; *P < 0.005 between A549 shRNA control versus 
A549 + hnRNP L shRNA, **P < 0.001 between A549 vector control versus 
A549 + C9b ectopic, student t-test. 
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Figure 2-5: Caspase 9 regulates the anchorage-independent growth in 
lung adenocarcinoma cell lines. A) Characterization of H838 and 
H2030s with caspase 9b shRNA or caspase 9b ectopic expression by 
quantitative/competitive RT-PCR analysis. B) Quantization of the number 
of colonies (% control) for H838 batch cell lines formed in soft agar. N=6; 
error bars represent SE. 
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The tumorigenic capacity of these A549 cell lines was also characterized using 
A549 xenograph tumor formation in SCID mice. Figure 2-6, Panel A shows that stable 
downregulation of of caspase 9b by shRNA technology also induced a complete loss of 
tumor formation in 10 out of 12 injections. The remaining tumors that formed in the 
caspase 9b shRNA expressing cells demonstrated a dramatic loss in tumor volume (Figure 
2-6, Panel A). Pathological analysis confirmed the complete loss of tumor formation for 
the caspase 9b shRNA experiments. In contrast, low ectopic expression of caspase 9b 
induced a dramatic increase in tumor volume (Figure 2-6, Panel A). Interestingly, a 
different pathological phenotype was observed in the two minor tumors formed from cell 
lines expressing caspase 9b shRNA (Figure 2-6, Panel B). Specifically, caspase 9b shRNA 
xenographs demonstrated a greater quantity of matrix along with no presence of gland-like 
structures or invasion into the adjacent tissue in comparison to the A549 vector control 
xenographs. Furthermore, the caspase 9b shRNA tumors formed from the caspase 9b 
shRNA cells lost major architectural features of adenocarcinomas, and an inflammatory 
response was also observed. Large quantities of neutrophils were also present along with 
visible apoptotic bodies, but there was a distinct absence of necrosis. Lastly, the effect of 
the downregulation of caspase 9b on anchorage-independent growth and tumorigenic 
capacity was not due to the enhancement of spontaneous apoptosis rates as no significant 
effect on these rates in the A549 caspase 9b shRNA cells was observed in comparison to 
vector control cells (data not shown) (Hagg et al., 2002). Overall, these data demonstrate 
that the loss of caspase 9b dramatically alters the tumorigenic capacity of NSCLC cells. 
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Figure 2-6: Caspase 9 regulates the tumorigenic capacity in 
A549 cells. A) The cell lines presented in Panel A were injected into 
SCID mice (5 x 106), and tumor volume was measured at the end of 
28 days as represented as average size of tumor (cm3); error bars 
indicate SE; *P <0.05 between A549 + control shRNA versus A549 + 
C9b shRNA; **P < 0.005 between A549 + vector control versus A549 
+ C9b ectopic student t-test. B) H&E stain of the tumors presented in 
Panel D with magnification ranging from 4X to 40X. 
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2.4 Discussion 
 Lung cancer is the leading cause of cancer mortality accounting for an estimated 
28% of all cancer deaths in the United States, and the mortality rates for lung cancer have 
not significantly deceased over the years.  Specifically, NSCLC accounts for 80% of lung 
cancers diagnosed in constrast to SCLC, which account for 20%.  Therefore, understanding 
key mechanisms underlying the maintainence of NSCLC is of key importance.  In this 
chapter, the data demonstrated that the alternative splicing of caspase 9 is dysregulated in a 
pro-survival manner (lower caspase 9a/9b mRNA ratio) in a sample population of 81 
pathologist-verified human NSCLC adenocarcinoma tumor samples.  Specifically, 85% of 
tumor samples presented with a moderately to highly dysregulated caspase 9a/caspase 9b 
splicing ratio. In addition, we utilized NSCLC cell lines because these involve pure 
population of cells and found that in comparison to our non-transformed HBEC3-KT cell 
line, the transformed cell lines (H838, A549, and H2030) demonstrated dysregulated 
caspase 9 splicing ratios.   
 These studies led us to investigate the role of the alternative splicing of csspase 9 in 
maintaining the transformed phenotype of NSCLC cells. Importantly, A549 cells stably 
expressing caspase 9b shRNA lost major architectural features of adenocarcinomas in 
contrast to control and caspase 9b cDNA cell lines.  In conclusion, these studies 
demonstrate that the ratio of caspase 9a/9b mRNA played a significant and physiologically 
relevant role in the activity of caspase 9 and the tumorigenic capacity of NSCLC cells. 
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CHAPTER 3 
 
IDENTIFICATION OF THE RNA TRANS-FACTOR HNRNP L AND ITS 
ASSOCIATION WITH AN EXONIC SPLICING SILENCER IN EXON 3 OF 
CASPASE 9 
 
 
 
 
3.1 Introduction 
 Alternative splicing of pre-mRNAs is a major contributor involved in protein 
diversity of organisms as well as the control of gene expression levels (Brett et al., 2002; 
Lareau et al., 2004; Modrek and Lee, 2002; Stetefeld and Ruegg, 2005).  The splicing 
process must occur with high fidelity to prevent catastrophic events such as altering anti- 
and pro- splice variant ratios (Akgul et al., 2004; Massiello et al., 2006), or producing 
soluble versus membrane bound forms of the Fas receptor (Cascino et al., 1995).  
While the core splicing signals known as the 5‟SS, 3‟SS, and BPS are highly 
important, these are not the only critical players for splicing regulation and specificity.  
Particularly, a bulk of information required for splicing relies on exonic and intronic cis-
regulatory elements.  Depending on their activity and location, cis-elements are known as 
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exonic/intronic splicing enhancers (ESE/ISE) or exonic/intronic splicing silencers 
(ESS/ISS).  These cis-regulatory elements function by recruiting trans-acting splicing 
factors that activate or suppress splice site recognition or spliceosomal assembly by 
various mechanisms (Chasin, 2007; Matlin et al., 2005).  Although these additional 
splicing regulatory elements contribute to splicing regulation, many aberrations (e.g. 
mutations) are commonly seen in these elements (Faustino and Cooper, 2003). 
The ESS/ISS cis-elements commonly recruit members of the heterogenous nuclear 
ribonuceloprotein (hnRNP) family (Black, 2003; Zheng, 2004).  The hnRNP proteins are 
structurally diverse and are well-known to associate with nascent pre-mRNA.  Members 
within this family have deemed an array of cellular activities such as mRNA stability, 
translocation, telomere maintainence, and alternative splicing (Dreyfuss et al., 2002; 
Krecic and Swanson, 1999; Tanaka et al., 2007).   
 The caspase 9 gene is a major player in the intrinsic pathway of apoptosis and is 
subject to alternative splicing.  The alternative spliced form of caspase 9, caspase 9b, lacks 
the catalytic domain (exon 3,4,5,6). Importantly, our laboratory has shown that the 
alternative splicing of caspase 9 is dysregulated in NSCLC tumors and cell lines.  In 
addition, studies with SCID mice demonstrate this splcing event to regulate the 
tumorigenic capacity of NSCLC cells. Thus, identifying the factors responsible for 
silencing the exon 3,4,5,6 cassette of caspase 9 is of significant importance.  
In this chapter, we describe the identification of an RNA cis-element, C9/E3-ESS, 
located in exon 3 of caspase 9 pre-mRNA.  Manipulation of C9/E3-ESS by replacement 
mutagenesis dramatically increased the minigene mRNA ratio of caspase 9a/caspase 9b.  
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Additionally, mass spectrometry analysis on the RNA:protein complexes at the purine-rich 
sequences in exon 3 of caspase 9 identified hnRNP L.  Moreover, affinity-assays 
demonstrated hnRNP L to specifically associate with the C9/E3-ESS.
49 
3.2 Materials and Methods 
3.2.1. Nuclear Extracts 
Nuclear extracts were prepared from A549 lung adenocarcinoma cells according to the 
method of Dignam et al. as described previously (Massiello et al., 2006). Protein 
concentrations were determined by a modification of the Bradford method using the Bio-
Rad protein assay reagent. 
 
 
3.2.2. Electromobility Shift Assay (EMSA)  
The following sequences was used for the FITC-tagged RNA oligonucleotides (FL-C9/E3-
ESS): Exon 3 of Caspase 9: (5‟Fl- GAG AGU UUG AGG GGA AAU).  The following 
competitor sequences were used: caspase 9 exon 3 non-specific competitor (NSC), (5‟-
GAA UUC GCA CGU UA); caspase 9 exon 3 specific competitor (SC), (5‟-GAG UUU 
GAG GGG AA).  RNA binding reactions were performed in a final volume of 25 μl 
containing: 100 ng of fluorescein-oligonucleotide, 50 μg A549 nuclear protein extract, 40 
U RNAsin, and 11.3 µg tRNAs in buffer composed of 10 mM HEPES, 5 mM DTT, 120 
mM KCl, 3mM MgCl2, and 5% glycerol.  The reactions were incubated on ice with either 
100-fold molar excess of NSC or SC oligonucleotides for 5 min, followed by 20 min 
incubation on ice with FL-C9/E3-ESS.  Samples were loaded on a 5% TBE-acrylamide gel 
for electrophoretic separation of RNA:protein complexes.  The gel was then scanned using 
Molecular Imager
®
 FX (Bio-Rad) with a 488 nm EX (530 nm BYPASS) laser. 
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3.2.3. Mass Spectrometry Analysis  
Identification of RNA:protein complexes was performed at the Emory University Mass 
Spectrometry Center. Briefly, RNA:protein complexes were excised from the gel and in-
gel trpysin digestion was performed. The tryptic mixtures were injected and analyzed by 
nano-LC-MS/MS. Proteins identified by nano-LC-MS/MS
 
were based on independent 
sequencing of peptides.  Nano-LC-MS/MS results were obtained by searching the Mascot
 
database (Matrix Science; Boston, MA). 
 
3.2.4. Streptavidin-agarose Affinity Purification   
The following sequences were used for biotinylated-tagged RNA oligonucleotides: 
Caspase 9, exon 3 (Bio-C9/E3-ESS): (5‟Bio- GAG AGU UUG AGG GGA AAU G 3‟); 
Caspase 9, exon 3 core mutant (Bio-C9/E3-ESS MUT): (5‟Bio- GAG AGU UUG CTA 
CTA AAU G 3‟); non-specific oligo (NSC2): (5‟Bio- ACU GCC AGU UAC GAC); 
unlabeled specific competititor (SC): (5‟- GAG UUU GAG GGG AA); and unlabeled non-
specific competitor (NSC1): (5‟- GAA UUC GCA CGU UA) (Dharmacon Inc., Lafayette, 
CO).  Also, see Table 3-1 for additional “cold” unlabeled RNA oligonucleotide 
competitors utilized in these studies. Reaction mixtures were first pre-cleared for 2 hrs at 
4ºC with streptavidin-agarose beads (20 µl) (50 μg A549 nuclear extract, 40 U RNASIN, 
11.3 µg tRNAs, 10 mM HEPES, 5 mM DTT, 120 mM KCl, 3 mM MgCl2, and 5% 
glycerol).  Reaction mixtures were then incubated with 100-fold molar excess of either 
NSC or SC oligo for 5 min following the addition of either 400 ng Bio-C9/E3-ESS or Bio-
NSC-2 incubated on ice for 30 min.  New streptavidin-agarose beads were then added to 
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RNA-binding reactions and incubated at 4º for 2 hours with gentle agitation.  
RNA:protein-binding reactions were washed with buffer containing 100 mM KCl, 20 mM 
Tris-HCl at pH 7.5, and 0.2 mM EDTA.  After washing, the complex was pelleted by 
centrifugation.  The pellet was resuspended in Laemmli buffer, dry boiled for 10 min, and 
subjected to SDS-PAGE/western immunoblotting analysis. 
 
3.2.5. Western Immunoblotting 
Cells were lysed using CelLytic™ lysis buffer (Sigma-Aldrich) supplemented with 
protease Inhibitor cocktail (Sigma-Aldrich). Total protein lysates were then diluted in SDS 
sample buffer and dry boiled for 10 minutes.  Protein samples (5 μg) were subjected to 
10% SDS-PAGE, transferred to a polyvinylidene difluoride membrane (PDVF) (Bio-Rad) 
and blocked in 5% milk/1 X PBS – 0.1% Tween (M-PBS-T) for 2 h. The membrane was 
incubated with the following primary antibodies: anti-caspase 9 (1:1,000, Assay Designs), 
anti-hnRNP L (1:1000, Santa Cruz), anti-hnRNP A2/B1 (1:1000, Santa Cruz), anti-myc-
tag (1:1000; Abcam), and anti-β-actin (1:5,000, Sigma-Aldrich). Secondary antibodies 
were HRP-conjugated goat anti-mouse (1:5,000, Sigma-Aldrich). Immunoblots were 
developed using Pierce enhanced chemiluminescence (ECL) reagents and Bio-Max film. 
 
3.2.6. Imaging/quantification  
All data presented in this chapter was generated via using multiple laser scans or film 
exposures and are not manipulated by adjusting brightness and contrast. Multiple 
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exposures and various scans at multiple laser intensities were utilized to present the data 
for easy discernment of the appropriate effects by readers. 
 
 
3.3 Results 
3.3.1. Identification of a purine-rich exonic splicing silencer in exon 3 of caspase 9 
pre-mRNA.  Due to the biological findings found in the previous chapter, our laboratory 
examined the mechanistic regulation of the pre-mRNA processing of caspase 9.  In an 
effort to identify exonic splicing enhancers and silencers, our laboratory constructed a 
functional minigene to assay the inclusion/exclusion of the exon 3, 4, 5, 6 cassette of 
caspase 9 in cells.  This was accomplished by ligation of three DNA fragments of the 
caspase 9 gene into pcDNA 3.1(-). The three fragments were: 1) a 603 bp fragment 
contained part of exon 2 and intron 2; 2) a 3962 bp fragment containing part of intron II, 
all of exons 3,4,5,6 along with their intervening intronic sequences (all of the sequence for 
introns 3, 4, and 5), and part of intron 6; and 3) a 431 bp DNA fragment containing part of 
intron 6 and part of exon 7 (Figure 3-1).  
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Figure 3-1: Caspase 9 minigene construct in pcDNA 3.1 (-). 
Schematic of the functional minigene construct for caspase 9 
constructed in pcDNA 3.1(–) zeocin with arrows indicating the location of 
primers used in the RT-PCR assay. 
 
 
Within the exon 3,4,5,6 cassette, ten purine-rich sequences were identified as 
possible exonic/intronic splicing enhancers (ESEs/ISEs) and exonic/intronic splicing 
silencers (ESSs/ISSs) by: 1) screening the exon 3,4,5,6 cassette for known RNA cis-
elements (e.g. purine-rich regions); 2) using ESE finder 2.0 (Cartegni et al., 2003) ; and 3) 
using Splicing Rainbow (Koscielny et al., 2009) (Figure 3-2). Replacement mutagenesis of 
these sequences identified a particular purine-rich sequence in exon 3 (Figure 3-2 and 
Figure 3-3, Panel A) that acted as an ESS.  Mutation of this purine-rich sequence in exon 
3, AGGGGA, resulted in a significant increase of the caspase 9a/caspase 9b mRNA ratio 
in A549 cells from 2.7 ± 0.05 to 5.3 ± 0.05 (p-value < 0.0002) (Figure 3-3, Panel B).  Of 
the ten purine-rich sequences mutated in the caspase 9 minigene, only the mutagenesis of 
this particular sequence had the effect of increasing the ratio of caspase 9a/9b mRNA.  
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Figure 3-2: Potential cis-regulatory elements in the exon 3,4,5,6 
cassette in caspase 9. Schematic representation of 10 potential 
regulatory cis-elements and their corresponding mutagenic sequences 
(No.’s 1-10) and location in caspase 9. Number 1 represents the 
sequence termed C9/E3-ESS. 
 
 
Mutation of this ESS also induced an increase in the ratio of caspase 9a/9b minigene 
mRNA in H2030 and H838 cells, but interestingly no effect on the C9a/C9b ratio was 
observed in non-transformed HBEC3-KT cells (Figure 3-3, Panel C).  Therefore, the 
purine-rich sequence, AGGGGA, in exon 3 of caspase 9 pre-mRNA acts as an exonic 
splicing silencer (ESS) for the inclusion/exclusion of the exon 3,4,5,6 cassette in 
transformed NSCLC cells and is designated as caspase 9 exon 3-ESS (C9/E3-ESS) for the 
remainder of the report. 
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Figure 3-3: Identification of an exonic splicing silencer in exon 3 of 
caspase 9 pre-mRNA. A) Schematic representation of the exonic splicing 
silencer (C9/E3-ESS) located in exon 3 of the caspase 9 gene.  * = 
Location of the C9/E3-ESS purine-rich sequence.  This figure also depicts 
the wild-type and mutagenic sequence of the C9/E3-ESS utilized in Panel 
C.  B) A549 cells were transfected with the pcDNA 3.1(-) zeocin plasmid 
containing the caspase 9 minigene (C9 WT MG) (1 µg), exon 3 mutant 
minigene (E3 MUT MG) (1 µg), or empty vector control (EV) (1 µg) for 24 
hours.  Total RNA was extracted and analyzed by competitive/quantitative 
RT-PCR for the ratio of minigene caspase 9a/9b mRNA.  C) Same assay 
as (B) including the cell lines H838, H2030, and HBEC3-KT. Data are N=4 
from two separate experiments. 
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3.3.2. hnRNP L binds specifically to the exonic splicing silencer in exon 3 of caspase 9 
pre-mRNA.  To study the RNA trans-factors interacting with C9/E3-ESS, a fluorescein-
tagged RNA oligonucleotide was produced corresponding to the purine-rich regions of 
exon 3, FL-5‟ GAGAGUUUGAGGGGAAAU. Electromobility shift assays (EMSAs) 
coupled with competitor studies demonstrated three specific protein:RNA complexes 
associated with this sequence designated complex I, II, and III (Figure 3-4, Panel A).  To 
identify the RNA trans-factors bound to the C9/E3-ESS, nanospray liquid 
chromatography-tandem mass spectrometry (nsno-LC-MS/MS) analysis was employed on 
the three complexes.  Besides the normal contaminants (e.g. keratin and HSP70), two RNA 
trans-factors were identified in the three RNA/protein complexes, both with x-corr values 
>20.  Specifically, hnRNP A2/B1 (36 kDa) was identified in complex I and III, while 
hnRNP L (65 kDa) was identified in complex II and III (Figure 3-4, Panel A).   
The specific interaction of these RNA trans-factors with exon 3 was verified by 
performing a biotin/streptavidin affinity assay using A549 nuclear extracts.  Biotinylated 
RNA oligonucleotides (ROs) corresponding to the purine-rich regions of exon 3 were 
utilized for this affinity assay (Table 3-1), Biotin-5‟ GAGAGUUUGAGGGGAAAU (Bio-
WT C9/E3-ESS), a mutant RO for the C9/E3-ESS, Biotin-5‟ 
GAGAGUUUGCTACTAAAU (Bio-C9/E3-ESS-mut), and a Biotin-5‟ non-specific 
control sequence (Bio-NSC2).  Analysis verified that both RNA trans-factors, hnRNP L 
and A2/B1, specifically interacted with the purine-rich regions in exon 3 of caspase 9 
(Figure 3-4, Panel B) as the non-specific RNA sequence (Bio-NSC2) did not show any 
interaction with these RNA trans-factors. More importantly, the Bio-C9/E3-ESS-mut, 
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which possesses the same mutations utilized in the minigene assays in Figure 3-3, did not 
significantly interact with hnRNP L in contrast to hnRNP A2/B1. Thus, both hnRNP L and 
hnRNP A2/B1 specifically interact with the purine-rich regions exon 3 of caspase 9 pre-
mRNA, but only hnRNP L interacts specifically with the C9/E3-ESS sequence. 
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Figure 3-4: hnRNP L associates to the purine-rich sequences in exon 
3 of caspase 9. A) A 5’ FITC-tagged RNA oligonucleotide (RO) 
corresponding to the purine-rich sequences in exon 3 of caspase 9 were 
incubated in the presence of nuclear extract from A549 cells or IgG 
(control) and subjected to EMSAs. Non-specific competitor-1 (NSC-1) or 
specific competitor (SC) ROs were also added (100-fold molar excess) as 
indicated. Arrows indicate the three specific RNA:protein complexes. The 
RNA:protein complexes (complexes I, II, and III) were also subjected to 
nano-LC-MS/MS analysis. The RNA trans-factors depicted obtained x-corr 
values > 20. B) A 5’ biotinylated wild-type C9/E3-ESS RO (Bio-C9/E3-
ESS), 5’biotinylated mutant ROs (Bio-Mut C9/E3-ESS), or a 5’ biotinylated 
non-specific RO (Bio-NSC-2) were incubated in the presence of nuclear 
extract from A549 cells or IgG (control), subjected to SDS-PAGE and 
western immunoblotting analysis (anti-hnRNP L antibody; anti-hnRNP 
A2/B1 antibody). Unlabeled non-specific ROs (e.g. NSC-1) at a 100-fold 
molar excess were also added to the reactions as indicated. Sup 
designates the corresponding supernatant from the Bio-WT C9/E3-ESS to 
show the remaining RNA trans-factor after affinity purification.  
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To determine where hnRNP A2/B1 specifically bound in exon 3 (e.g. AGGGGA) 
as well as identify other important nucleic acid residues for the hnRNP L interaction, ROs 
that possess mutations in various sites within the purine-rich regions of exon 3 were 
designed (Table 3-2).  In particular, RO4 and RO2 possess similar and flanking mutations  
 
 
 
 
compared to the “core” mutations utilized to identify C9/E3-ESS using the caspase 9 
minigene in Figure 3-3. The competition affinity-based assays utilized in Figure 3-4 were 
repeated utilizing each mutant RO as an unlabeled “cold” competitor in comparison to 
“cold” NSC and SC competitors. RO4 was unable to compete for hnRNP L interaction 
with Bio-C9/E3-ESS (Figure 3-5, Panel A). Furthermore, RO2 was only a partial 
competitor for the hnRNP L/Bio-C9/E3-ESS interaction. In contrast, the hnRNP A2/B1 
interaction with exon 3 was abolished to the same extent by RO4 and RO2 as unmutated 
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exon 3 competitor sequence (SC) (Figure 3-5, Panel B).  In further contrast, RO3 and to an 
extent RO1 were unable to compete for hnRNP A2/B1 binding in contrast to hnRNP L 
(Figure 3-5, Panel B). Therefore, hnRNP L specifically associates with C9/E3-ESS in exon 
3 as well as flanking nucleotide sequences, whereas hnRNP A2/B1 associates to a purine-
rich region 6-11 bp upstream of the previously identified C9/E3-ESS sequence (Figure 3-5, 
Panel C).  
 
 
 
Figure 3-5: hnRNP L associates specifically with the C9-E3/ESS. A and 
B) The Panel B experiments was repeated but with the addition (100-fold 
molar excess) of either unlabeled non-specific competitor (NSC1), unlabeled 
competitor ROs (RO1-RO4, or unlabeled specific competitor (SC)) as 
indicated. Data in Figure 4 are N=4 on two separate occasions. C) A cartoon 
schematic indicating the locations of the hnRNP L and hnRNP A2/B1 
interaction with exon 3 of caspase 9 pre-mRNA. 
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3.3 Discussion 
 While the alternative splicing of capsase 9 plays a role in maintaining the 
transformed phenotype of NSCLC cells, the underlying mechanism regulating this event is 
still at question. Previously, our laboratory identified an SR protein, SRp30a, as a critical 
splicing factor in the alternative splicing of caspase 9 pre-mRNA (Massiello and Chalfant, 
2006).  This led us to investigate the exon 3,4,5,6 cassette of caspase 9 for exonic splicing 
enhancers that would potentially associate with SRp30a.  Surprisingly, the studies in this 
chapter led to the identification of a purine-rich sequence in exon 3 which acted as an 
exonic splicing silencer. Mass spectrometry analysis of the RNA trans-factor associating 
with the ESS identified hnRNP L and hnRNP A2/B1.  Moreover, competition affinity 
assays demonstrated hnRNP specifically associates with the purine-rich sequence, 
AGGGGA, in comparison to hnRNP A2/B1 that associated upstream.   
 These findings are important for many reasons.  First, they provide insight to the 
mechanistic understanding of the RNA cis-elements and RNA trans-factors involved in the 
alternative splicing of caspase 9.  This is highly important as the splicing ratio of caspase 9 
has been demonstrated to be dysregulated in a significant amount of NSCLC tumors as 
well as cell lines.  In addition, the demonstration that hnRNP L associated with a purine-
rich sequence (AGGGGA) is novel as the literature has only found hnRNP L to associate 
with C/A rich cis-elements (Hui et al., 2003b; Hung et al., 2008; Yu et al., 2009).  In 
conclusion, these results demonstrate the identification of the RNA trans-factor hnRNP L 
as binding to C9-E3/ESS of the caspase 9 pre-mRNA transcript and an insight into the 
mechanistic regulation of the alternative splicing of caspase 9.  
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CHAPTER 4 
 
 
HNRNP L REGULATES THE TUMORIGENIC CAPACITY OF LUNG CANCER 
XENOGRAFTS IN MICE VIA THE ALTERNATIVE SPLICING OF CASPASE 9 
 
 
4.1. Introduction  
 Abberations in alternative splicing occurs in many cancers.  The altered transcripts 
which arise from dysregulated splicing events can bring about different protein isoforms 
with possible tumorigenic properties (Kalnina et al., 2005; Schwerk and Schulze-Osthoff, 
2005; Venables, 2006). One way in which alternative splicing events are dysregulated can 
result from the changes in concentration, localization, modification, or activity of trans-
acting factors.   
The role of alternative RNA splicing in cancer phenotypes is largely understudied, 
but several recent reports have brought to light the possibility that these RNA trans-factors 
can act as oncogenic factors.  For example, Sharp and co-workers recently demonstrated 
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that the RNA trans-factor, SRm160, played a prominent role in regulating the alternative 
splicing of CD44 stimulated by H-ras
V12
 with a biological role in the anchorage-
independent growth ability of cancer cells (Cheng and Sharp, 2006). In another report, 
Krainer and co-workers demonstrated that overexpression of SRp30a acted as an oncogene 
cooperating to enhance the tumorigenic capacity of NIH 3T3 cells in nude mice (Karni et 
al., 2007). More recently, Carstens and co-workers found that the RNA trans-factors, 
ESRP1 and ESRP2, are regulators of FRFR2 splicing. Importantly, when these regulators 
are downregulated in cells that express FGFR2-IIIb, a switch from an epithelial to a 
mesenchymal phenotype occurs (Warzecha et al., 2009). These recent reports show that 
alternative splicing plays a prominent role in the oncogenic potential of cancer cells. 
Since hnRNP L was found to be associated with an exonic splicing silencer in exon 
3 of caspase 9, we investigated the role of hnRNP L on the alternative splicing of caspase 
9.  Our studies found hnRNP L modulated the caspase 9a/9b mRNA ratio.  Further studies 
demonstrated that the phospho-state of hnRNP L is higher in NSCLC cells versus non-
transformed lung epithelial cells, and phosphorylated hnRNP L modulates the alternative 
splicing of caspase 9. Our studies also show that hnRNP L regulated the tumorigenic 
capacity of NSCLC cells via post-transcriptional processing of caspase 9 pre-mRNA.  
Therefore, this study identifies the regulation of the phospho-state of hnRNP L and 
subsequent post-transcriptional processing of caspase 9 as a key cellular mechanism for the 
growth and maintenance of NSCLC tumors. 
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4.2. Materials and Methods 
4.2.1. Cell Culture  
 
A549 cells were grown in 50% RPMI 1640 (Invitrogen Life Technologies, Carlsbad, CA) 
and 50% Dulbecco's modified Eagle's medium (Invitrogen Life Technologies, Carlsbad, 
CA) supplemented with L-glutamine, 10% (v/v) fetal bovine serum (Sigma), 100 units/ml 
penicillin G sodium (Invitrogen Life Technologies, Carlsbad, CA), and 100 μg/ml 
streptomycin sulfate (Invitrogen Life Technologies, Carlsbad, CA). H2030 and H838 cells 
were grown in RPMI 1640 supplemented with 10% (v/v) fetal bovine serum (Sigma), 100 
units/ml penicillin G sodium (Invitrogen Life Technologies, Carlsbad, CA), and 100 μg/ml 
streptomycin sulfate (Invitrogen Life Technologies, Carlsbad, CA). All adenocarcinoma 
cell lines were purchased from ATCC (Rockville, MD, USA). HBEC-3KT cells, a 
generous gift from J.D. Minna, were cultured with keratinocyte serum-free medium 
containing 50μg/ml bovine pituitary extract and 5ng/ml recombinant epidermal growth 
factor (Life Technologies, Gaithersburg, MD). All cell lines were maintained at less than 
80% confluency under standard incubator conditions (humidified atmosphere, 95% air, 5% 
CO2, 37 °C).  For all comparison studies between cell lines, 1.2 x 10
5
 cells were plated in 
tissue culture plates (6-well dish). The following day, media was removed, cells were 
washed with 1 x PBS and plated in keratinocyte serum-free medium without supplements 
overnight. Total RNA and/or protein was then isolated for analysis. 
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4.2.2. Quantitative/Competitive RT-PCR 
Total RNA from cell lines were isolated using the RNeasy® Mini Kit (Qiagen Inc., 
Valencia, CA) according to the manufacturer„s protocol. Total RNA (1 μg) was reverse-
transcribed using Superscript III reverse transcriptase (SuperScript™ First-Strand 
Synthesis System for RT-PCR, Invitrogen™, Carlsbad, CA) and oligo (dT) as the priming 
agent. After 50 min of incubation at 42°C, the reactions were terminated by heating at 
70°C for 15 min. Template RNA was then removed using RNase H (Invitrogen, Carlsbad, 
CA). To quantitatively evaluate the expression of endogenous caspase 9 splice variants, an 
upstream 5„ primer to caspase-9 (5„-GCT CTT CCT TTG TTC ATC TCC-3„) and a 3„ 
primer (5„-CAT CTG GCT CGG GGT TAC TGC-3„) (Integrated DNA Technologies, Inc., 
Coralville, IA) were used. Using these primers, 20% of the reverse transcriptase reaction 
was amplified for 25 cycles (94°C, 30 s melt; 57°C, 30 s anneal; 72°C, 1 min extension) 
using Platinum Taq DNA polymerase (Invitrogen Life Technologies, Carlsbad, CA). Gene 
products produced from endogenous caspase 9 PCR resulted in a 1248 base pair caspase 9a 
splice variant and 798 base pair caspase 9b splice variant. The primers used to evaluate 
caspase 8 splice variants are sense (5„-GCA TTA GGG ACA GGA ATG GA-3„) and 
antisense (5„-GAA GGG GAC TTC AAA CCA GTG-3„). The PCR conditions for caspase 
8 were 95ºC for 5 mins followed by 25 cycles of 94ºC for 30s, 60ºC for 30s and 72ºC for 
1min. The primers used to evaluate caspase 2 splice variants are sense (5„-ACT TGC TGC 
CTA AGA GGG GTC- 3„) and antisense (5„-CTT GGG CAG TTG GCG TTG TC -3„). 
The PCR conditions for caspase 2 were 95ºC for 5 mins followed by 25 cycles of 94ºC for 
30s, 64ºC for 30s and 72ºC for 1min. The primers used to evaluate Bcl-x splice variant 
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were (5„-GAG GCA GGC GAC GAG TTT GAA-3„) and (5„-TGG GAG GGT AGA GTG 
GAT GGT-3„). The PCR conditions for analyzing the expression of Bcl-x splice variants 
were 95ºC for 5 mins followed by 25 cycles of 94ºC for 30s, 58ºC for 30s and 72ºC for 
1min. The final PCR products were resolved on a 5% TBE acrylamide gel electrophoresis, 
stained with SYBR® Gold (Invitrogen™, Carlsbad, CA) and visualized using a Molecular 
Imager® FX (Bio-Rad) with a 488 nm EX (530 nm BYPASS) laser. 
 
4.2.3. Silence interfering RNA transfection   
For inhibition of hnRNP A2/B1 and hnRNP L, cell lines were transfected with either 
hnRNP A2/B1 SMARTpool multiplex, hnRNP L SMARTpool multiplex or scrambled 
control siRNA (Dharmacon; Lafayette, CO) using Dharmafect 1 transfection reagent 
(Dharmacon; Lafayette, CO) following the manufacturer„s protocol. Briefly, cell lines 
were plated in six-well tissue culture dishes and allowed to rest overnight. At 50% 
confluence, cells were transfected with siRNA [100nM] using Dharmafect 1 in Opti-Mem 
I reduced-serum medium. Forty-eight hours post-transfection, RNA and/or protein were 
isolated. 
 
4.2.4. Plasmid Transfection  
Cell lines were transfected with caspase 9 minigene constructs and additional plasmid 
vectors using Effectene
® 
Transfection Reagent (Qiagen; Valencia, CA) following the 
manufacturers protocol. Briefly, cell lines were plated at ~ 70% confluency in 6-well tissue 
culture dishes. Cells were transfected with plasmid constructs (1 µg) (see Table 2-3) 
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followed by 24 h standard incubation.  After 24 h standard incubation, cells were examined 
for minigene expression or endogenous expression by quantitative/competitive reverse 
transcription (RT)-PCR.  This procedure routinely gave 50% transfection efficiency for 
A549 cells. 
 
4.2.5. Stable transfections  
Lentivirus transfection/selection: A549 cells (15 x 10
4
) were  transduced with lentivirus 
(20 MOI) as described by manufacturers protocol for 24 hrs. The following day, lentivirus 
containing media was switched with pre-warmed media for 24 hrs followed by puromycin 
(50 µg/mL) selection for 2 weeks.  For batch culture cell lines, cells were consistently 
treated with puromycin selection marker for 2 weeks.  For clonal cell lines, clonal rings 
were placed over individual colonies, trypsinized, and placed in 12-well plates.   
 
Plasmid transfection/selection: A549 cells (15 x 10
4
) were transfected with the appropriate 
plasmid (1 µg) using effectene following the manufacturer‟s protocol (Qiagen). For 
selection purposes, cells were passaged into zeocin selection medium 24 hrs after 
transfection to produce batch and clonal cell lines.  
 
4.2.6. Immunoprecipitation  
Cells were washed with 1 x PBS and scraped in 1 x IP buffer containing: 1% Triton x-100, 
150 mM NaCl, 10 mM Tris pH 7.4, 1 mM Na3VO4, 1 mM EDTA pH 8.0, 0.5% NP-40, 0.2 
mM PMSF, 0.5 mM 4-DOP, and 1 x complete protease inhibitor.  The lysates were then 
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sonicated, centrifuged, and the resulting supernatant was collected for analysis.  200 µg of 
each sample lysate was pre-cleared with pre-washed protein G sepharose beads for 1 hour 
at 4º with gentle agitation.  After pre-clearing, samples were centrifuged and sample 
lysates were collected.  For phosphorylation comparison amongst different cell lines, 
hnRNP L monoclonal antibody (3 µg) was placed in each sample and in 4ºC with gentle 
agitation overnight.  For serine
52
 phosphorylation studies, 3 µg of myc-tag was placed into 
the samples. The following day, pre-washed protein G sepharose beads were added to each 
sample and placed in 4º with gentle agitation for 1 h.  After 1 h incubation, bead 
complexes were centrifuged, washed extensively with 1 x IP buffer, pelleted by 
centrifugation, resuspended in Laemmli buffer, dry boiled for 10 min, and subjected to 
SDS-PAGE/western immunoblotting analysis. 
 
4.2.7. Confocal Microscopy  
For confocal microscopy, the cells were seeded onto 22 x 22
 
mm coverslips in 35 mm 
plates in their appropriate
 
medium and incubated at 37°C under 5% CO2 overnight. The
 
next day, cells were washed twice with
 
1 x
  
PBS then fixed with 100% cold methanol for 
10 min at –20°C. The slides were then washed with 1 x PBS containing 10 mM glycine and 
0.2% sodium azide, followed by incubation (40 min) with the primary antibody: anti-
hnRNP L (1:100) (Sigma). After the primary antibody incubation, cells were washed with 
1 x PBS, followed by incubation with anti-mouse Alexafluor 488 secondary antibody 
(1:500) for 30 min at room temperature.
  
Coverslips were mounted in 10 mM n-propagalate 
in glycerol and
 
viewed using a Leica confocal microscope (TCS-SP2 (AOBS)). 
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4.2.8. Statistical analysis  
Statistical differences between treatment groups were determined by a 2-tailed, unpaired 
student t-test when appropriate. P-values less than or equal to 0.05 were considered 
significant.  
 
4.2.9. Imaging/quantification  
All data presented in this chapter was generated via using multiple laser scans or film 
exposures and are not manipulated by adjusting brightness and contrast. Multiple 
exposures and various scans at multiple laser intensities were utilized to present the data 
for easy discernment of the appropriate effects by readers. 
 
4.2.10. Animals and Tumor Models  
Six-week-old male CB17-Prkdc
scid
/NCrCrl ORIGIN SCID mice were purchased from 
Charles River Laboratories. Animal experiments were conducted at Virginia 
Commonwealth University (VCU) (Richmond, VA).  The research protocol IACUC 
AM10070: NSCLC xenografts in SCID mice was approved by the VCU Institutional 
Animal Care and Use Committee (IACUC) involving animal care in accordance with the 
USDA Animal Welfare Regulations; the Public Health Service Policy on the Humane Care 
and Use of Laboratory Animals; and The U.S. Government Principles for the Utilization 
and Care of Vertebrate Animals Used in Testing, Research, and Training.  VCU is in 
compliance with all provisions of the Animal Welfare Act and other federal statues and 
regulations relating to animals.  VCU is registered under the Animal Welfare Act as a 
70 
Class “R” Research Facility with the USDA-APHIS-Animal Care (Registration number: 
52-R-0007).  The Office of Laboratory Animal Welfare (OLAW) has approved the VCU‟s 
Animal Welfare Assurance in compliance with the PHS Policy (Assurance number: 
A3281-01).  The SCID mice were acclimatized to the VCU‟s Medical School Animal 
Facility for 1 week before they received injections of cancer cells: 5 x 10
6
 A549 human 
NSCLC cells were resuspended in 100 µL Matrigel (BD Biosciences) and injected 
subcutaneously into the right hind flank.  Tumors were allowed to develop up until 4 
weeks.  After, mice were sacrificed and tumors were extracted for further analysis. 
 
 
 
4.3. Results 
4.3.1. hnRNP L regulates the alternative splicing of caspase 9 in non-small cell lung 
cancer cells.  Although hnRNP A2/B1 did not assoicate specifically to the C9/E3-ESS as 
compared to hnRNP L demonstrated in the previous chapter, a role for this RNA trans-
factor in repressing the inclusion of the exon 3,4,5,6 cassette was still a possibility. To 
examine the role of both hnRNP A2/B1 and hnRNP L in regulating the ratio of caspase 9 
splice variants, small interference RNA (siRNA) technology was utilized.  Downregulation 
of hnRNP L using a multiplex siRNA (100 nM (25 nM for each sequence)) resulted in a 
significant increase in the ratio of caspase 9a/9b mRNA from 2.2 ± 0.07 to 3.9 ± 0.07, p < 
0.005 (N=4) (Figure 4-1, Panel A).  On the other hand, multiplex siRNA treatment against 
hnRNP A2/B1 had no significant effect on the ratio of caspase 9a/9b mRNA (Figure 4-1, 
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Panel B). Western immunoblot analysis confirmed a > 80% downregulation of both 
hnRNP A2/B1 and hnRNP L compared to samples from cells treated with control siRNA 
(Figure 4-1, Panels A and B).  Importantly, the effect of hnRNP L siRNA on the caspase 
9a/9b mRNA ratio translated to the protein level (Figure 4-1, Panel C). 
The observed effect of hnRNP L downregulation on the caspase 9a/9b mRNA ratio 
could not be attributed to off-target effects as multiple siRNA sequences targets against 
hnRNP L produced the same result (Figure 4-2, Panel A) with no effect for hnRNP A2/B1 
(Figure 4-2, Panel B), and a dose response curve for the most effective siRNA 
demonstrated an IC50 < 25 nM for hnRNP L siRNA with again no effect observed for 
hnRNP A2/B1 siRNA (Figure 4-3, Panels A and B).  Lastly, several stable cell lines were 
produced from hnRNP L and hnRNP A2/B1 shRNA.  All of the hnRNP L shRNA cell 
lines demonstrated a significant effect on the ratio of caspase 9a/9b mRNA (Figure 4-3, 
Panel C).  In contrast, none of the hnRNP A2/B1 shRNA cell lines presented with an 
increase in the ratio of caspase 9a/9b mRNA (Figure 4-3, Panel D).  As caspase 9a and 9b 
are transcribed from the same gene, possess the same 5‟UTR, and the same 3‟UTR 
sequences: the effect of hnRNP L downregulation is likely attributed to the regulation of 
the alternative splicing of caspase 9, and not attributed to effects on transcription, 
translation, or mRNA stability.  Specifically, transcriptional activation/repression could not 
account for the changes in the C9a/9b mRNA ratio as both are derived from the same 
promoter, and actinomycin D treatment did not affect the caspase 9a/9b mRNA ratio (data 
not shown).  Our observed effect of hnRNP L siRNA also cannot be attributed to 
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Figure 4-1: Downregulation of hnRNP L, but not hnRNP A2/B1 
increases the ratio of caspase 9a/9b mRNA. A549 cells were 
transfected with either control siRNA (100 nM), hnRNP L 
SMARTpool siRNA (100 nM), or hnRNP A2/B1 SMARTpool siRNA 
(100 nM) for 48 h. Total RNA was isolated and analyzed by 
competitive/quantitative RT-PCR for caspase 9 splice variants. A) 
hnRNP L siRNA and B) hnRNP A2/B1 siRNA). Simultaneously, 
total protein lysates were also produced, subjected to SDS-PAGE 
analysis and immunoblotted for hnRNP L, hnRNP A2/B1, caspase 
9, and β-actin. Of note, the data in panel (C) are from the same 
western membrane depicted in Panel A for hnRNP L and β-actin. 
Data are N=4 on two separate occasions. 
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Figure 4-2: A549 cells were transfected with 3 different duplex sequences 
of hnRNP L siRNA and hnRNP A2/B1 siRNA at a final concentration of 100 
nM. As a control, scrambled siRNA (100 nM) was utilized. Total RNA was 
isolated and analyzed by competitive/quantitative RT-PCR for caspase 9 
splice variants. The ratio of caspase 9a/9b mRNA was determined by 
densitometric analysis of RT-PCR fragments. Simultaneously, total protein 
lysates were also produced, subjected to SDS-PAGE analysis and 
immunoblotted for anti-hnRNP L, anti-hnRNP A2/B1, and β-actin as 
described in the “Materials and Methods” section. (A) hnRNP L; B) hnRNP 
A2/B1). 
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Figure 4-3: Both siRNA and shRNA against hnRNP L demonstrate an increase in the 
caspase 9 spicing ratio. A,B) A549 cells were transfected with a final concentration of 
100nM control siRNA or dose-responsive treatments of 25 nM and 50 nM for sihnRNP L 
or sihnRNP A2/B1. Total RNA was isolated and analyzed by competitive/quantitative RT-
PCR for caspase 9 splice variants. The ratio of caspase 9a/9b mRNA was determined by 
densitometric analysis of RT-PCR fragments. Simultaneously, total protein lysates were 
also produced, subjected to SDS-PAGE analysis and immunoblotted for hnRNP L, hnRNP 
A2/B1, and β-actin as described in the “Materials and Methods” section (A) hnRNP A2/B1; 
B) hnRNP L). Data represent 4 separate determinations on 3 separate occasions. C,D) 
Total RNA was isolated from A549 stable cell lines and analyzed by 
competitive/quantitative RT-PCR for caspase 9 splice variants. Total protein lysates were 
also produced, subjected to SDS-PAGE analysis and immunoblotted for hnRNP L, hnRNP 
A2/B1, and β-actin (C) hnRNP L; D) hnRNP A2/B1). 
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translation as the observed changes in the ratio of caspase 9a/9b mRNA were mirrored at 
the protein level.  There is the possibility that changes in mRNA stability played a role in 
our observations as hnRNP L has been shown to regulate the stability of specific mRNAs 
(Hui et al., 2003a; Shih and Claffey, 1999), but the half-life of caspase 9a and 9b mRNA 
was previously shown by our laboratory to be unaffected
 
by agonists (Chalfant et al., 
2002). Furthermore, treatment of A549 control shRNA and A549 hnRNP L shRNA cell 
lines with actinomycin D demonstrated no significant difference in the decay rates (e.g. 
T½) of caspase 9a and caspase 9b mRNAs in the presence or absence of hnRNP L (data not 
shown).  This finding suggests that hnRNP L does not regulate the mRNA stability of 
either splice variant although known caveats in the use of actinomycin D makes definitive 
conclusions difficult. Overall, the data support the conclusion that hnRNP L and not 
hnRNP A2/B1 acts as a repressor of the inclusion of the exon 3,4,5,6 cassette of caspase 9 
via manipulation of the alternative splicing of caspase 9 pre-mRNA.   
To determine whether this mechanism demonstrated translatability in NSCLC, 
hnRNP L siRNA was again employed in H838 and H2030 cells. The role of hnRNP L was 
further corroborated in these NSCLC cell lines as downregulation of hnRNP L by siRNA 
produced a concomitant increase in the ratio of caspase 9a/9b mRNA or H838: 2.0 ± 0.13 
for siControl to 4.1 ± 0.09 for sihnRNP L and H2030: 2.1 ± 0.13 for siControl to 3.7 ± 0.22 
for sihnRNP L (Figure 4-4, Panels A and B).  
To demonstrate the specificity of hnRNP L in regulating the alternative splicing of 
caspase 9, other major factors of apoptosis were also examined (e.g. caspase 8, caspase 2, 
and Bcl-x) using quantitative/competitive RT-PCR.  Downregulation of hnRNP L with 
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siRNA demonstrated no effect on the alternative splicing of caspase 8, caspase 2, and Bcl-
x (Figure 4-5).  Thus, the effect of downregulating hnRNP L is specific for regulating the 
alternative splicing of caspase 9, and not a generalized effect on pre-mRNA processing. 
Since siRNA and shRNA can have numerous biological and sequence-specific 
effects, the reciprocal experiment was also undertaken in which low ectopic expression of 
hnRNP L in conjunction with the caspase 9 minigene was utilized.  Transfection of A549 
cells with hnRNP L (low ectopic expression) induced the opposite effect of hnRNP L 
siRNA inducing a moderate, but significant reduction in the ratio of caspase 9a/9b 
minigene mRNA (Figure 4-6, Panel A) (Note: the ratio of minigene caspase 9a/9b mRNA 
gives a slightly higher ratio ranging from 2.7 – 3.2 in A549 cells compared the a ratio of 
1.9 – 2.2 for endogenous caspase 9a/9b mRNA).  To demonstrate translatability, H2030 
and H838 cells were again utilized and low ectopic expression of hnRNP L demonstrated 
the same effect on lowering the ratio of the caspase 9a/9b minigene mRNA (Figure 4-6, 
Panels B and C).   
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Figure 4-4: H838 and H2030 cell lines were transfected with scrambled 
siRNA (100 nM), or hnRNP L SMARTpool siRNA (100 nM), for 48 hr. Total 
RNA was isolated and analyzed by competitive/quantitative RT-PCR for 
caspase 9 splice variants. The ratio of caspase 9a/9b mRNA was 
determined by densitometric analysis of RT-PCR fragments. 
Simultaneously, total protein lysates were also produced, subjected to 
SDS-PAGE analysis and immunoblotted for anti-hnRNP L and β-actin as 
described in the “Materials and Methods” section. Data are representative 
of three separate determinations on two separate occasions (A) H2030; B) 
H838). 
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Figure 4-5: A549 cells were transfected with scrambled siRNA (100 nM), 
or hnRNP L SMARTpool siRNA (100 nM) for 48 hr. Total RNA was isolated 
and analyzed by competitive/quantitative RT-PCR for the designated splice 
variants. The ratio of: A) caspase-2S/2L, B) Bcl-xL/Bcl-xS, and C) 
caspase-8L/caspase 8 mRNA was determined by densitometric analysis of 
RT-PCR fragments. Data are representative of three separate 
determinations on two separate occasions. Samples utilized for the 
presented data were verified to demonstrate significant effects on caspase 
9 splicing in response to hnRNP L siRNA. 
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Figure 4-6:  Low ectopic expression of hnRNP L decreases the 
caspase 9a/9b splicing ratio. A) A549, B) H838, C) H2030 cell lines were 
transfected with either wild-type hnRNP L (WT-hnRNP L) (0.25 μg) in 
conjunction with caspase 9 minigene (C9 WT MG) (0.25 μg) or caspase 9 
minigene (C9 WT MG) (0.25 μg) in conjunction with empty vector (EV) 
(0.25 μg) for 24 h. Total RNA was extracted and analyzed by 
competitive/quantitative RT-PCR for caspase 9 minigene splice variants. 
Data are N=4 from two separate occasions. Of note: the ratio of capsase 
9a/9b minigene mRNA tends to present with a slightly higher ratio than 
endogenous caspase 9a/9b mRNA. 
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4.3.2. hnRNP L regulates the anchorage-independent growth of NSCLC cells via the 
pre-mRNA processing of caspase 9.  Modulation of the levels of splice variants of 
caspase 9 had dramatic effects on anchorage-independent growth (AIG) and the 
tumorigenic capacity of NSCLC cells.  Thus, we hypothesized that hnRNP L plays a major 
role in maintaining the transformed phenotype of NSCLC cells through modulation of the 
pre-mRNA processing of caspase 9. To test this hypothesis, multiple clones of A549 cells 
stably expressing hnRNP L shRNA were produced (Figure 4-7, Panel A and Table 2-3).  
As with the studies utilizing caspase 9b shRNA cell lines, the first physiologic parameter 
examined was AIG. Stable expression of hnRNP L shRNA abolished the ability of A549 
cells to grow in soft agar (Figure 4-7, Panels B and C). More importantly, low ectopic 
expression of caspase 9b cDNA (e.g. returned the ratio of caspase 9a/9b mRNA from 3.8 
to 1.6) in the hnRNP L shRNA cell lines “rescued” the loss of AIG in A549 cells (Figure 
4-7, Panel B and C). These effects did not require stable expression and were not due to 
integration artifacts as short term expression of hnRNP L shRNA or use of stable “batch” 
cell lines produced comparable results (data not shown).  Furthermore, the effect on AIG 
induced by downregulation of hnRNP L was specific for the loss of caspase 9b as ectopic 
of expression of other apoptosis inhibitory factors, CrmA and Bcl-x(L), could not “rescue” 
the phenotype (Figure 4-7, Panel D, Upper Panel).  Lastly, the stable re-expression of 
shRNA-resistant hnRNP L also “rescued” the loss of AIG induced by the loss of hnRNP L 
shRNA demonstrating the specificity for the loss of hnRNP L in both the RNA splicing 
and biological mechanisms (Figure 4-7, Panel D, Lower Panel). 
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Figure 4-7: hnRNP L regulates the anchorage-independent growth  in 
A549 cells via the alternative splicing of caspase 9. A) Total RNA was 
isolated from the listed clonal cell lines and analyzed by 
competitive/quantitative RT-PCR for caspase 9 splice variants. B) Colony 
formation assays in soft agar for the A549 shRNA and vector control, A549 
+ hnRNP L shRNA, and A549 + hnRNP L shRNA + C9b ectopic cell lines. 
A total of 2,000 cells were plated into 6-well tissue culture dishes in soft 
agar and cultured for 14 days before the colony count. C) Quantization 
(mean) of the number of colonies for the indicated clonal cell lines. N=6; 
error bars represent SE; *P < 0.005 between A549 + shRNA control versus 
A549 + hnRNP L shRNA; **P < 0.001 between A549 + vector control 
versus A549 + hnRNP L shRNA + C9b ectopic, student t-test.   
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Figure 4-7 cont.: D) Upper Panel: Characterization of A549 + Control 
shRNA, and A549 + hnRNP L shRNA with null, CrmA, or Bcl-xL 
adenoviruses at a 20 MOI. Total protein was isolated from the listed cell 
lines, subjected to SDS-PAGE analysis, and immunoblotted for hnRNP L, 
Bcl-xL, and β-actin. Lower Panel: Colony formation assays in soft agar for 
upper panel cell lines. Cells (2 x 103) were plated into 6-well dishes in soft 
agar and cultured for 14 days before the colony count.  N=9, error bars 
represent SD; significant effect was observed as compared with vector 
control cells (e.g. P < 0.005 by students t-test). E) Left Panel: Total RNA 
was isolated from the listed clonal cell lines and analyzed by 
competitive/quantitative RT-PCR for caspase 9 splice variants. Right 
Panel: Quantization (mean) of the number of colonies for the indicated 
stable batch culture cell lines. N=6; error bars represent SE. 
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Figure 4-7 cont. E) Left Panel: Total RNA was isolated from the listed 
clonal cell lines and analyzed by competitive/quantitative RT-PCR for 
caspase 9 splice variants. Right Panel: Quantization (mean) of the number 
of colonies for the indicated stable batch culture cell lines. N=6; error bars 
represent SE. 
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These observations translated to the NSCLC cell lines, H838 and H2030 cells, as 
no stable clones of either cell line were obtained for hnRNP L shRNA in contrast to 
control shRNA and null lentivirus. Thus, both H838 and H2030 completely lost clonogenic 
capacity in the absence of hnRNP L, which correlated in the induction of apoptosis as 
assayed by PARP cleavage (e.g. caspase activation) (data not shown).  Importantly, stable 
expression of caspase 9b cDNA “rescued” this phenotype allowing for stable clones to be 
obtained for hnRNP L shRNA (data not shown). Thus, the loss of clonogenic capacity by 
stable expression of hnRNP L shRNA was at least in part via loss of caspase 9b 
expression. Therefore, the biological effects of hnRNP L downregulation and subsequent 
modulation of the pre-mRNA processing of caspase 9 translates to other NSCLC cell lines. 
   
4.3.3. hnRNP L regulates the tumorigenic capacity of NSCLC cells via the pre-mRNA 
processing of caspase 9.  The tumorigenic capacity of these cell lines were also 
characterized using A549 xenograph tumor formation in severe combined-
immunodeficiency mice.  Figure 4-8, Panel A shows that stable downregulation of hnRNP 
L in A549 cells led to a complete loss of tumor formation (0/8). Pathological analysis 
confirmed the complete loss of tumor formation for hnRNP L shRNA cell lines. 
Comparable to the AIG effects, ectopic expression of caspase 9b completely “rescued” the 
loss of tumor formation induced by downregulation of hnRNP L (7/7 xenographs). 
Furthermore, pathological analysis of the hnRNP L shRNA/caspase 9b cell line 
demonstrated that ectopic expression of C9b also “rescued” the classification/grade of the 
hnRNP L shRNA cell line (Figure 4-8, Panel B). Overall, these data demonstrate that the 
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loss of hnRNP L dramatically alters the tumorigenic capacity of NSCLC cells. 
Furthermore, these data demonstrate that the effect of hnRNP L shRNA on the tumorigenic 
capacity is predominantly via manipulation of the pre-mRNA processing of caspase 9. 
 
 
Figure 4-8: hnRNP L regulates the tumorigenic capacity in A549 cells 
via the alternative splicing of caspase 9. A) The cell lines presented 
Panel A were injected into SCID mice (5 x 106), and tumor volume was 
measured at the end of 28 days as represented as average size of tumor 
(cm3); error bars indicate SE; *P <0.05 between A549 + hnRNP L shRNA 
versus A549 + hnRNP L shRNA + RM (resistant mutant), student t-test. B) 
H&E stain of the tumors presented in Panel D with magnification. 
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4.3.4. hnRNP L is hyper-phosphorylated in a cancer specific manner.  The expression 
of hnRNP L was not increased in NSCLC cells, thus, hnRNP L expression did not 
correlate with a low ratio of caspase 9a/9b mRNA (Figure 4-9, Panel A).  This disparity 
was further enhanced by the observation that neither downregulation of hnRNP L nor 
ectopic expression of hnRNP L in immortalized HBEC-3KT cells affected the 
inclusion/exclusion of the exon 3,4,5,6 cassette of caspase 9 in the same manner as 
NSCLC cells (Figure 4-9, Panels B and C).   
 The above results suggested several possibilities for the contrasting findings in 
NSCLC cells versus non-transformed cells such as mis-localization (Taguchi et al., 2004), 
post-translational modifications of hnRNP L (Melton et al., 2007; Yu et al., 2009), or both 
which modifies the repressing capabilities of hnRNP L. To date, no confirmed phospho-
site(s) have been established for hnRNP L functionality. Figure 4-10 presents data that 
“ruled out” the mis-localization of hnRNP L as no difference in cellular distribution was 
observed between HBEC-3KT cells and several NSCLC cell lines. The phospho-state of 
hnRNP L between these cell lines was then examined using specific phospho-residue 
antibodies, and A549 cells demonstrated a dramatic enhancement of phosphorylated 
hnRNP L compared to HBEC-3KT cells (Figure 4-11). Specifically, hnRNP L presented 
with a dramatic increase (10-fold) in phospho-threonine along with a significant increase 
in both serine (4-fold) and tyrosine (2-fold) phosphorylation in A549 cells compared to the 
non-transformed HBEC-3KT cells.  To determine whether this observed phosphorylation 
demonstrated translatability in NSCLC, hnRNP L immunoprecipitation was employed in 
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H838 cells, and this NSCLC cell line also presented with a significant increase in serine 
and threonine phosphorylation (data not shown).  Thus, an enhanced phospho-state of 
hnRNP L was observed in NSCLC cells versus non-transformed cells. 
 
 
 
 
Figure 4-9: The role of hnRNP L in regulating the alternative splicing of 
caspase 9 in non-transformed human bronchial epithelial cells. A) Total 
protein lysates from A549, H838, H2030, and HBEC-3KT cell lines were 
subjected to SDS-PAGE analysis and immunoblotted for hnRNP L and β-
actin. B) HBEC-3KT cells were transfected with 100 nM control siRNA or 100 
nM hnRNP L SMARTpool siRNA for 48 h. Total RNA was isolated and 
analyzed by competitive/quantitative RT-PCR for caspase 9 splice variants. 
Simultaneously, protein lysates were also produced, subjected to SDS-PAGE, 
and immunoblotted for hnRNP L and β-actin. Data are N=4 from two separate 
occasions. C) HBEC-3KT cell lines were transfected with either wild-type 
hnRNP L (WT-hnRNP L) (1 μg) in conjunction with caspase 9 minigene (C9 
WT MG) (1 μg) or caspase 9 minigene (C9 WT MG) (1 μg) in conjunction with 
empty vector (EV) (1 μg) for 24 h. Total RNA was extracted and analyzed by 
competitive/quantitative RT-PCR for caspase 9 minigene splice variants. Data 
are N=3 on two separate occasions. Of note: the ratio of capsase 9a/9b 
minigene mRNA tends to present with a slightly higher ratio than endogenous 
caspase 9a/9b mRNA.  
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Figure 4-10: For confocal microscopy, the A549, H838, H2030, and 
HBEC-3KT cell lines (5 x 103) were seeded onto coverslips and 
subjected to standard incubator conditions for 24 hrs. Cells were then 
fixed with 100% cold methanol for 10 min at –20°C. The slides were 
washed extensively after fixing with PBS containing 10 mM glycine and 
0.2% sodium azide. The cells were then incubated for 1 hr with the 
primary antibody, hnRNP L (1:100), followed by incubation with an 
AlexaFlour488 anti-mouse secondary antibody (1:500) (green). 
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Figure 4-11: hnRNP L is hyper-phosphorylated in NSCLC cells versus 
non-transformed cells. A549 and HBEC-3KT cell lines were seeded at 
the same confluency and incubated in the same culture media 24 h before 
the immunoprecipitation extract was isolated. Immunoprecipitated (IP) 
hnRNP L was resolved by SDS-PAGE and immunoblotted (WB) with 
specific phospho-serine, phospho-threonine, phospho-tyrosine, and hnRNP 
L antibodies as indicated 
 
 
4.3.5. The phosphorylation of hnRNP L on serine
52
 regulates the alternative splicing 
of caspase 9 in NSCLC.  Once hnRNP L was determined to be hyper-phosphorylated in a 
cancer-specific manner, we analyzed the amino acid sequence for hnRNP L for 
phosphorylation sites by mitogenic, cell survival, and oncogenic kinases. Several mass 
spectrometry databases were also consulted for references to identified/verified 
phosphorylated amino acids for hnRNP L. Table 4-1 designates the possible phospho-sites 
for hnRNP L as predicted by PhosphositePlus, a phosphosite determination database (Cell 
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Signaling Technology, Danvers, MA) (Sui et al., 2008), Human Protein Reference 
Database resource (HPRD) (Keshava Prasad et al., 2009), Scansite (MIT) (Obenauer et al., 
2003), and UniProtKB/Swiss-Prot (2009).  
 
 
 
To determine which of these residues of hnRNP L regulated the exclusion of the 
exon 3,4,5,6 cassette of caspase 9, site-directed mutagenesis was utilized to convert 
relevant serines and threonines to alanine and tyrosines to phenylalanine.  A549 cells were 
transiently transfected (> 50% transfection efficiency) with each mutant or wild-type 
hnRNP L, and the effect on the alternative splicing of endogenous caspase 9 assayed by 
competitive/quantitative RT-PCR.  Only ectopic expression of hnRNP L (Ser
52
Ala) 
induced a significant increase in the splicing ratio of caspase 9 in comparison ectopic 
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expression wild-type hnRNP L and empty vector controls (Figure 4-12, Panel A; Table 4-
1). To verify this result and “rule out” structural problems caused by mutation of this 
residue, a phospho-mimic mutation was created, hnRNP L (Ser
52
Asp).   In contrast to the 
Ser
52
Ala mutation, transfection of hnRNP L (Ser
52
Asp) in A549 cells did not significantly 
affect the endogenous splicing ratio of caspase 9 in comparison to ectopic expression of 
wild-type hnRNP L suggesting that either the levels of phosphorylated hnRNP L in 
NSCLC cells are sufficient to affect limiting levels of endogenous caspase 9 pre-mRNA or 
this mutation cannot mimic the phosphorylation of serine
52
 appropriately (Figure 4-12, 
Panel A). Equivalent expression was verified by western immunoblotting for the myc-tag 
associated with ectopically expressed hnRNP L (Figure 4-12, Panel B). Both phospho-
mutants of hnRNP L also localized to only the nucleus (data not shown). 
To demonstrate that phosphorylation on Ser
52
 was responsible for the serine hyper-
phosphorylation of hnRNP L in NSCLC cells, wild-type hnRNP L and the Ser
52
Ala mutant 
of hnRNP L were transfected into A549 and HBEC-3KT cells followed by specific 
immunoprecipitation of ectopically expressed/myc-tagged hnRNP L.  Whereas wild-type 
hnRNP L (ectopically expressed) in A549 cells demonstrated a >3-fold increase in serine 
phosphorylation in comparison to ectopic expression in HBEC-3KT cells (in complete 
agreement with the endogenous findings for hnRNP L presented in Figure 4-11), the 
Ser
52
Ala mutant of hnRNP L demonstrated a dramatic reduction in serine phosphorylation 
now comparable to non-transformed HBEC-3KT cells (Figure 4-12, Panel C). To further 
demonstrate that hnRNP L is phosphorylated on Ser
52 
in a cancer-specific manner, we 
created a custom phospho-specific Ser
52 
hnRNP L antibody.  Whole cell lysates from  
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A549, H838, H2030 and non-transformed HBEC-3KT cell lines were utilized to examine 
phospho-Ser
52
 state of hnRNP L by western immunoblot analysis.  All three cell lines 
demonstrated the expression of phospho-Ser
52
 hnRNP L compared to the non-transformed 
HBEC-3KT cells, which demonstrated no discernable phospho-Ser
52
 hnRNP L (Figure 4-
12, Panel D).  Thus, hnRNP L is specifically phosphorylated on Ser
52
 in NSCLC cells, and 
the phospho-state of this residue of hnRNP L regulates the pre-mRNA processing of 
caspase 9. 
 To examine whether Ser
52
 of hnRNP L played a role in AIG of NSCLC cells, the 
hnRNP L (Ser
52
Ala) mutant and wild-type hnRNP L were stably expressed (“batch”) in 
A549 cells.  Analogous to transient expression of the hnRNP L Ser
52
Ala mutant, stable 
expression of the hnRNP L Ser
52
Ala mutant induced an increase in the caspase 9a/9b 
mRNA ratio from 2.0 ± 0.13 to 3.2 ± 0.10. Stable transfection of the hnRNP L (Ser
52
Ala) 
mutant dramatically decreased the AIG ability of A549 cells in comparison to stable 
expression of wild-type hnRNP L (Figure 4-13).  Furthermore, re-expression of caspase 9b 
in the same cell lines completely “rescued” the effect of the hnRNP L (Ser52Ala) mutant on 
AIG (Figure 4-13).  Therefore and in an analogous fashion to hnRNP shRNA, the 
phosphorylation of hnRNP L on Ser
52
 regulates the ability of NSCLC cells to grow in 
anchorage-independent manner via the pre-mRNA processing of caspase 9.   
 
93 
 
 
Figure 4-12: Serine52 of hnRNP L is hyper-phosphorylated in NSCLC cells and 
regulates the alternative splicing of caspase 9. A) A549 cells were transfected 
with either wild-type hnRNP L (WT-hnRNP L) (1 μg), Ser52Ala hnRNP L (S52-A) (1 
μg), or Ser52Asp hnRNP L (S52-D) (1 μg) for 24 hrs. Total RNA was extracted and 
analyzed by competitive/quantitative RT-PCR for caspase 9 splice variants. Data 
are N=4 from 3 separate occasions. B) A549 cells were transfected with either 
hnRNP L-WT, S52-A, and S52-D plasmids. After 24 hrs, total protein lysates were 
produced, subjected to SDS-PAGE analysis and immunoblotted for myc-tag and β-
actin to demonstrate equivalent expression of each plasmid. (Note: The equivalent 
expression experiment presented in this panel was generated concurrently with the 
data presented in Panels B and C.) Empty vector control was examined separately 
and showed no expression of a myc-tagged protein C) A549 and HBEC-3KT cell 
lines were seeded at the same confluency and incubated in the same culture media 
for 24 h before immunoprecipitation extracts were isolated. Cell lines were 
transfected with either wild-type hnRNP L (WT-hnRNP L) (1 μg), or Ser52Ala hnRNP 
L (Ser52-A) (1 μg) for 24 hrs. Ectopically expressed hnRNP L was 
immunoprecipitated (IP) with c-myc tag antibody (myc), resolved by SDS-PAGE, 
and immunoblotted (WB) with anti-phospho-serine, and anti-c-myc tag antibodies as 
indicated. D) Total protein lysates were produced for A549, H838, and non-
transformed HBEC-3KT cell lines, subjected to SDS-PAGE analysis, and 
immunoblotted for phospho-Ser52-hnRNP L, and hnRNP L.  The phospho-ser52 
antbody for hnRNP L was validated by ELISA, hnRNP shRNA samples, and lack of 
identifying the Ser52Ala mutant of hnRNP L. 
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Figure 4-13. Ser52 of hnRNP L regulates the anchorage-independent 
growth of NSCLC cells.  Colony formation assays in soft agar for the 
A549 vector control, A549 + WT hnRNP L, A549 + S52-A hnRNP L, A549 
+ WT hnRNP L + C9b ectopic, and A549 + S52-A hnRNP L + C9b ectopic 
cell lines.  A total of 2,000 cells were plated into 6-well tissue culture dishes 
in soft agar and cultured for 14 days before the colony count.  Quantization 
(mean) of the number of colonies for the indicated clonal cell lines.  N=6; 
error bars represent SE; *P < 0.005 between A549 + S52-A hnRNP L + 
C9b ectopic versus A549 + S52-A hnRNP L, student t-test.   
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4.4. Discussion 
Results from the previous chapter demonstrated that hnRNP L associates with the 
purine-rich sequence in exon 3 of caspase 9 which acts as an ESS.  From this, initial 
studies presented in this chapter demonstrate the downregulation of hnRNP L significantly 
increases the caspase 9a/ caspase 9b mRNA splicing ratio in transformed cell lines.  In 
comparison, downregulation of hnRNP L in non-transformed cells resulted in no affect on 
the caspase 9 splicing ratio. 
 Various studies in the literature have proposed hnRNP L to be phosphorylated.  
More specifically, Xie and co-workers demonstrated hnRNP L mediates the alternative 
splicing of the Ca+/voltage-sensitive Slo potassium channel pre-mRNA via CAMKIV, 
which correlated with a 4-fold change in the expression of hnRNP L and an 8-fold increase 
phospho-status of the RNA trans-factor (Yu et al., 2009). In addition, Lynch and co-
workers found a pH shift toward acidity in hnRNP L in T-cells activated by phorbol esters 
with effects on the inclusion of exon 4 into mature CD45 mRNA proposing a 
phosphorylation event (Melton et al., 2007). Although both of these studies propose 
hnRNP L phosphorylation, a phosphorylation site was never determined.  Further studies 
in this chapter found Ser52 of hnRNP L to be phosphorylated and regulate the alternative 
splicing of caspase 9.  Lastly, studies presented in this chapter demonstrated that the 
phosphorylation status of Ser52 of hnRNP L were also important in modulating the 
anchorage-independent growth of A549s.   
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CHAPTER 5 
HNRNP U, A NOVEL SPLICING ENHANCER, REGULATES THE 
ALTERNATIVE SPLICING OF CASPASE 9 
 
 
 
5.1 Introduction 
RNA splicing is a process which must be executed with high fidelity.  Besides the 
5‟SS, 3‟SS, and BPS which make up the major splicing signals, other components known 
as RNA trans-factors help regulate the splicing process (Black, 2003).  There are two main 
groups of RNA trans-factors known as SR family of proteins and the hnRNP family of 
proteins.  It is well-known that the SR proteins act as enhancers where as the hnRNP 
proteins act as repressers.   
hnRNP proteins are a family of proteins that are structurally diverse and 
demonstrate an array of cellular activities. Recently, numerous studies have presented 
individual hnRNP members to have roles in translation, mRNA stability, transcription, and 
alternative splicing (Dreyfuss et al., 2002; Krecic and Swanson, 1999). In regards to 
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alternative splicing, hnRNP proteins usually are bound with ESS/ISSs demonstrating 
represser activity (Caputi et al., 1999; Zheng, 2004).   
In this chapter, we identified two hnRNP proteins, hnRNP U and hnRNP R, which 
associates with exon 3 of caspase 9 by mass spectrometry analysis.  In addition, we 
verified our mass spectrometry results showing hnRNP U associates to exon 3 of caspase 9 
by affinity assays.  Moreover, downregulation of hnRNP U demonstrates a marked 
decrease in the caspase 9a/9b mRNA ratio in both non-transformed and transformed cell 
lines.   
 
5.2 Materials and Methods 
5.2.1. Mass Spectrometry Analysis  
Identification of RNA:protein complexes was performed at the Emory University Mass 
Spectrometry Center. Briefly, RNA:protein complexes were excised from the gel and in-
gel trpysin digestion was performed. The tryptic mixtures were injected and analyzed by 
nano-LC-MS/MS. Proteins identified by nano-LC-MS/MS
 
were based on independent 
sequencing of peptides.  Nano-LC-MS/MS results were obtained by searching the Mascot
 
database (Matrix Science; Boston, MA). 
 
5.2.2. Streptavidin-agarose Affinity Purification   
The following sequences were used for biotinylated-tagged RNA oligonucleotides: 
Caspase 9, exon 3 (Bio-C9/E3-ESS): (5‟Bio- GAG AGU UUG AGG GGA AAU G 3‟); 
Caspase 9, exon 3 core mutant (Bio-C9/E3-ESS MUT): (5‟Bio- GAG AGU UUG CTA 
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CTA AAU G 3‟); non-specific oligo (NSC2): (5‟Bio- ACU GCC AGU UAC GAC); 
unlabeled specific competititor (SC): (5‟- GAG UUU GAG GGG AA); and unlabeled non-
specific competitor (NSC1): (5‟- GAA UUC GCA CGU UA) (Dharmacon Inc., Lafayette, 
CO).  Also, see Table 3-1 for additional “cold” unlabeled RNA oligonucleotide 
competitors utilized in these studies. Reaction mixtures were first pre-cleared for 2 hrs at 
4ºC with streptavidin-agarose beads (20 µl) (50 μg A549 nuclear extract, 40 U RNASIN, 
11.3 µg tRNAs, 10 mM HEPES, 5 mM DTT, 120 mM KCl, 3 mM MgCl2, and 5% 
glycerol).  Reaction mixtures were then incubated with 100-fold molar excess of either 
NSC or SC oligo for 5 min following the addition of either 400 ng Bio-C9/E3-ESS or Bio-
NSC-2 incubated on ice for 30 min.  New streptavidin-agarose beads were then added to 
RNA-binding reactions and incubated at 4º for 2 hours with gentle agitation.  
RNA:protein-binding reactions were washed with buffer containing 100 mM KCl, 20 mM 
Tris-HCl at pH 7.5, and 0.2 mM EDTA.  After washing, the complex was pelleted by 
centrifugation.  The pellet was resuspended in Laemmli buffer, dry boiled for 10 min, and 
subjected to SDS-PAGE/western immunoblotting analysis. 
 
5.2.3. Cell Culture 
A549 cells were grown in 50% RPMI 1640 (Invitrogen Life Technologies, Carlsbad, CA) 
and 50% Dulbecco's modified Eagle's medium (Invitrogen Life Technologies, Carlsbad, 
CA) supplemented with L-glutamine, 10% (v/v) fetal bovine serum (Sigma), 100 units/ml 
penicillin G sodium (Invitrogen Life Technologies, Carlsbad, CA), and 100 μg/ml 
streptomycin sulfate (Invitrogen Life Technologies, Carlsbad, CA). H838 cells were grown 
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in RPMI 1640 supplemented with 10% (v/v) fetal bovine serum (Sigma), 100 units/ml 
penicillin G sodium (Invitrogen Life Technologies, Carlsbad, CA), and 100 μg/ml 
streptomycin sulfate (Invitrogen Life Technologies, Carlsbad, CA). All adenocarcinoma 
cell lines were purchased from ATCC (Rockville, MD, USA). HBEC-3KT cells, a 
generous gift from J.D. Minna, were cultured with keratinocyte serum-free medium 
containing 50μg/ml bovine pituitary extract and 5ng/ml recombinant epidermal growth 
factor (Life Technologies, Gaithersburg, MD). All cell lines were maintained at less than 
80% confluency under standard incubator conditions (humidified atmosphere, 95% air, 5% 
CO2, 37 °C).  For all comparison studies between cell lines, 1.2 x 10
5
 cells were plated in 
tissue culture plates (6-well dish). The following day, media was removed, cells were 
washed with 1 x PBS and plated in keratinocyte serum-free medium without supplements 
overnight. Total RNA and/or protein was then isolated for analysis. 
 
5.2.4. Silence interfering RNA transfection   
For inhibition of hnRNP U and hnRNP R, cell lines were transfected with either hnRNP U 
SMARTpool multiplex, hnRNP R SMARTpool multiplex or scrambled control siRNA 
(Dharmacon; Lafayette, CO) using Dharmafect 1 transfection reagent (Dharmacon; 
Lafayette, CO) following the manufacturer„s protocol. Briefly, cell lines were plated in six-
well tissue culture dishes and allowed to rest overnight. At 50% confluence, cells were 
transfected with siRNA [100nM] using Dharmafect 1 in Opti-Mem I reduced-serum 
medium. Forty-eight hours post-transfection, RNA and/or protein were isolated. 
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5.2.5. Quantitative/Competitive RT-PCR 
Total RNA from cell lines were isolated using the RNeasy® Mini Kit (Qiagen Inc., 
Valencia, CA) according to the manufacturer„s protocol. Total RNA (1 μg) was reverse-
transcribed using Superscript III reverse transcriptase (SuperScript™ First-Strand 
Synthesis System for RT-PCR, Invitrogen™, Carlsbad, CA) and oligo (dT) as the priming 
agent. After 50 min of incubation at 42°C, the reactions were terminated by heating at 
70°C for 15 min. Template RNA was then removed using RNase H (Invitrogen, Carlsbad, 
CA). To quantitatively evaluate the expression of endogenous caspase 9 splice variants, an 
upstream 5„ primer to caspase-9 (5„-GCT CTT CCT TTG TTC ATC TCC-3„) and a 3„ 
primer (5„-CAT CTG GCT CGG GGT TAC TGC-3„) (Integrated DNA Technologies, Inc., 
Coralville, IA) were used. Using these primers, 20% of the reverse transcriptase reaction 
was amplified for 25 cycles (94°C, 30 s melt; 57°C, 30 s anneal; 72°C, 1 min extension) 
using Platinum Taq DNA polymerase (Invitrogen Life Technologies, Carlsbad, CA). Gene 
products produced from endogenous caspase 9 PCR resulted in a 1248 base pair caspase 9a 
splice variant and 798 base pair caspase 9b splice variant. The final PCR products were 
resolved on a 5% TBE acrylamide gel electrophoresis, stained with SYBR® Gold 
(Invitrogen™, Carlsbad, CA) and visualized using a Molecular Imager® FX (Bio-Rad) 
with a 488 nm EX (530 nm BYPASS) laser. 
 
5.2.6. Western Immunoblotting 
Cells were lysed using CelLytic™ lysis buffer (Sigma-Aldrich) supplemented with 
protease Inhibitor cocktail (Sigma-Aldrich). Total protein lysates were then diluted in SDS 
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sample buffer and dry boiled for 10 minutes.  Protein samples (5 μg) were subjected to 
10% SDS-PAGE, transferred to a polyvinylidene difluoride membrane (PDVF) (Bio-Rad) 
and blocked in 5% milk/1 X PBS – 0.1% Tween (M-PBS-T) for 2 h. The membrane was 
incubated with the following primary antibodies: anti-hnRNP U (1:1000, Abcam), anti-
hnRNP R (1:1000, Abcam), and anti-β-actin (1:5,000, Sigma-Aldrich). Secondary 
antibodies were HRP-conjugated goat anti-mouse (1:5,000, Sigma-Aldrich). Immunoblots 
were developed using Pierce enhanced chemiluminescence (ECL) reagents and Bio-Max 
film. 
 
5.2.7. Imaging/quantification  
All data presented in this chapter was generated via using multiple laser scans or film 
exposures and are not manipulated by adjusting brightness and contrast. Multiple 
exposures and various scans at multiple laser intensities were utilized to present the data 
for easy discernment of the appropriate effects by readers. 
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5.3. Results 
5.3.1. The RNA trans-factor hnRNP U interacts with exon 3 of caspase 9.  The 
previous chapter demonstrated that the definition of exon 3 was a critical step in the 
inclusion of the entirety of the exon 3,4,5,6 cassette in the mature caspase 9 mRNA.  
Furthermore, the same chapter defined an exon splicing silencer in exon 3, which the RNA 
trans-factor, hnRNP L, associates and represses the inclusion of exon 3 in transformed 
cells.   
 As hnRNP L has been shown to antagonize enhancing RNA trans-factors for exon 
definition, we revisited our mass spectrometry analysis of proteins associating with exon 3 
in nuclear extracts from transformed cells.  Two additional RNA trans-factors were 
identified when examining proteins with an x-corr value < 20. Specifically, these results 
suggested the possibility that hnRNP U and hnRNP R were partially lost in the association 
with exon 3 of caspase 9 due to the transformed nuclear extract utilized in the EMSA 
assays and antagonism with hnRNP L (Table 5-1).  Indeed, the specific interaction of these 
RNA trans-factors with exon 3 was verified by performing biotin/streptavidin affinity 
assays utilizing biotinylated RNA oligonucleotides (ROs) corresponding to exon 3.  A 
biotin-5‟ GAGAGUUUGAGGGGAAAU (Bio-WT C9/E3) and a Biotin-5‟ non-specific 
control sequence (Bio-NSC2) were utilized for these studies.  Analysis verified that the 
RNA trans-factor, hnRNP U, specifically interacted with exon 3 of caspase 9 (Figure 5-1) 
as the non-specific RNA sequence (Bio-NSC2) did not show any interaction with these 
RNA trans-factors (Figure 5-1). 
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Figure 5-1: hnRNP U associates to exon 3 of caspase 9. A 5’ biotinylated 
wild-type C9/E3-ESS RO (Bio-C9/E3-ESS), or a 5’ biotinylated non-specific 
RO (Bio-NSC-2) were incubated in the presence of nuclear extract from 
A549 cells or IgG (control), subjected to SDS-PAGE and western 
immunoblotting analysis (anti-hnRNP U antibody). Unlabeled non-specific 
ROs (e.g. NSC-1) at a 100-fold molar excess were also added to the 
reactions as indicated. Sup designates the corresponding supernatant from 
the Bio-WT C9/E3-ESS to show the remaining RNA trans-factor after 
affinity purification.  
 
 
 
5.3.2. hnRNP U regulates the alternative splicing of caspase 9 in non-small cell lung 
cancer cells. Since our findings demonstrated hnRNP U associating within exon 3 of 
caspase 9, we hypothesized that perhaps this RNA trans-factor played a role in regulating 
the alternative splicing of caspase 9.  To examine the role of both hnRNP R and hnRNP U 
in regulating the ratio of caspase 9 splice variants, small interference RNA (siRNA) 
technology was utilized. Downregulation of hnRNP U in A549 cells using a multiplex 
siRNA (100 nM (25 nM for each sequence)) resulted in a significant decrease in the ratio 
of caspase 9a/9b mRNA from 2.1 to 1.3, (N=3) (Figure 5-2, Panel A).  On the other hand, 
multiplex siRNA downregulation of hnRNP R in A549 cells had no significant effect on 
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the ratio of caspase 9a/9b mRNA (Figure 5-2, Panel B). Western immunoblot analysis 
confirmed a > 80% downregulation of both hnRNP U and hnRNP R compared to samples 
from cells treated with control siRNA (Figure 5-2, Panels A and B).  
To determine whether the effect of hnRNP U downregulation demonstrated 
translatability in NSCLC, hnRNP U siRNA was again employed in H838 cells. The role of 
hnRNP U was further corroborated in this NSCLC cell line as downregulation of hnRNP U 
by siRNA produced a concomitant decrease in the ratio of caspase 9a/9b mRNA: H838: 
2.0 for siControl to 1.0 for sihnRNP U, N=4, (Figure 5-3).  
 
 
 
Figure 5-2:  Downregulation of hnRNP U, but not hnRNP R decreases 
the ratio of caspase 9a/9b mRNA. A549 cells were transfected with either 
control siRNA (100 nM), hnRNP U SMARTpool siRNA (100 nM), or hnRNP 
R SMARTpool siRNA (100 nM) for 48 h. Total RNA was isolated and 
analyzed by competitive/quantitative RT-PCR for caspase 9 splice variants. 
A) hnRNP U siRNA and B) hnRNP R siRNA). Simultaneously, total protein 
lysates were also produced, subjected to SDS-PAGE analysis and 
immunoblotted for hnRNP U, hnRNP R and β-actin. Data are N=3 on two 
separate occasions. 
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Figure 5-3: H838 cells were transfected with scrambled siRNA (100 nM), 
or hnRNP U SMARTpool siRNA (100 nM), for 48 hr. Total RNA was 
isolated and analyzed by competitive/quantitative RT-PCR for caspase 9 
splice variants. The ratio of caspase 9a/9b mRNA was determined by 
densitometric analysis of RT-PCR fragments. Simultaneously, total protein 
lysates were also produced, subjected to SDS-PAGE analysis and 
immunoblotted for anti-hnRNP U and β-actin. 
 
 
 
5.3.3. hnRNP U regulates the alternative splicing of caspase 9 in non-transformed 
cells.  Since hnRNP U downregulation demonstrated a significant decrease in the caspase 
9a/9b mRNA ratio, we wanted to examine this mechanism in the non-transformed cell line, 
HBEC-3KT.  To study, hnRNP U siRNA was again employed in HBEC-3KT cells.  
Suprisingly, the role of hnRNP U siRNA produced a significant decrease in the ratio of 
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caspase 9a/9b mRNA just like the NSCLC cell lines (Figure 5-4).  From these studies, 
hnRNP U demonstrates to be a necessary enhancer for both transformed and non-
transformed cells.   
 
 
 
 
Figure 5-4: HBEC-3KT cells were transfected with scrambled siRNA (100 
nM), or hnRNP U SMARTpool siRNA (100 nM), for 48 hr. Total RNA was 
isolated and analyzed by competitive/quantitative RT-PCR for caspase 9 
splice variants. The ratio of caspase 9a/9b mRNA was determined by 
densitometric analysis of RT-PCR fragments. Simultaneously, total protein 
lysates were also produced, subjected to SDS-PAGE analysis and 
immunoblotted for anti-hnRNP U and β-actin. 
 
  
5.4 Discussion 
Previous results from the last chapter demonstrated hnRNP L associating with the 
purine-rich sequences in exon 3 of caspase 9.  Moreover, hnRNP L demonstrated to 
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repress inclusion of the exon 3,4,5,6 cassette of caspase 9.  It has been demonstrated that 
hnRNP L can antagonize RNA trans-factors for exon definition.  In effort to investigate 
potential RNA trans-factors we re-visited our mass spectrometry results.  From this, initial 
studies showed that hnRNP R and hnRNP U were identified by mass spectrometry analysis 
scoring an x-corr < 20.  Perhaps the low x-corr value was due to the fact we utilized 
transformed nuclear extracts.  Specifically, downregulation of hnRNP U in both 
transformed and non-transformed cells demonstrated a marked decrease in the caspase 
9a/9b mRNA ratio.   
Literature has proposed many functions for hnRNP U.  Specifically, Lin et al. 
demonstrated hnRNP U can shuttle between the cytoplasm and nucleus induced by the 
tobacco-specific carcinogen NNK (Lin et al.). In addition, Yugami et al. found hnRNP U 
has a role in mRNA stability enhancing the expression of various genes (Yugami et al., 
2007).  Furthermore, hnRNP U has been demonstrated to play a role in transcription.  
More specifically, Matsuoka et al. revealed hnRNP U interacts with the c-myc-max 
complex on the E-box promoter region which ultimately induces the ornithine 
decarboxylase gene (Matsuoka et al., 2009).  Studies in this chapter revealed a novel role 
for hnRNP U dealing with alternative splicing which has never been demonstrated thus far.  
Lastly, studies presented found hnRNP U to be a novel splicing enhancer in both 
transformed and non-transformed cells.   
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CHAPTER 6 
GENERAL DISCUSSION 
 
Lung cancer is the leading cause of cancer mortality accounting for an estimated 
28% of all cancer deaths in the United States, and the mortality rates for lung cancer have 
not significantly deceased over the years.  Thus, there is an urgent need for further 
understanding of the molecular mechanisms of NSCLC and to find new molecular targets 
for the treatment of this disease.  Indeed, the presented study identifies key molecular 
events specific to transformed/NSCLC cells (e.g. the pre-mRNA processing of caspase 9) 
that are required for the ability of these cells to form/maintain tumors. The mechanistic 
part of this study began with the simple observation that mutation of a purine-rich 
sequence in exon 3 of the exon 3,4,5,6 cassette of caspase 9 led to the loss of the caspase 
9b splice variant.  These original studies were screening for possible exonic splicing 
enhancers interacting with SRp30a, a required RNA trans-factor for the inclusion of the 
exon 3,4,5,6 cassette of caspase 9 (Massiello and Chalfant, 2006).  The surprising finding 
of an ESS instead of an ESE led to the identification of hnRNP L associated with exon 3 at 
the ESS.  The observation that hnRNP L interacted with the purine-rich RNA sequence, 
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AGGGGA, was also surprising as several groups have shown that hnRNP L prefers CA-
repeats.  Our findings raise the intriguing possibility that the phospho-status of hnRNP L 
may affect the RNA sequence specificity for this RNA trans-factor, explaining the 
disparity of our findings. Alternatively, hnRNP L may be associated with a protein 
complex at C9/E3-ESS when phosphorylated and therefore, does not interact directly with 
the RNA sequence.  The data presented in this study support both possibilities as hnRNP L 
was shown to interact with the C9/E3-ESS when phosphorylated, and dephosphorylation 
of hnRNP L in A549 cells induced a significant reduction in the ability of hnRNP L to 
associate with the C9/E3-ESS (data not shown).  Irrespective of the exact mechanism and 
because of the requirement for phosphorylation in this interaction, the present study adds a 
new dimension to our current knowledge of the role of RNA trans-factors in the 
development and maintenance of cancer cells/tumors.  Specifically, the phosphorylation of 
hnRNP L, at Ser
52
 was required for this RNA trans-factor to act as a repressor of the exon 
3,4,5,6 cassette of caspase 9 pre-mRNA.  The requirement of specific phosphorylation 
event in an RNA trans-factor regulating biological mechanisms related to cancer (e.g. 
anchorage-independent growth and tumorigenic capacity) was unexpected and novel due to 
recent reports.  In particular, several laboratories have published that 
expression/overexpression of a specific RNA trans-factor (e.g. SRp30a, ESRPs, and 
SRm160) was the critical mechanism for conferring anchorage-independent growth, 
epithelial-mesenchymal transition, or tumor formation (Cheng and Sharp, 2006; Karni et 
al., 2007; Warzecha et al., 2009).  This study now provides an additional level of 
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regulation of RNA trans-factors in relation to tumorigenesis; specific phosphorylation of 
an RNA trans-factor.  
Our findings on the phospho-state of hnRNP L regulating the pre-mRNA 
processiong of caspase 9 are in accord with a recent report by Lynch and co-workers 
(Melton et al., 2007). This laboratory reported a correlation of an observed pH shift toward 
acidity in hnRNP L in T-cells activated by phorbol esters with effects on the inclusion of 
exon 4 into mature CD45 mRNA (Melton et al., 2007).  Whereas this laboratory group 
could not determine whether the pH change was due to acetylation or phosphorylation, our 
data would suggest the latter.  Furthermore, Xie and co-workers recently demonstrated that 
hnRNP L mediates the alternative splicing of the Ca21/voltage-sensitive Slo potassium 
channel pre-mRNA via CAMKIV, which correlated with a 4-fold change in the expression 
of hnRNP L and an 8-fold increase phospho-status of the RNA trans-factor (Yu et al., 
2009). The observed increase in the phosho-status of hnRNP L may have been due to basal 
stoichimetric phosphorylation as this RNA trans-factor is phosphorylated on serine and 
tyrosine in non-transformed/unstimulated cells (Yu et al., 2009).  Regardless, Xie and co-
workers further showed that in vitro dephosphorylation of nuclear extracts reduced the 
affinity of hnRNP L to CA-repeats.  Whereas both reports and this study all support a role 
for phosphorylation in regulating the function of hnRNP L, our data do not support a role 
for Ser
52
 phosphorylation mediating the RNA affinity of hnRNP L.  Specifically, our data 
show that expression of hnRNP L (Ser
52
Ala) mutant competes with the phosphorylated 
form of hnRNP L in A549 cells to induce an increase in the caspase 9a/9b ratio.  Thus, this 
particular phosphorylation site likely affects protein:protein interactions and not the RNA 
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affinity of hnRNP L.  If phosphorylation of Ser
52
 was an event that enhanced the affinity of 
hnRNP L to the C9/E3-ESS or even CA-repeats, the hnRNP L (Ser
52
Ala) mutant would 
not have been able to compete with the high affinity phospho-form of hnRNP L in A549 
cells, and no effect would have been observed.  Thus, the phosphorylation event reported 
by Xie and co-workers that regulated the association of hnRNP L with CA-repeats is 
unlikely to be Ser
52
 as well as the association with the C9/E3-ESS (Supplemental Figure 
9).  This inference may also explain the lack of effect for other mutants examined in this 
study and cannot completely dispel tyrosines and threonines as regulatory sites.  Other 
serine residues in hnRNP L are still unlikely candidates as Ser
52
 phosphorylation accounts 
for all of the observed increase in serine phosphorylation in NSCLC cells.  Overall, our 
data suggests that phosphorylation of hnRNP L on Ser
52
 may regulate its association with 
accessory RNA trans-factors modifying the function of a protein complex or possibly 
inhibits the association of a required enhancing RNA trans-factor with the caspase 9 pre-
mRNA.  Preliminary studies from our laboratory find a significant loss of the association 
of hnRNP L with other RNA trans-factors in NSCLC cells suggesting the former 
mechanism is correct. 
In regards to a possible role for the phosphorylation of hnRNP L in cellular 
transformation, there are several candidate survival/oncogenic kinases (e.g. GSK3β, AKT, 
and casein kinase II) that are predicted to phosphorylate Ser
52
 of hnRNP L. Whereas these 
kinases have many targets and can affect cells via modulation of many signaling cascades, 
this study identifies the phosphorylation of hnRNP L by a currently unknown protein 
kinase as a key downstream target for oncogenic signaling in NSCLC cells. Based on these 
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inferences, one can rationalize the hypothesis that a specific oncogenic pathway may 
require the phosphorylation of hnRNP L on Ser
52
, which would essentially block intrinsic 
apoptotic pathways by lowering the ratio of caspase 9a/9b, and enhance cellular 
transformation.  This is not surprising since previous studies in the literature have 
demonstrated that caspase 9 (caspase 9a) is a possible tumor suppressor (Soengas et al., 
1999). The presented study supports the findings of Lowe and co-workers, which showed 
enhancement of cellular transformation of murine embryonic fibroblasts from caspase 9 -/- 
mice by H-Ras
V12
/c-Myc
 
(Soengas et al., 1999) as well as the studies utilizing a dominant-
negative caspase 9 that completely alleviated pressure to inactivate p53 during 
lymphomagenesis (Schmitt et al., 2002). Our study applies these concepts to NSCLC 
demonstrating the importance of the endogenous mechanism of blocking caspase 9 activity 
(e.g. alternative splicing) in the maintenance of NSCLC cells and tumors.  Although this 
study supports the finds of Lowe and co-workers, there is disparity and controversy in the 
literature over these original studies showing caspase 9 as a tumor suppressor.  For 
example, Ekert et al. (2004) showed caspase 9 is not necessary for apoptosis of factor-
dependent cells, but merely affects its rate. Another contrasting report from Scott and co-
workers demonstrated that caspase 9 did not play a role in lymphomagenesis (Scott et al., 
2004).  Furthermore, lymphocytes from caspase 9 -/- animals underwent apoptosis 
comparable to wild-type lymphocytes (Scott et al., 2004). On the other hand, Chipuk and 
Green pointed out in 2005 that no evidence was provided in these contrasting studies 
demonstrating that caspase inhibitors blocked cell death (Chipuk and Green, 2005). Thus, 
caspase-independent cell death was a plausible mechanism in the cell death observed in 
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both the Ekert and Scott studies (Chipuk and Green, 2005; Ekert et al., 2004; Scott et al., 
2004). Although our data support the work of Lowe and colleagues, the role of caspase 9b 
in regulating anchorage-independent growth and tumorigenic capacity could be outside the 
realm of direct inhibition of caspase 9a.  In this regard, a role in cell signaling for caspase 
9b has been reported by Latchman and co-workers (Stephanou et al., 2002).   Specifically, 
the authors demonstrated that ectopic expression of caspase 9b induced the activation of 
NF-κB irrespective of caspase activity (Stephanou et al., 2002).  Activation of NF-κB is 
known to cooperate with K-ras mutations in regard to cellular transformation, and thus 
may explain the function of caspase 9b (Stephanou et al., 2002).  In essence, caspase 9b 
may elicit downstream signaling events outside the role of simple inactivation of caspase 
9a.  In support of this hypothesis, caspase 8 is suggested to play roles in the recruitment 
cell survival factors such as the p85 subunit of PI3 kinase (Senft et al., 2007).  Although 
these initiator caspases have roles in extrinsic pathways of programmed cell death, caspase 
9b may be playing an analogous role in survival signaling to block the intrinsic pathway of 
programmed cell death.   
Although this study produces a possible new paradigm in the regulation of 
alternative splicing in regards to oncogenic signaling, the mechanisms discussed above are 
likely an over simplification of a complex and highly regulated RNA processing event.  
Whereas the phosphorylation of hnRNP L and the association of this RNA trans-factor 
with the C9/E3-ESS complex are required for exclusion of the exon 3,4,5,6 cassette, this 
exon 3 mechanism may just be one part of a large regulating complex that entails interplay 
with a number of RNA trans-factors to regulate the inclusion/exclusion of the exon 3,4,5,6 
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cassette. One such candidate RNA trans-factor that may interplay with hnRNP L is 
SRp30a (ASF/SF2).  This RNA trans-factor has been identified by our laboratory as a 
required enhancing RNA trans-factor for the inclusion of the exon 3,4,5,6 cassette 
(Massiello and Chalfant, 2006).  Our laboratory has also shown correlation between the 
phospho-state of SR proteins and the inclusion of the exon 3,4,5,6 cassette in regards to 
ceramide treatment of NSCLC cells (Massiello and Chalfant, 2006).  As several past 
studies have shown that the phospho-state of SRp30a regulates its ability to modulate 
particular RNA splicing events, this is a logical hypothesis to test. Whether exclusion of 
the exon 3,4,5,6 cassette requires phosphorylation of hnRNP L on Ser
52
 as well as hyper-
phosphorylation of SRp30a is not currently known nor addressed in this study, but 
coordinated phosphorylation of repressing and enhancing RNA trans-factors interacting 
with multiple RNA cis-elements throughout the caspase 9 pre-mRNA may be required to 
repress the inclusion of the exon 3,4,5,6 cassette.  Indeed, several high affinity sites for 
SRp30a are predicted using Rainbow Splicer software (Koscielny et al., 2009), and in 
particular, one RNA cis-element for SRp30a is located adjacent to the C9/E3-ESS 
sequence. A recent study by Lynch and co-workers observed an interplay between 
SF2/ASF and hnRNP L for CD45 alternative splicing (Melton et al., 2007).  Specifically, 
cell-based assays utilizing minigenes demonstrated that a balance between hnRNP L 
repression and SF2/ASF enhancing activities ultimately determines the extent of exon 5 
inclusion into CD45 (Motta-Mena et al.). As more regulating factors for caspase 9 RNA 
splicing are identified, future studies will be geared to investigate this complex interplay in 
regards to regulating the inclusion/exclusion of this exonic cassette.  Unfortunately, these 
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studies may require the identification of specific regulatory phospho-sites within SRp30a, 
and the number of constitutive phosphorylation sites in SRp30a alone as well as the 
promiscuity of protein kinases for multiple sites in this RNA trans-factor make this a 
rather daunting task.   
Important from a therapeutic stand point, only a two base pair mutation was 
required to eliminate the association of hnRNP L to the C9/E3-ESS. Thus, the association 
of the C9/E3-ESS and the hnRNP L complex is highly specific. Since technologies are 
being developed to efficiently deliver small RNA sequences effectively to cells and whole 
animals, these data suggest that a scavenger RNA can be developed to the C9/E3-ESS. 
Another possibility is RNA aptamer technology, which is currently being employed 
towards nucleolin in phase 2 clinical trials
 
(Soundararajan et al., 2008).  From a 
philosophical standpoint as to the development of new therapeutics for NSCLC patients, 
the targeting of cancer-specific as well as distal signaling mechanisms (e.g. 
phosphorylation of hnRNP L on Ser
52
, the interaction of with the hnRNP L/C9/E3-ESS, or 
the direct manipulation of the alternative splicing of caspase 9) is of key importance for 
two reasons.  First, therapeutics based on a cancer-specific mechanism would limit the 
side-effects of anti-cancer therapies by essentially only affecting the tumor cells.  Second, 
the targeting of a distal mechanism limits the adaptability of a cancer cell to circumvent the 
anti-cancer therapy through utilization of a secondary pathway. The fewer opportunities for 
a cancer cell to adapt, the more likely a specific therapy will show prolonged efficiency.  
Both hnRNP L and the alternative splicing of caspase 9 can be categorized as cancer-
specific and distal points for therapeutic development in the treatment of NSCLC.  The 
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effect of using therapies targeted to either hnRNP L or caspase 9b would also be very 
limited on normal lung epithelial cells as caspase 9b is not expressed in non-transformed 
epithelial cells, and hnRNP L is also dephosphorylated.  In support of this hypothesis, 
unpublished data from our laboratory demonstrate that hnRNP L siRNA did not induce 
apoptosis in HBEC-3KT cells in contrast to H838 and H2030 cells as assayed by PARP 
cleavage.   
In conclusion, this rmanuscript is a comprehensive study that began with the 
observation that the ratio of caspase 9a/9b mRNA was dysregulated in a large percentage 
of human lung adenocarcinoma tumors.  Experiments followed, which demonstrated that 
the ratio of caspase 9a/9b mRNA played a significant and physiologically relevant role in 
the activity of caspase 9 and the tumorigenic capacity of NSCLC cells.  Mechanistic 
studies then defined an exonic splicing silencer (C9/E3-ESS) for the inclusion of the exon 
3,4,5,6 cassette of caspase 9. This observation led to the identification of hnRNP L 
association with the C9/E3-ESS and regulating the alternative splicing of caspase 9. 
Furthermore, this study demonstrated that an increase in the phospho-state of hnRNP L on 
Ser
52
 regulates the alternative splicing of caspase 9 in NSCLC.  Lastly, these studies 
demonstrate that hnRNP L is required for the tumorigenic capacity of NSCLC cells via the 
regulation of this distal splicing event. Collectively, our data identifies the interaction of 
hnRNP L with the C9/E3-ESS in the exon 3 of caspase 9 pre-mRNA as well as the 
phosphorylation of hnRNP L on Ser
52
 as possible therapeutic targets for NSCLC.  
 
 
118 
 
 
 
 
 
 
 
 
 
 
Literature Cited 
119 
 
 
Literature Cited 
 
2009. The Universal Protein Resource (UniProt) 2009. Nucleic Acids Res. 37:D169-74. 
Akgul, C., D.A. Moulding, and S.W. Edwards. 2004. Alternative splicing of Bcl-2-related 
genes: functional consequences and potential therapeutic applications. Cell Mol 
Life Sci. 61:2189-99. 
Berget, S.M. 1995. Exon recognition in vertebrate splicing. J Biol Chem. 270:2411-4. 
Black, D.L. 2003. Mechanisms of alternative pre-messenger RNA splicing. Annu Rev 
Biochem. 72:291-336. 
Boldin, M.P., E.E. Varfolomeev, Z. Pancer, I.L. Mett, J.H. Camonis, and D. Wallach. 
1995. A novel protein that interacts with the death domain of Fas/APO1 contains a 
sequence motif related to the death domain. J Biol Chem. 270:7795-8. 
Breasted, J.H. 1930. The Edwin Smith papyrus: published in facsimile andhieroglyphic 
transliteration with translation and commentary in two volumes. Chicago: 
University of Chicago Press. 
Brett, D., H. Pospisil, J. Valcarcel, J. Reich, and P. Bork. 2002. Alternative splicing and 
genome complexity. Nat Genet. 30:29-30. 
Caceres, J.F., T. Misteli, G.R. Screaton, D.L. Spector, and A.R. Krainer. 1997. Role of the 
modular domains of SR proteins in subnuclear localization and alternative splicing 
specificity. J Cell Biol. 138:225-38. 
Caputi, M., A. Mayeda, A.R. Krainer, and A.M. Zahler. 1999. hnRNP A/B proteins are 
required for inhibition of HIV-1 pre-mRNA splicing. EMBO J. 18:4060-7. 
Cartegni, L., M. Maconi, E. Morandi, F. Cobianchi, S. Riva, and G. Biamonti. 1996. 
hnRNP A1 selectively interacts through its Gly-rich domain with different RNA-
binding proteins. J Mol Biol. 259:337-48. 
Cartegni, L., J. Wang, Z. Zhu, M.Q. Zhang, and A.R. Krainer. 2003. ESEfinder: A web 
resource to identify exonic splicing enhancers. Nucleic Acids Res. 31:3568-71. 
Cascino, I., G. Fiucci, G. Papoff, and G. Ruberti. 1995. Three functional soluble forms of 
the human apoptosis-inducing Fas molecule are produced by alternative splicing. J 
Immunol. 154:2706-13. 
Chalfant, C.E., H. Mischak, J.E. Watson, B.C. Winkler, J. Goodnight, R.V. Farese, and 
D.R. Cooper. 1995. Regulation of alternative splicing of protein kinase C beta by 
insulin. J Biol Chem. 270:13326-32. 
Chalfant, C.E., K. Rathman, R.L. Pinkerman, R.E. Wood, L.M. Obeid, B. Ogretmen, and 
Y.A. Hannun. 2002. De novo ceramide regulates the alternative splicing of caspase 
9 and Bcl-x in A549 lung adenocarcinoma cells. Dependence on protein 
phosphatase-1. J Biol Chem. 277:12587-95. 
120 
Chalfant, C.E., J.E. Watson, L.D. Bisnauth, J.B. Kang, N. Patel, L.M. Obeid, D.C. Eichler, 
and D.R. Cooper. 1998. Insulin regulates protein kinase CbetaII expression through 
enhanced exon inclusion in L6 skeletal muscle cells. A novel mechanism of 
insulin- and insulin-like growth factor-i-induced 5' splice site selection. J Biol 
Chem. 273:910-6. 
Chasin, L.A. 2007. Searching for splicing motifs. Adv Exp Med Biol. 623:85-106. 
Cheng, C., and P.A. Sharp. 2006. Regulation of CD44 alternative splicing by SRm160 and 
its potential role in tumor cell invasion. Mol Cell Biol. 26:362-70. 
Chinnaiyan, A.M., K. O'Rourke, M. Tewari, and V.M. Dixit. 1995. FADD, a novel death 
domain-containing protein, interacts with the death domain of Fas and initiates 
apoptosis. Cell. 81:505-12. 
Chipuk, J.E., and D.R. Green. 2005. Do inducers of apoptosis trigger caspase-independent 
cell death? Nat Rev Mol Cell Biol. 6:268-75. 
Cooper, T.A. 2005. Use of minigene systems to dissect alternative splicing elements. 
Methods. 37:331-40. 
Cooper, T.A., and C.P. Ordahl. 1989. Nucleotide substitutions within the cardiac troponin 
T alternative exon disrupt pre-mRNA alternative splicing. Nucleic Acids Res. 
17:7905-21. 
Cortes-Funes, H. 2002. New treatment approaches for lung cancer and impact on survival. 
Semin Oncol. 29:26-9. 
Coulter, L.R., M.A. Landree, and T.A. Cooper. 1997. Identification of a new class of 
exonic splicing enhancers by in vivo selection. Mol Cell Biol. 17:2143-50. 
Das, R., Z. Zhou, and R. Reed. 2000. Functional association of U2 snRNP with the ATP-
independent spliceosomal complex E. Mol Cell. 5:779-87. 
Dechant, M.J., J. Fellenberg, C.G. Scheuerpflug, V. Ewerbeck, and K.M. Debatin. 2004. 
Mutation analysis of the apoptotic "death-receptors" and the adaptors TRADD and 
FADD/MORT-1 in osteosarcoma tumor samples and osteosarcoma cell lines. Int J 
Cancer. 109:661-7. 
Deveraux, Q.L., and J.C. Reed. 1999. IAP family proteins--suppressors of apoptosis. 
Genes Dev. 13:239-52. 
Dreyfuss, G., V.N. Kim, and N. Kataoka. 2002. Messenger-RNA-binding proteins and the 
messages they carry. Nat Rev Mol Cell Biol. 3:195-205. 
Earnshaw, W.C., L.M. Martins, and S.H. Kaufmann. 1999. Mammalian caspases: 
structure, activation, substrates, and functions during apoptosis. Annu Rev Biochem. 
68:383-424. 
Ebert, A.D., F. Chen, X. He, V.L. Cryns, and M.C. Bohn. 2005. A tetracycline-regulated 
adenovirus encoding dominant-negative caspase-9 is regulated in rat brain and 
protects against neurotoxin-induced cell death in vitro, but not in vivo. Exp Neurol. 
191 Suppl 1:S80-94. 
Ekert, P.G., S.H. Read, J. Silke, V.S. Marsden, H. Kaufmann, C.J. Hawkins, R. Gerl, S. 
Kumar, and D.L. Vaux. 2004. Apaf-1 and caspase-9 accelerate apoptosis, but do 
not determine whether factor-deprived or drug-treated cells die. J Cell Biol. 
165:835-42. 
121 
Fairbrother, W.G., R.F. Yeh, P.A. Sharp, and C.B. Burge. 2002. Predictive identification 
of exonic splicing enhancers in human genes. Science. 297:1007-13. 
Faustino, N.A., and T.A. Cooper. 2003. Pre-mRNA splicing and human disease. Genes 
Dev. 17:419-37. 
Ferreira, C.G., C. Huisman, and G. Giaccone. 2002. Novel approaches to the treatment of 
non-small cell lung cancer. Crit Rev Oncol Hematol. 41:57-77. 
Finucane, D.M., E. Bossy-Wetzel, N.J. Waterhouse, T.G. Cotter, and D.R. Green. 1999. 
Bax-induced caspase activation and apoptosis via cytochrome c release from 
mitochondria is inhibitable by Bcl-xL. J Biol Chem. 274:2225-33. 
Fulda, S., and K.M. Debatin. 2006. Extrinsic versus intrinsic apoptosis pathways in 
anticancer chemotherapy. Oncogene. 25:4798-811. 
Gallego, M.E., R. Gattoni, J. Stevenin, J. Marie, and A. Expert-Bezancon. 1997. The SR 
splicing factors ASF/SF2 and SC35 have antagonistic effects on intronic enhancer-
dependent splicing of the beta-tropomyosin alternative exon 6A. EMBO J. 
16:1772-84. 
Garcia M, J.A., Ward EM, Center MM, Hao Y, Siegel RL, Thun MJ. 2007. Global Cancer 
Facts & Figures 2007. American Cancer Society. 
Glisovic, T., J.L. Bachorik, J. Yong, and G. Dreyfuss. 2008. RNA-binding proteins and 
post-transcriptional gene regulation. FEBS Lett. 582:1977-86. 
Graveley, B.R. 2000. Sorting out the complexity of SR protein functions. RNA. 6:1197-
211. 
Groeger, A.M., V. Esposito, A. De Luca, R. Cassandro, G. Tonini, V. Ambrogi, F. Baldi, 
R. Goldfarb, T.C. Mineo, A. Baldi, and E. Wolner. 2004. Prognostic value of 
immunohistochemical expression of p53, bax, Bcl-2 and Bcl-xL in resected non-
small-cell lung cancers. Histopathology. 44:54-63. 
Guil, S., J.C. Long, and J.F. Caceres. 2006. hnRNP A1 relocalization to the stress granules 
reflects a role in the stress response. Mol Cell Biol. 26:5744-58. 
Hagg, M., K. Biven, T. Ueno, L. Rydlander, P. Bjorklund, K.G. Wiman, M. Shoshan, and 
S. Linder. 2002. A novel high-through-put assay for screening of pro-apoptotic 
drugs. Invest New Drugs. 20:253-9. 
Hakem, R., A. Hakem, G.S. Duncan, J.T. Henderson, M. Woo, M.S. Soengas, A. Elia, J.L. 
de la Pompa, D. Kagi, W. Khoo, J. Potter, R. Yoshida, S.A. Kaufman, S.W. Lowe, 
J.M. Penninger, and T.W. Mak. 1998. Differential requirement for caspase 9 in 
apoptotic pathways in vivo. Cell. 94:339-52. 
Hampson, R.K., L. La Follette, and F.M. Rottman. 1989. Alternative processing of bovine 
growth hormone mRNA is influenced by downstream exon sequences. Mol Cell 
Biol. 9:1604-10. 
Hanahan, D., and R.A. Weinberg. 2000. The hallmarks of cancer. Cell. 100:57-70. 
Hui, J., and A. Bindereif. 2005. Alternative pre-mRNA splicing in the human system: 
unexpected role of repetitive sequences as regulatory elements. Biol Chem. 
386:1265-71. 
Hui, J., G. Reither, and A. Bindereif. 2003a. Novel functional role of CA repeats and 
hnRNP L in RNA stability. RNA. 9:931-6. 
122 
Hui, J., K. Stangl, W.S. Lane, and A. Bindereif. 2003b. HnRNP L stimulates splicing of 
the eNOS gene by binding to variable-length CA repeats. Nat Struct Biol. 10:33-7. 
Hung, L.H., M. Heiner, J. Hui, S. Schreiner, V. Benes, and A. Bindereif. 2008. Diverse 
roles of hnRNP L in mammalian mRNA processing: a combined microarray and 
RNAi analysis. RNA. 14:284-96. 
Igney, F.H., and P.H. Krammer. 2002. Death and anti-death: tumour resistance to 
apoptosis. Nat Rev Cancer. 2:277-88. 
Jiang, X., and X. Wang. 2000. Cytochrome c promotes caspase-9 activation by inducing 
nucleotide binding to Apaf-1. J Biol Chem. 275:31199-203. 
Jiang, Z.H., and J.Y. Wu. 1999. Alternative splicing and programmed cell death. Proc Soc 
Exp Biol Med. 220:64-72. 
Kalnina, Z., P. Zayakin, K. Silina, and A. Line. 2005. Alterations of pre-mRNA splicing in 
cancer. Genes Chromosomes Cancer. 42:342-57. 
Kan, Z., E.C. Rouchka, W.R. Gish, and D.J. States. 2001. Gene structure prediction and 
alternative splicing analysis using genomically aligned ESTs. Genome Res. 11:889-
900. 
Karczmarek-Borowska, B., A. Filip, J. Wojcierowski, A. Smolen, E. Korobowicz, I. 
Korszen-Pilecka, and M. Zdunek. 2006. Estimation of prognostic value of Bcl-xL 
gene expression in non-small cell lung cancer. Lung Cancer. 51:61-9. 
Karni, R., E. de Stanchina, S.W. Lowe, R. Sinha, D. Mu, and A.R. Krainer. 2007. The 
gene encoding the splicing factor SF2/ASF is a proto-oncogene. Nat Struct Mol 
Biol. 14:185-93. 
Kerr, J.F., C.M. Winterford, and B.V. Harmon. 1994. Apoptosis. Its significance in cancer 
and cancer therapy. Cancer. 73:2013-26. 
Kerr, J.F., A.H. Wyllie, and A.R. Currie. 1972. Apoptosis: a basic biological phenomenon 
with wide-ranging implications in tissue kinetics. Br J Cancer. 26:239-57. 
Keshava Prasad, T.S., R. Goel, K. Kandasamy, S. Keerthikumar, S. Kumar, S. 
Mathivanan, D. Telikicherla, R. Raju, B. Shafreen, A. Venugopal, L. Balakrishnan, 
A. Marimuthu, S. Banerjee, D.S. Somanathan, A. Sebastian, S. Rani, S. Ray, C.J. 
Harrys Kishore, S. Kanth, M. Ahmed, M.K. Kashyap, R. Mohmood, Y.L. 
Ramachandra, V. Krishna, B.A. Rahiman, S. Mohan, P. Ranganathan, S. 
Ramabadran, R. Chaerkady, and A. Pandey. 2009. Human Protein Reference 
Database--2009 update. Nucleic Acids Res. 37:D767-72. 
Kohtz, J.D., S.F. Jamison, C.L. Will, P. Zuo, R. Luhrmann, M.A. Garcia-Blanco, and J.L. 
Manley. 1994. Protein-protein interactions and 5'-splice-site recognition in 
mammalian mRNA precursors. Nature. 368:119-24. 
Koscielny, G., V. Le Texier, C. Gopalakrishnan, V. Kumanduri, J.J. Riethoven, F. 
Nardone, E. Stanley, C. Fallsehr, O. Hofmann, M. Kull, E. Harrington, S. Boue, E. 
Eyras, M. Plass, F. Lopez, W. Ritchie, V. Moucadel, T. Ara, H. Pospisil, A. 
Herrmann, G.R. J, R. Guigo, P. Bork, M.K. Doeberitz, J. Vilo, W. Hide, R. 
Apweiler, T.A. Thanaraj, and D. Gautheret. 2009. ASTD: The Alternative Splicing 
and Transcript Diversity database. Genomics. 93:213-20. 
123 
Krecic, A.M., and M.S. Swanson. 1999. hnRNP complexes: composition, structure, and 
function. Curr Opin Cell Biol. 11:363-71. 
Kuida, K., T.F. Haydar, C.Y. Kuan, Y. Gu, C. Taya, H. Karasuyama, M.S. Su, P. Rakic, 
and R.A. Flavell. 1998. Reduced apoptosis and cytochrome c-mediated caspase 
activation in mice lacking caspase 9. Cell. 94:325-37. 
Lander, E.S., L.M. Linton, B. Birren, C. Nusbaum, M.C. Zody, J. Baldwin, K. Devon, K. 
Dewar, M. Doyle, W. FitzHugh, R. Funke, D. Gage, K. Harris, A. Heaford, J. 
Howland, L. Kann, J. Lehoczky, R. LeVine, P. McEwan, K. McKernan, J. 
Meldrim, J.P. Mesirov, C. Miranda, W. Morris, J. Naylor, C. Raymond, M. Rosetti, 
R. Santos, A. Sheridan, C. Sougnez, N. Stange-Thomann, N. Stojanovic, A. 
Subramanian, D. Wyman, J. Rogers, J. Sulston, R. Ainscough, S. Beck, D. Bentley, 
J. Burton, C. Clee, N. Carter, A. Coulson, R. Deadman, P. Deloukas, A. Dunham, I. 
Dunham, R. Durbin, L. French, D. Grafham, S. Gregory, T. Hubbard, S. 
Humphray, A. Hunt, M. Jones, C. Lloyd, A. McMurray, L. Matthews, S. Mercer, S. 
Milne, J.C. Mullikin, A. Mungall, R. Plumb, M. Ross, R. Shownkeen, S. Sims, 
R.H. Waterston, R.K. Wilson, L.W. Hillier, J.D. McPherson, M.A. Marra, E.R. 
Mardis, L.A. Fulton, A.T. Chinwalla, K.H. Pepin, W.R. Gish, S.L. Chissoe, M.C. 
Wendl, K.D. Delehaunty, T.L. Miner, A. Delehaunty, J.B. Kramer, L.L. Cook, R.S. 
Fulton, D.L. Johnson, P.J. Minx, S.W. Clifton, T. Hawkins, E. Branscomb, P. 
Predki, P. Richardson, S. Wenning, T. Slezak, N. Doggett, J.F. Cheng, A. Olsen, S. 
Lucas, C. Elkin, E. Uberbacher, M. Frazier, et al. 2001. Initial sequencing and 
analysis of the human genome. Nature. 409:860-921. 
Lareau, L.F., R.E. Green, R.S. Bhatnagar, and S.E. Brenner. 2004. The evolving roles of 
alternative splicing. Curr Opin Struct Biol. 14:273-82. 
Li, H., H. Zhu, C.J. Xu, and J. Yuan. 1998. Cleavage of BID by caspase 8 mediates the 
mitochondrial damage in the Fas pathway of apoptosis. Cell. 94:491-501. 
Lichtenstein, M., W. Guo, and A.M. Tartakoff. 2001. Control of nuclear export of hnRNP 
A1. Traffic. 2:261-7. 
Lin, R.K., Y.S. Hsieh, P. Lin, H.S. Hsu, C.Y. Chen, Y.A. Tang, C.F. Lee, and Y.C. Wang. 
The tobacco-specific carcinogen NNK induces DNA methyltransferase 1 
accumulation and tumor suppressor gene hypermethylation in mice and lung cancer 
patients. J Clin Invest. 120:521-32. 
Liu, H.X., S.L. Chew, L. Cartegni, M.Q. Zhang, and A.R. Krainer. 2000. Exonic splicing 
enhancer motif recognized by human SC35 under splicing conditions. Mol Cell 
Biol. 20:1063-71. 
Liu, H.X., M. Zhang, and A.R. Krainer. 1998. Identification of functional exonic splicing 
enhancer motifs recognized by individual SR proteins. Genes Dev. 12:1998-2012. 
Long, J.C., and J.F. Caceres. 2009. The SR protein family of splicing factors: master 
regulators of gene expression. Biochem J. 417:15-27. 
Luo, X., I. Budihardjo, H. Zou, C. Slaughter, and X. Wang. 1998. Bid, a Bcl2 interacting 
protein, mediates cytochrome c release from mitochondria in response to activation 
of cell surface death receptors. Cell. 94:481-90. 
124 
Manley, J.L., and R. Tacke. 1996. SR proteins and splicing control. Genes Dev. 10:1569-
79. 
Mardon, H.J., G. Sebastio, and F.E. Baralle. 1987. A role for exon sequences in alternative 
splicing of the human fibronectin gene. Nucleic Acids Res. 15:7725-33. 
Massiello, A., and C.E. Chalfant. 2006. SRp30a (ASF/SF2) regulates the alternative 
splicing of caspase-9 pre-mRNA and is required for ceramide-responsiveness. J 
Lipid Res. 47:892-7. 
Massiello, A., J.R. Roesser, and C.E. Chalfant. 2006. SAP155 Binds to ceramide-
responsive RNA cis-element 1 and regulates the alternative 5' splice site selection 
of Bcl-x pre-mRNA. FASEB J. 20:1680-2. 
Matlin, A.J., F. Clark, and C.W. Smith. 2005. Understanding alternative splicing: towards 
a cellular code. Nat Rev Mol Cell Biol. 6:386-98. 
Matsuoka, Y., N. Uehara, and A. Tsubura. 2009. hnRNP U interacts with the c-Myc-Max 
complex on the E-box promoter region inducing the ornithine decarboxylase gene. 
Oncol Rep. 22:249-55. 
Mayeda, A., and A.R. Krainer. 1992. Regulation of alternative pre-mRNA splicing by 
hnRNP A1 and splicing factor SF2. Cell. 68:365-75. 
Mayeda, A., S.H. Munroe, J.F. Caceres, and A.R. Krainer. 1994. Function of conserved 
domains of hnRNP A1 and other hnRNP A/B proteins. EMBO J. 13:5483-95. 
Mayrand, S.H., P. Dwen, and T. Pederson. 1993. Serine/threonine phosphorylation 
regulates binding of C hnRNP proteins to pre-mRNA. Proc Natl Acad Sci U S A. 
90:7764-8. 
Melton, A.A., J. Jackson, J. Wang, and K.W. Lynch. 2007. Combinatorial control of 
signal-induced exon repression by hnRNP L and PSF. Mol Cell Biol. 27:6972-84. 
Mironov, A.A., J.W. Fickett, and M.S. Gelfand. 1999. Frequent alternative splicing of 
human genes. Genome Res. 9:1288-93. 
Modrek, B., and C. Lee. 2002. A genomic view of alternative splicing. Nat Genet. 30:13-9. 
Modrek, B., A. Resch, C. Grasso, and C. Lee. 2001. Genome-wide detection of alternative 
splicing in expressed sequences of human genes. Nucleic Acids Res. 29:2850-9. 
Motta-Mena, L.B., F. Heyd, and K.W. Lynch. Context-dependent regulatory mechanism of 
the splicing factor hnRNP L. Mol Cell. 37:223-34. 
Nagata, S. 1999. Fas ligand-induced apoptosis. Annu Rev Genet. 33:29-55. 
Obenauer, J.C., L.C. Cantley, and M.B. Yaffe. 2003. Scansite 2.0: Proteome-wide 
prediction of cell signaling interactions using short sequence motifs. Nucleic Acids 
Res. 31:3635-41. 
Pai, S.I., G.S. Wu, N. Ozoren, L. Wu, J. Jen, D. Sidransky, and W.S. El-Deiry. 1998. Rare 
loss-of-function mutation of a death receptor gene in head and neck cancer. Cancer 
Res. 58:3513-8. 
Pan, Q., O. Shai, L.J. Lee, B.J. Frey, and B.J. Blencowe. 2008. Deep surveying of 
alternative splicing complexity in the human transcriptome by high-throughput 
sequencing. Nat Genet. 40:1413-5. 
Park, J.W., Y.J. Choi, S.I. Suh, W.K. Baek, M.H. Suh, I.N. Jin, D.S. Min, J.H. Woo, J.S. 
Chang, A. Passaniti, Y.H. Lee, and T.K. Kwon. 2001. Bcl-2 overexpression 
125 
attenuates resveratrol-induced apoptosis in U937 cells by inhibition of caspase-3 
activity. Carcinogenesis. 22:1633-9. 
Patel, N.A., C.E. Chalfant, J.E. Watson, J.R. Wyatt, N.M. Dean, D.C. Eichler, and D.R. 
Cooper. 2001. Insulin regulates alternative splicing of protein kinase C beta II 
through a phosphatidylinositol 3-kinase-dependent pathway involving the nuclear 
serine/arginine-rich splicing factor, SRp40, in skeletal muscle cells. J Biol Chem. 
276:22648-54. 
Philips, A.V., and T.A. Cooper. 2000. RNA processing and human disease. Cell Mol Life 
Sci. 57:235-49. 
Pinol-Roma, S., Y.D. Choi, M.J. Matunis, and G. Dreyfuss. 1988. Immunopurification of 
heterogeneous nuclear ribonucleoprotein particles reveals an assortment of RNA-
binding proteins. Genes Dev. 2:215-27. 
Pitti, R.M., S.A. Marsters, D.A. Lawrence, M. Roy, F.C. Kischkel, P. Dowd, A. Huang, 
C.J. Donahue, S.W. Sherwood, D.T. Baldwin, P.J. Godowski, W.I. Wood, A.L. 
Gurney, K.J. Hillan, R.L. Cohen, A.D. Goddard, D. Botstein, and A. Ashkenazi. 
1998. Genomic amplification of a decoy receptor for Fas ligand in lung and colon 
cancer. Nature. 396:699-703. 
Pozzoli, U., and M. Sironi. 2005. Silencers regulate both constitutive and alternative 
splicing events in mammals. Cell Mol Life Sci. 62:1579-604. 
Pullman, J.M., and T.E. Martin. 1983. Reconstitution of nucleoprotein complexes with 
mammalian heterogeneous nuclear ribonucleoprotein (hnRNP) core proteins. J Cell 
Biol. 97:99-111. 
Query, C.C., M.J. Moore, and P.A. Sharp. 1994. Branch nucleophile selection in pre-
mRNA splicing: evidence for the bulged duplex model. Genes Dev. 8:587-97. 
Reeve, J.G., J. Xiong, J. Morgan, and N.M. Bleehen. 1996. Expression of apoptosis-
regulatory genes in lung tumour cell lines: relationship to p53 expression and 
relevance to acquired drug resistance. Br J Cancer. 73:1193-200. 
Roth, W., S. Isenmann, M. Nakamura, M. Platten, W. Wick, P. Kleihues, M. Bahr, H. 
Ohgaki, A. Ashkenazi, and M. Weller. 2001. Soluble decoy receptor 3 is expressed 
by malignant gliomas and suppresses CD95 ligand-induced apoptosis and 
chemotaxis. Cancer Res. 61:2759-65. 
Salvesen, G.S., and C.S. Duckett. 2002. IAP proteins: blocking the road to death's door. 
Nat Rev Mol Cell Biol. 3:401-10. 
Sato, M., M.B. Vaughan, L. Girard, M. Peyton, W. Lee, D.S. Shames, R.D. Ramirez, N. 
Sunaga, A.F. Gazdar, J.W. Shay, and J.D. Minna. 2006. Multiple oncogenic 
changes (K-RAS(V12), p53 knockdown, mutant EGFRs, p16 bypass, telomerase) 
are not sufficient to confer a full malignant phenotype on human bronchial 
epithelial cells. Cancer Res. 66:2116-28. 
Schaal, T.D., and T. Maniatis. 1999. Selection and characterization of pre-mRNA splicing 
enhancers: identification of novel SR protein-specific enhancer sequences. Mol Cell 
Biol. 19:1705-19. 
Schmitt, C.A., J.S. Fridman, M. Yang, E. Baranov, R.M. Hoffman, and S.W. Lowe. 2002. 
Dissecting p53 tumor suppressor functions in vivo. Cancer Cell. 1:289-98. 
126 
Schwerk, C., and K. Schulze-Osthoff. 2005. Regulation of apoptosis by alternative pre-
mRNA splicing. Mol Cell. 19:1-13. 
Scott, C.L., M. Schuler, V.S. Marsden, A. Egle, M. Pellegrini, D. Nesic, S. Gerondakis, 
S.L. Nutt, D.R. Green, and A. Strasser. 2004. Apaf-1 and caspase-9 do not act as 
tumor suppressors in myc-induced lymphomagenesis or mouse embryo fibroblast 
transformation. J Cell Biol. 164:89-96. 
Sell, S.M., D. Reese, and V.M. Ossowski. 1994. Insulin-inducible changes in insulin 
receptor mRNA splice variants. J Biol Chem. 269:30769-72. 
Senft, J., B. Helfer, and S.M. Frisch. 2007. Caspase-8 interacts with the p85 subunit of 
phosphatidylinositol 3-kinase to regulate cell adhesion and motility. Cancer Res. 
67:11505-9. 
Seol, D.W., and T.R. Billiar. 1999. A caspase-9 variant missing the catalytic site is an 
endogenous inhibitor of apoptosis. J Biol Chem. 274:2072-6. 
Shi, Y. 2002. Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell. 
9:459-70. 
Shih, S.C., and K.P. Claffey. 1999. Regulation of human vascular endothelial growth 
factor mRNA stability in hypoxia by heterogeneous nuclear ribonucleoprotein L. J 
Biol Chem. 274:1359-65. 
Shiozaki, E.N., J. Chai, D.J. Rigotti, S.J. Riedl, P. Li, S.M. Srinivasula, E.S. Alnemri, R. 
Fairman, and Y. Shi. 2003. Mechanism of XIAP-mediated inhibition of caspase-9. 
Mol Cell. 11:519-27. 
Siebert, P.D., and J.W. Larrick. 1992. Competitive PCR. Nature. 359:557-8. 
Siomi, M.C., P.S. Eder, N. Kataoka, L. Wan, Q. Liu, and G. Dreyfuss. 1997. Transportin-
mediated nuclear import of heterogeneous nuclear RNP proteins. J Cell Biol. 
138:1181-92. 
Soengas, M.S., R.M. Alarcon, H. Yoshida, A.J. Giaccia, R. Hakem, T.W. Mak, and S.W. 
Lowe. 1999. Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor 
inhibition. Science. 284:156-9. 
Soundararajan, S., W. Chen, E.K. Spicer, N. Courtenay-Luck, and D.J. Fernandes. 2008. 
The nucleolin targeting aptamer AS1411 destabilizes Bcl-2 messenger RNA in 
human breast cancer cells. Cancer Res. 68:2358-65. 
Srinivasula, S.M., M. Ahmad, Y. Guo, Y. Zhan, Y. Lazebnik, T. Fernandes-Alnemri, and 
E.S. Alnemri. 1999. Identification of an endogenous dominant-negative short 
isoform of caspase-9 that can regulate apoptosis. Cancer Res. 59:999-1002. 
Srinivasula, S.M., R. Hegde, A. Saleh, P. Datta, E. Shiozaki, J. Chai, R.A. Lee, P.D. 
Robbins, T. Fernandes-Alnemri, Y. Shi, and E.S. Alnemri. 2001. A conserved 
XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity 
and apoptosis. Nature. 410:112-6. 
Stamm, S., J. Zhu, K. Nakai, P. Stoilov, O. Stoss, and M.Q. Zhang. 2000. An alternative-
exon database and its statistical analysis. DNA Cell Biol. 19:739-56. 
Stephanou, A., T.M. Scarabelli, R.A. Knight, and D.S. Latchman. 2002. Antiapoptotic 
activity of the free caspase recruitment domain of procaspase-9: a novel 
endogenous rescue pathway in cell death. J Biol Chem. 277:13693-9. 
127 
Stetefeld, J., and M.A. Ruegg. 2005. Structural and functional diversity generated by 
alternative mRNA splicing. Trends Biochem Sci. 30:515-21. 
Sui, S., J. Wang, B. Yang, L. Song, J. Zhang, M. Chen, J. Liu, Z. Lu, Y. Cai, S. Chen, W. 
Bi, Y. Zhu, F. He, and X. Qian. 2008. Phosphoproteome analysis of the human 
Chang liver cells using SCX and a complementary mass spectrometric strategy. 
Proteomics. 8:2024-34. 
Taguchi, F., H. Kusaba, A. Asai, Y. Iwamoto, K. Yano, H. Nakano, T. Mizukami, N. 
Saijo, H. Kato, and K. Nishio. 2004. hnRNP L enhances sensitivity of the cells to 
KW-2189. Int J Cancer. 108:679-85. 
Tanaka, E., H. Fukuda, K. Nakashima, N. Tsuchiya, H. Seimiya, and H. Nakagama. 2007. 
HnRNP A3 binds to and protects mammalian telomeric repeats in vitro. Biochem 
Biophys Res Commun. 358:608-14. 
ten Dam, G.B., C.F. Zilch, D. Wallace, B. Wieringa, P.C. Beverley, L.G. Poels, and G.R. 
Screaton. 2000. Regulation of alternative splicing of CD45 by antagonistic effects 
of SR protein splicing factors. J Immunol. 164:5287-95. 
Thornberry, N.A., and Y. Lazebnik. 1998. Caspases: enemies within. Science. 281:1312-6. 
van der Houven van Oordt, W., M.T. Diaz-Meco, J. Lozano, A.R. Krainer, J. Moscat, and 
J.F. Caceres. 2000. The MKK(3/6)-p38-signaling cascade alters the subcellular 
distribution of hnRNP A1 and modulates alternative splicing regulation. J Cell 
Biol. 149:307-16. 
Venables, J.P. 2006. Unbalanced alternative splicing and its significance in cancer. 
Bioessays. 28:378-86. 
Venter, J.C., M.D. Adams, E.W. Myers, P.W. Li, R.J. Mural, G.G. Sutton, H.O. Smith, M. 
Yandell, C.A. Evans, R.A. Holt, J.D. Gocayne, P. Amanatides, R.M. Ballew, D.H. 
Huson, J.R. Wortman, Q. Zhang, C.D. Kodira, X.H. Zheng, L. Chen, M. Skupski, 
G. Subramanian, P.D. Thomas, J. Zhang, G.L. Gabor Miklos, C. Nelson, S. Broder, 
A.G. Clark, J. Nadeau, V.A. McKusick, N. Zinder, A.J. Levine, R.J. Roberts, M. 
Simon, C. Slayman, M. Hunkapiller, R. Bolanos, A. Delcher, I. Dew, D. Fasulo, M. 
Flanigan, L. Florea, A. Halpern, S. Hannenhalli, S. Kravitz, S. Levy, C. Mobarry, 
K. Reinert, K. Remington, J. Abu-Threideh, E. Beasley, K. Biddick, V. Bonazzi, R. 
Brandon, M. Cargill, I. Chandramouliswaran, R. Charlab, K. Chaturvedi, Z. Deng, 
V. Di Francesco, P. Dunn, K. Eilbeck, C. Evangelista, A.E. Gabrielian, W. Gan, W. 
Ge, F. Gong, Z. Gu, P. Guan, T.J. Heiman, M.E. Higgins, R.R. Ji, Z. Ke, K.A. 
Ketchum, Z. Lai, Y. Lei, Z. Li, J. Li, Y. Liang, X. Lin, F. Lu, G.V. Merkulov, N. 
Milshina, H.M. Moore, A.K. Naik, V.A. Narayan, B. Neelam, D. Nusskern, D.B. 
Rusch, S. Salzberg, W. Shao, B. Shue, J. Sun, Z. Wang, A. Wang, X. Wang, J. 
Wang, M. Wei, R. Wides, C. Xiao, C. Yan, et al. 2001. The sequence of the human 
genome. Science. 291:1304-51. 
Wang, X. 2001. The expanding role of mitochondria in apoptosis. Genes Dev. 15:2922-33. 
Ward, A.J., and T.A. Cooper. The pathobiology of splicing. J Pathol. 220:152-63. 
Warzecha, C.C., T.K. Sato, B. Nabet, J.B. Hogenesch, and R.P. Carstens. 2009. ESRP1 
and ESRP2 are epithelial cell-type-specific regulators of FGFR2 splicing. Mol Cell. 
33:591-601. 
128 
Wu, J.Y., and T. Maniatis. 1993. Specific interactions between proteins implicated in 
splice site selection and regulated alternative splicing. Cell. 75:1061-70. 
Wyllie, A.H., J.F. Kerr, and A.R. Currie. 1980. Cell death: the significance of apoptosis. 
Int Rev Cytol. 68:251-306. 
Xie, J., J.A. Lee, T.L. Kress, K.L. Mowry, and D.L. Black. 2003. Protein kinase A 
phosphorylation modulates transport of the polypyrimidine tract-binding protein. 
Proc Natl Acad Sci U S A. 100:8776-81. 
Yu, J., Y. Hai, G. Liu, T. Fang, S.K. Kung, and J. Xie. 2009. The heterogeneous nuclear 
ribonucleoprotein L is an essential component in the Ca2+/calmodulin-dependent 
protein kinase IV-regulated alternative splicing through cytidine-adenosine repeats. 
J Biol Chem. 284:1505-13. 
Yugami, M., Y. Kabe, Y. Yamaguchi, T. Wada, and H. Handa. 2007. hnRNP-U enhances 
the expression of specific genes by stabilizing mRNA. FEBS Lett. 581:1-7. 
Zha, H., C. Aime-Sempe, T. Sato, and J.C. Reed. 1996a. Proapoptotic protein Bax 
heterodimerizes with Bcl-2 and homodimerizes with Bax via a novel domain (BH3) 
distinct from BH1 and BH2. J Biol Chem. 271:7440-4. 
Zha, J., H. Harada, E. Yang, J. Jockel, and S.J. Korsmeyer. 1996b. Serine phosphorylation 
of death agonist BAD in response to survival factor results in binding to 14-3-3 not 
BCL-X(L). Cell. 87:619-28. 
Zheng, Z.M. 2004. Regulation of alternative RNA splicing by exon definition and exon 
sequences in viral and mammalian gene expression. J Biomed Sci. 11:278-94. 
 
 
129 
 
 
 
 
VITA 
 
 
 
RACHEL WILSON GOEHE 
Department of Biochemistry & Molecular Biology 
Virginia Commonwealth University, School of Medicine 
1101 E. Marshall Street, Sanger Hall, Room 2-016 
Richmond, VA 23298, USA 
Phone: (804)-828-1140 
E-mail: wilsonra@vcu.edu 
 
 
 
PERSONAL INFORMATION 
Date of Birth  June 11
th
, 1984 
Place of Birth  Honolulu, Hawaii 
Citizenship  United States of America 
 
EDUCATION 
December, 2010   Ph.D. in Biochemistry & Molecular Biology 
Dissertation: The Regulation of the Alternative Splicing of 
Caspase 9 
Cumulative GPA: 3.5 
130 
Virginia Commonwealth University, Richmond, VA 
School of Medicine, Department of Biochemistry & 
Molecular Biology 
 
May, 2006    B.S. in Biology 
University of Mary Washington, Fredericksburg, Virginia 
Department of Biology 
 
 
 
SKILLS 
 
 Biochemistry/Molecular Biology 
o Electrophoresis, western blotting, isolations (DNA, RNA, protein), cloning, 
EMSA, affinity assays, immunoprecipitation, cell fractionation, RT-PCR, 
qPCR, gene silencing techniques (siRNA/shRNA), adenovirus/lentivirus, 
mutagenesis, WST, hoescht staining, RFLP 
 
 Cell Culture 
o Primary cells and NSCLC cell lines 
o Stable cell line creation; “batch” and clonal cell lines 
o Anchorage independent growth (soft agar) 
 
 In viv work (mice) 
o Work with SCID mice 
o A549 xenografts – administration by IP injection 
o Tissue collection 
 
 Imaging 
o Fluorescent microscope 
o H&E stain imaging 
o Confocal microscopy 
o Immunocytochemistry (ICC) 
 
 
 
RESEARCH POSITIONS 
 
2006-Present  Virginia Commonwealth University, Richmond, Virginia 
   Graduate Student, Department of Biochemistry & Mol. Biology 
   Advisor: Charles E. Chalfant, Ph.D. 
 
131 
2009 (Summer) Virginia Commonweatlth University, Richmond, Virginia 
   Teaching Volunteer, Department of Biochemistry & Mol. Biology 
Participated in Students, Transitions, Advising and Registration 
program (STAR). Guided the student in the basics of laboratory 
research (Cell culture, PCR, protein isolation, background literature, 
interpreting data). 
 
2005-2006  University of Mary Washington, Fredericksburg, Virignia 
   Undergraduate Research Assistant, Department of Biology 
   Advisor: Alan D. Griffiths, Ph.D. 
 
 
AWARDS 
 
2008  Travel Award at the Southeastern Regional Lipid Conference 
(SERLC) 
   Cashiers, North Carolina 
 
2005-2006  Undergraduate Research Grant from UMW 
   University of Mary Washington 
   Fredericksburg, Virginia 
 
 
 
 
ATTENDED CONFERENCES & SYMPOSIUMS 
 
January 2009          Keystone Symposia Conference, Sagebrush Conference 
Center 
Emerging Tumor Suppressors  
Taos, New Mexico 
Poster Presentation: hnRNP L regulates the tumorigenic 
capacity of lung cancer cells in mice via caspase 9 pre-mRNA 
processing. 
 
 
November 2008 43
st
 Annual Southeastern Regional Lipid Conference.  
  High Hampton Inn Country Club 
  Cashiers, North Carolina 
Seminar Presentation: hnRNP L regulates the 
tumorigenic capacity of lung cancer cells in mice via 
caspase 9 pre-mRNA processing. (Award) 
 
 
132 
October 2008           Daniel T. Watts Research Poster Symposium. 
                                Virginia Commonwealth University  
   Richmond, Virginia 
Poster Presentation: hnRNP U, a necessary enhancer 
element, regulates the alternative splicing of caspase 9. 
 
October 2008   Massey Cancer Center Research Retreat 
    Virginia Commonwealth University 
    Richmond, Virginia 
Poster Presentation: hnRNP L regulates the tumorigenic 
capacity of lung cancer cells in mice via caspase 9 pre-
mRNA processing. 
Poster Presentation: Laser capture microdissection 
technology to interpret molecular events in tissues 
 
 
November 2007 42
nd
 Annual Southeastern Regional Lipid 
Conference 
   High Hampton Inn Country Club 
   Cashiers, North Carolina 
Poster Presentation: SRp30a (ASF/SF2) regulates the 
alternative splicing of caspase 9 via a novel intronic 
splicing enhancer in intron 6.  
    
 
October 2007           Daniel T. Watts Research Poster Symposium. 
                                Virginia Commonwealth University  
   Richmond, Virginia 
Poster Presentation: The early diagnostic indicators, 
hnRNP L and hnRNP A2/B1, regulate the alternative 
splicing of caspase 9. 
 
 
November 2006  41
st
 Annual Southeastern Regional Lipid Conference 
   High Hampton Inn Country Club 
   Cashiers, North Carolina 
 
 
 
 
ACTIVITIES AND HONORS 
 
2007-Present  Women in Science 
2005-2006   Biology student tutor 
133 
2004-2006  Varsity Cheerleading Team 
2004-2006   Dean‟s List 
   
 
MANUSCRIPTS 
Rachel W. Goehe, Jacqueline C. Shultz, Sanja Usanovic, Nadia F. Lamour, Jerry W. 
Shay, John D. Minna,
 
Lian Zhang, Ross Camidge, and Charles E. Chalfant. hnRNP L 
regulates the tumorigenic capacity of lung cancer cells in mice via caspase 9 pre-mRNA 
processing. Journal of Clinical Investigation. (2010)  
 
Jaqueline C. Shultz, Rachel W. Goehe, D. Wijesinghe, Charuta Murudkar, Amy Hawkins, 
Jerry Shay, John Minna, and Charles Chalfant. Alternative splicing of Caspase 9 is 
modulated by the PI3K/Akt pathway via phosphorylation of SRp30a. Cancer Research. 
(2010)  
 
